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Abstract 
This thesis investigates the clinical impact of a point-of-care diagnostic strategy for 
pulmonary tuberculosis (TB) in a setting at the heart of the TB and human 
immunodeficiency virus (HIV) epidemics in rural KwaZulu-Natal, South Africa. 
Although the identification and prompt treatment of active pulmonary TB disease 
remains the cornerstone of global TB control strategies, weak diagnostic systems 
contribute to substantial delays and default during the diagnostic process. As new 
diagnostic technologies are developed, evidence is needed around how best to 
deliver them within health systems in order to maximize their impact.  
 
The impact of positioning of a molecular diagnostic system (Xpert MTB/RIF) was 
investigated in a cluster randomised trial. Clusters (two-week time periods) were 
randomised to one of two strategies: centralised laboratory Xpert MTB/RIF testing 
or point-of-care Xpert MTB/RIF at the clinic. The trial enrolled 1297 adults with 
symptoms of pulmonary TB who were HIV infected and/or at high risk of drug-
resistant TB.  There was some evidence that point-of-care placement shortened the 
time to initiation of treatment but there was no difference in the overall proportion of 
culture-positive pulmonary TB cases initiated on appropriate anti-TB treatment 
within 30 days. Overall mortality was lower than anticipated and, although it was 
higher with the point-of-care strategy, this effect was not maintained after adjusting 
for the presence of TB disease and CD4+ T-cell count.   
 
Further analysis suggested that the point-of-care strategy increased the proportion of 
valid Xpert results from the initial sputum specimen, increased the proportion of 
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individuals receiving test results and allowed same-day treatment initiation for half 
of all culture-positive cases that tested positive with Xpert. The diagnostic 
performance of the Xpert MTB/RIF system was comparable under both strategies. 
However, delays in initiation of treatment for drug-resistant TB cases and for Xpert-
negative/culture-positive cases occurred similarly with both strategies, reducing the 
potential to detect a real impact on outcomes. Although not a primary focus of the 
study, the results highlighted deficiencies in the performance of sputum culture, 
which raise questions about its place as the gold standard diagnostic test.  
 
The development of simple, rapid diagnostics suitable for point-of-care use remains 
important for TB control in high burden settings. The findings will improve 
understanding of the key requirements for successful diagnostic strategies and the 
lessons learnt will help to inform future diagnostic clinical trials. Further research is 
needed to evaluate how different diagnostic strategies might impact on TB 
transmission in health care facilities and more broadly in the community.  
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Chapter 1 Introduction 
1.1 Background 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
and other closely related Mycobacterium species. Effective antimicrobial 
chemotherapy that can cure most cases of TB disease has been available for over 50 
years. Despite this, every day in 2013 an estimated 25 000 people were diagnosed 
with TB disease and over 4000 people died as a result of TB disease.[1] The World 
Health Organization (WHO) declared TB a global public health emergency in 
1993.[2] Two decades later, tuberculosis remains one of the ten leading causes of 
death globally.[3] 
 
The WHO approach to TB control is currently framed within the Stop TB 
Strategy[4,5]; and more broadly within the Millennium Development Goals 
(MDGs)[6]: by 2015 to reduce the prevalence of TB and mortality due to TB by 50% 
compared to 1990 levels. The prevalence target has already been met globally and 
the mortality target is expected to be met in most regions by 2015. The longer-term 
target is to eliminate TB as a public health problem by 2050 (defined as annual 
global incidence of less than one case per million population). Whilst this target may 
not be achieved with the tools available to us today, elimination could be achieved 
by 2050 with the parallel development and implementation of new diagnostics, 
vaccines and drugs.[7,8]    
 
Control of the TB epidemic in sub-Saharan Africa, and particularly in South Africa, 
has been a particular challenge, due to the co-existent human immunodeficiency 
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virus (HIV) epidemic and the spread of drug-resistant M. tuberculosis strains.[9-13] 
Approximately one quarter of global TB cases occur in Africa and estimated 
incidence rates remained higher in 2010 than in 1990.[14] Africa is not on track to 
meet the MDG TB targets, in particular the target to halve TB mortality by 2015; 
mortality has fallen at an annual average of only 1.5% between 1990 and 2010.[14]  
 
In South Africa, the combined TB and HIV epidemics have had an enormous impact 
on population health in the last two decades. TB incidence increased progressively 
from the 1920’s until the 1960’s; this was then followed by a modest decline up until 
1990.[15,16] TB incidence rates more than trebled between 1990 and 2010 in 
concert with the explosive HIV epidemic leading to some of the highest population 
rates of TB disease anywhere in the world (Figure 1-1). In South Africa now almost 
1% of the population develop TB disease every year and the country is behind only 
India and the People’s Republic of China in terms of the total number of notified TB 
cases, with 328 896 cases notified in 2013.[1]  
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Figure 1-1 Estimated TB incidence and antenatal HIV prevalence in South Africa 1990-2011 [Data 
sources: WHO Global TB database (http://www.who.int/tb/country/en/); South African National HIV 
and syphilis antenatal sero-prevalence surveys (http://indicators.hst.org.za/healthstats/13/data)] 
 
 
The impact of the co-existent epidemics of TB and HIV has been greatest in 
KwaZulu-Natal province. This predominantly rural province has the highest HIV 
prevalence (antenatal prevalence 37.4% in 2011) and the highest TB notification rate 
(1120 per 100 000 in 2011) in the country. In one rural community in northern 
KwaZulu-Natal, HIV and TB were estimated together to be responsible for 60.1% of 
all adult deaths between 2000 and 2010.[17] KwaZulu-Natal is also the epicentre of 
the drug-resistant TB epidemic, with the emergence of multidrug-resistant (MDR) 
strains from the 1990s onwards[18,19]; and the later emergence of extensively drug-
resistant (XDR) strains, most notably associated with an explosive nosocomial 
outbreak centred on a single rural district hospital.[20-22]  
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1.2 TB diagnosis 
Given the lack of an effective TB vaccine and the lack of efficacy of population-
level prevention strategies,[23,24] TB control at present relies primarily on the 
identification and treatment of individuals with active TB disease. As M. 
tuberculosis is transmitted primarily by cases with active pulmonary disease, 
detection of pulmonary TB is the priority for TB control programmes. Early case 
detection and initiation of appropriate anti-TB therapy is necessary to reduce TB-
related mortality and to reduce infectivity in order to interrupt transmission. 
Evidence from transmission studies suggests that appropriate anti-TB treatment 
rapidly renders most individuals with pulmonary TB non-infectious within a few 
days, in both drug-sensitive and drug-resistant disease.[25,26]  
 
Definitive diagnosis of active TB disease requires the culture of M. tuberculosis in a 
clinical sample from the site of disease. As M. tuberculosis is a slow-growing 
organism, culture-based methods are time-consuming and they generally require 
complex laboratory infrastructure. As a proxy, direct observation of M. tuberculosis 
organisms in sputum by microscopy (sputum smear microscopy) remains the 
primary diagnostic method in most of the world. However, this diagnostic method 
has been poorly equipped to control the current TB epidemic in sub-Saharan Africa 
given its poor sensitivity, particularly in HIV co-infection, and inability to detect 
drug resistance.[27] Sputum smear microscopy has other limitations, particularly the 
inability to discriminate between M. tuberculosis and non-tuberculous mycobacteria 
and the inability to determine the viability of observed organisms.  
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1.3 Positioning of diagnostics 
In general, in low- and middle-income countries, people are investigated and treated 
for TB at primary health care facilities with no supporting on-site laboratory 
infrastructure. The need for specimens to be sent to centralised laboratories and for 
patients to return to the facility contributes to delays and default during the 
diagnostic process, an issue that will be discussed in more detail in chapter 2. The 
need for simple diagnostic technologies for TB suitable for use at the point of care 
has been recognised for some time.[28-38] Particularly in the context of the 
decentralisation and integration of HIV and TB care,[39,40] and even now drug-
resistant TB management,[41] South African primary health care services need to be 
supported by appropriate diagnostic systems.      
 
In the field of HIV, decentralisation of care has been supported by the deployment of 
simple, rapid point-of-care tests for diagnosis.[30] Furthermore, technologies for 
point-of-care CD4+ T-cell and HIV RNA monitoring are now being developed and 
implemented, and already there is some evidence of positive impact.[34,42,43] 
However, challenges in realising the potential of point-of-care technologies have 
also been uncovered, for example with a study of point-of-care CD4+ T-cell testing 
where only 30% of participants received a test on the day of enrolment.[43]   
 
Whilst the benefits of point-of-care strategies might seem clear, there is a need for 
evidence of impact in different settings, not only to inform implementation of new 
diagnostics but also to feed back into the development of next generation 
technologies and systems.  
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1.4 Project starting points 
The development of molecular diagnostics has provided a new opportunity to 
address some of the deficiencies with systems based on smear microscopy and 
culture-based diagnostics. Molecular diagnostics are based on the detection of the 
genetic material of a pathogen (in this case the deoxyribonucleic acid (DNA) of M. 
tuberculosis). Molecular diagnostics for TB have advantages over sputum smear 
microscopy; in particular improved sensitivity, the ability to differentiate between M. 
tuberculosis and non-tuberculous mycobacteria, and the potential to identify genetic 
mutations associated with drug resistance. One particular test, the Xpert MTB/RIF 
assay, was developed with near-patient use in mind.[44-46] This provided the 
opportunity to evaluate the impact of point-of-care positioning on the diagnosis and 
treatment of TB.  
 
The framework for the evaluation of diagnostic tests is much less rigorous than for 
vaccines or drugs.[47-49] In general, evidence of diagnostic test accuracy in the 
laboratory is sufficient for marketing approval and evidence of impact on patient-
relevant outcomes is often not generated. However, diagnostics are different from 
vaccines and drugs as they do not alter prognosis by themselves but rely on 
interpretation and appropriate action to be taken based on the test result. Diagnostic 
tests therefore do not function in isolation but within broader health systems and 
therefore evaluation of the real world impact requires evidence from well-designed 
clinical studies with patient-relevant outcomes. Determining the impact of a point-
of-care diagnostic strategy has implications for the future development of 
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diagnostics, not only for tuberculosis but for other infectious diseases of global 
importance.  
 
1.5 Aims and objectives 
The overall aim was to evaluate the impact of a point-of-care diagnostic strategy, 
using the Xpert MTB/RIF assay, in a rural setting with high levels of TB drug 
resistance and HIV infection.  
 
The specific objectives were: 
 to test the hypothesis that timely initiation of appropriate TB treatment would 
be improved with the point-of-care strategy (Xpert MTB/RIF positioned at 
the primary health care clinic) compared to the laboratory strategy 
 to evaluate the impact of Xpert MTB/RIF positioning on additional clinical 
outcomes (time to appropriate TB treatment, mortality, hospital admission, 
time to initiation of antiretroviral therapy) 
 to compare the diagnostic accuracy of the Xpert MTB/RIF system in the two 
positioning strategies 
 
1.6 Outline of thesis 
The introduction to the thesis (chapter 1) describes the current state of the TB 
epidemic globally and, more specifically, in South Africa. The framework and the 
aims and objectives for the research are outlined.  
 
25 
 
  
In chapter 2, a review of published literature relating to the issue of delays and 
default during the TB diagnostic process is presented, with a focus on studies from 
Africa. Specific studies exploring delays and default during the diagnostic process 
for multidrug-resistant TB are also reviewed. The empirical evidence about 
interventions to reduce delays and default is also reviewed alongside evidence from 
mathematical models that have explored the potential impact of alternative TB 
diagnostic strategies. 
 
Chapter 3 contains a review of the literature to date on the Xpert MTB/RIF assay, 
exploring the diagnostic performance as well as evidence to date of its impact in 
programmatic settings. 
 
The methodologies for the design and analysis of the cluster randomised trial are 
outlined in chapter 4, with a detailed description of the study setting. 
 
The main results from the cluster randomised trial are presented in chapter 5, and the 
results of the diagnostic accuracy evaluation are presented in chapter 6. 
 
Chapter 7 incorporates discussion of the trial results in the context of other published 
research and highlights the lessons learnt during the study that are relevant for future 
diagnostic research.   
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Chapter 2 TB diagnostic delay and default 
 
Timely initiation of TB treatment is important to improve prognosis at an individual 
level but also for population-level impact through interruption of TB transmission. 
Existing diagnostic strategies based around sputum smear microscopy and culture, 
often in centralised laboratories removed from the point of care, have significant 
limitations.[27] This has been particularly apparent in sub-Saharan Africa, where the 
high prevalence of HIV infection and emergence of drug-resistant M. tuberculosis 
strains have exposed the deficiencies of these diagnostics.[50] The poor sensitivity of 
sputum smear microscopy and the time taken for culture and drug susceptibility 
testing contribute substantially to diagnostic delay and default, which in turn impacts 
on individual and population health outcomes.[51]  
 
2.1 TB diagnostic delay  
2.1.1 Studies of diagnostic delay in sub-Saharan Africa 
Several studies have investigated delays in diagnosis of TB, often with 
disaggregation of total delay into patient delay and health system delay (Figure 2-1). 
The results of studies conducted in countries of sub-Saharan Africa where both 
patient delay and health system delay are reported are shown in Table 2-1.[52-79] 
Almost exclusively, these studies involve retrospective analysis of TB cases on 
treatment. There is considerable heterogeneity in the delays reported, at least in part 
reflecting the different case groups, settings, health system structures, and diagnostic 
modalities available. Despite this, it is notable that over half of the studies (16/28, 
57%) report health system delay longer than the patient delay and a similar majority 
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(16/28, 57%) describe health system delay of at least four weeks. For the studies 
exploring pulmonary TB, median overall delay was approximately three months and 
median health system delay was over 30 days.  
 
Whilst it may seem intuitive to separate delay into patient delay and health system 
delay, they should not be regarded as unrelated as the underlying factors for delay 
might in some cases be common to both categories. For example, a poor quality 
health system might inherently lead to health system delays but also give rise to 
delays in patients accessing care due to the perceived poor quality. Conversely, 
factors such as poverty and distance to health facility could lead to delays in patients 
seeking care but then also further delays during the diagnostic process because of 
continued problems with health care access. 
     
 
 
 
Figure 2-1 Schema for TB diagnostic delay 
 
 
Another perspective on diagnostic delay is to focus on the number of health facility 
visits prior to diagnosis and treatment. Relatively few studies have reported on the 
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number of visits, but those that have reported an average number of visits (median or 
mean) of between three and four.[52,58,61,68,75] In Malawi, Harries et al. defined 
the maximum number of visits that anyone should make before a TB diagnosis in 
Malawi as five based on the diagnostic algorithms within national guidelines, yet 
found that one in three pulmonary TB cases had greater than five visits before 
diagnosis.[80]  
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Table 2-1 Studies of TB diagnostic delay from sub-Saharan Africa 
Study Country Location Year N  Delay  
     Overall Patient Health system 
Smear-positive pulmonary TB 
Lawn 1998[52] Ghana Single teaching hospital 1995 100 4 months 4 weeks 8 weeks 
Wandwalo 2000[53]  Tanzania Urban & rural districts 1998 300 136 days 120 days 15 days 
Yimer 2005[54]  Ethiopia 20 facilities 2003 384 80 days 15 days 61 days 
Kiwuwa 2005[55]  Uganda Single urban referral hospital 2002 231 12 weeks 1 week 9 weeks 
Ayuo 2008[56] Kenya Referral hospital 2002-4 230 44 days 42 days 2 days 
Ngadaya 2009[57] Tanzania 16 facilities 2007 226 90 days 62 days 28 days 
Sendagire 2010[58]  Uganda 3 urban PHC clinics 2007-8 242 8 weeks 4 weeks 4 weeks 
Lugga 2011[59] South Sudan 3 treatment centres 2007 129 16 weeks 4 weeks 10 weeks 
Hussen 2012[60] Ethiopia 4 facilities  2011 129 97 days 63 days 34 days 
Overall*     90 days (80-112) 28 days (28-62) 34 days (28-61) 
All pulmonary TB 
Steen 1998 [61] Botswana Single district 1993-4 212 12 weeks 3 weeks 5 weeks 
Pronyk 2001[62] South Africa 3 district hospitals 1999 298 10 weeks 4 weeks 1 week 
Demissie 2002[63]  Ethiopia 17 public health centres (urban) 1998 700 64 days 60 days 6 days 
Odusanya 2004[64]  Nigeria Single teaching hospital 2000-1 141 14.3 weeks† 12.3 weeks† 1.3 weeks† 
Wondimu 2007[65]  Ethiopia 13 facilities 2006 197 90 days 28 days 42 days 
Ngangro 2012[66] Chad 3 hospitals 2009 286 57.5 days 15 days 36 days 
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Study Country Location Year N  Delay  
     Overall Patient Health system 
Saifodine 2013[67] Mozambique 5 clinics 2009-10 622 150 days 61 days 62 days 
Ukwaja 2013[68] Nigeria 3 rural hospitals 2011 450 11 weeks 8 weeks 3 weeks 
Makwakwa 2014 [69] Malawi 3 urban TB referral centres 2011 588 80 days 14 days 59 days 
Overall*     80 days (70-90) 28 days (21-60) 35 days (9-42) 
All forms TB 
Lienhardt 2001[70]  The Gambia 4 facilities (urban & rural) 1997 152 8.6 weeks 0.3 weeks 8.3 weeks 
Mesfin 2005[71] Ethiopia 16 facilities (hospital/health centre) 2001-2 237 99 days 60 days 9 days 
Lorent 2008[72]  Rwanda Single urban referral hospital 2006 104 57 days 25 days 28 days 
Meintjes 2008[73]  South Africa Single urban referral hospital 2003 104 60 days 14 days 30 days 
Verhagen 2010[74] Tanzania 1 district hospital 2008 30 188 days 21 days 26 days 
Van Wyk 2011[75] South Africa 1 urban PHC clinic 2009 210 31 days 8 days 17 days 
Belay 2012[76] Ethiopia 2 facilities in rural region 2009-10 216 70.5 days 20 days 33.5 days 
Lusignani 2013[77] Angola 21 facilities 2008 385 45 days 30 days 7 days 
Otwombe 2013[78] South Africa 3 tertiary hospitals NS 891 28 days 28 days 1 day 
Yimer 2014[79] Ethiopia Single urban referral hospital 2010 201 60 days 21 days 27 days 
Overall*     60 days (48-68) 21 days (16-27) 27 days (11-30) 
PHC, primary health care; PTB, pulmonary tuberculosis 
All data for delays from individual studies are medians, unless otherwise stated, and are presented in the time units reported in the study manuscript 
* Summary measures of delay for each group of studies are medians (interquartile range) 
† Mean
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2.1.2 Factors associated with health system delay 
The majority of quantitative studies that have assessed factors associated with health 
system delays have tended to focus on individual socio-demographic and structural 
health system factors rather than factors specific to diagnostic systems. Amongst the 
factors consistently associated with longer health system delays are rural (vs. urban) 
residence, [52,53,60,65,66,79] longer distance to health care facility, 
[53,54,62,63,66] the first visit at a more peripheral level or outside of the public 
health system.[54,60,61,68,75-77] In a meta-analysis (which included only two 
studies), longer distance to health care facility was associated with higher odds of 
health system delay (unadjusted odds ratio 1.87, 95% CI 1.38-2.53).[81] 
 
Qualitative studies in Zambia and South Africa have highlighted additional factors 
more specifically related to the diagnostic system.[82,83] The design of the health 
systems with respect to TB diagnosis, and particularly the need for referrals between 
different facilities, was identified as a key contributor to diagnostic delays. 
Additionally, other characteristics of the health system and health care providers as 
perceived by individual patients, such as quality of care, waiting times and staff 
attitudes were recognised as contributing to delays. One of the main contributory 
factors in diagnostic delay is the cost associated with proceeding through the 
diagnostic pathway. In urban Zambia and urban Malawi the cost attributable to 
achieving a TB diagnosis was equivalent respectively to 158% and 248% of mean 
monthly income.[84,85] The majority of these costs were not direct medical costs 
(e.g. fees for consultation, diagnostic tests and drugs) but related to lost income, 
transport to health facilities and food costs during care-seeking episodes. 
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2.1.3 Impact of diagnostic delay on individual morbidity and mortality 
Although it is generally understood that delays in TB diagnosis and treatment 
initiation lead to poorer individual outcomes, there are actually relatively few 
empirical data to support this and most retrospective studies of delays suffer from the 
potential for survival bias when exploring the impact of delays on individual 
outcomes.  
 
Autopsy studies have consistently demonstrated TB to be the most common cause of 
death or contributor to death in HIV-infected adults in sub-Saharan Africa.[86-93] In 
some studies that documented the clinical diagnosis of TB prior to death, around half 
of those who died from TB were not diagnosed prior to death.[87,92,93] None of 
these studies specifically documented diagnostic practices prior to death or were able 
to discriminate patient delays in accessing care from health system and diagnostic 
delays. Nevertheless, these studies highlight broadly the failure of existing TB 
diagnostic systems to prevent death in HIV-infected individuals.      
 
In terms of TB disease severity at diagnosis, the evidence of an association with 
diagnostic delay is quite limited. Again there are clear limitations to retrospective 
studies and the issue is complicated by the fact that more severe illness may impact 
on access to care. In rural South Africa, performance status (a measure of general 
well-being) was worse with increasing overall diagnostic delay, with an increase in 
median delay from 21 days for fully active individuals (performance status zero) to 
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90 days for symptomatic individuals unable to carry out work activities or confined 
to bed or chair (performance status 2-4).[94] In an urban referral centre in Uganda, 
lung cavitation and sputum smear grade were both associated with diagnostic delay, 
although the strength of the associations was not reported.[55] In Ghana, conversely, 
delay of three months or less vs. more than three months was not associated with any 
difference in the number of radiographic zones involved in pulmonary disease.[52]  
 
In The Gambia, the duration of delay was associated with mortality after treatment 
initiation, with a five-fold increased relative risk for mortality with delay >8 weeks 
compared to ≤8 weeks, although the number of deaths overall was small (n = 9) and 
the confidence intervals wide (relative risk 5, 95% CI 1.1-24).[70] In that study, the 
vast majority of the overall delay was reported to be attributable to health system 
delays as opposed to patient delay. In Limpopo, South Africa, overall delay was 
associated with mortality (for each month of treatment delay, odds ratio (OR) 1.64, 
95% CI 1.23-2.18).[94] This study did not disaggregate delays into patient and 
health system delays. In the Western Cape province of South Africa, health system 
delay ≥30 days was associated with higher mortality compared to delay <30 days 
(12% vs. 2%, p < 0.001).[73] All of these studies only captured deaths after the 
initiation of TB treatment and were not designed to identify other deaths during the 
diagnostic process and so may underestimate the impact of diagnostic delays. 
2.1.4 Impact of diagnostic delay on TB transmission 
In terms of the impact of diagnostic delay on TB transmission, there are no studies 
from sub-Saharan Africa specifically exploring this issue. However, there are data 
addressing this from the United States, China and Yemen.[95-97] These studies used 
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tuberculin skin test (TST) positivity as a measure of TB infection in contacts of 
pulmonary TB cases. This has the limitation in this context that TST positivity 
cannot discriminate between recent and remote exposure to M. tuberculosis and so 
may overestimate the extent of transmission from cases.  
 
In a study of 310 contacts of 54 US-born culture-positive pulmonary TB cases, TST 
positivity (≥5 mm) was associated with overall delay in the index case (TST+ 24% 
with delay <90 days vs. 40% with delay ≥90 days). After adjustment for smear 
positivity and radiological extent of disease in cases, this association was maintained 
(for delay ≥90 days vs. <90 days, adjusted odds ratio (aOR) 2.34, 95% CI 1.07 – 
5.12). In a parallel group in the same study, there was no association between delays 
for foreign-born cases and TST positivity in their close contacts, which could be 
explained by higher levels of baseline TST positivity (indicating latent TB infection) 
in foreign-born contacts.[95] In a second study from a rural region of southern 
China, TST positivity (≥10 mm) in 1360 household contacts of 393 smear-positive 
pulmonary TB cases was compared to TST positivity in 308 household contacts of 
90 controls without active TB disease. TST positivity was higher in the contacts of 
TB cases (23.3% vs. 9.7%). With the control contacts as a reference (and after 
adjustment for age, radiological evidence of cavitation, and sleeping site), aOR for 
TST positivity was 0.61 (95% CI 0.20-1.87) for delay ≤30 days, 1.86 (95% CI 1.20-
2.89) for delay 30-60 days, 2.37 (95% CI 1.56-4.11) for delay 60-90 days, and 2.27 
(95% CI 1.46-3.63) for delay >90 days.[96] Conversely, in a study of 505 smear-
positive pulmonary TB cases and their household contacts in Yemen, there was no 
association between delay in TB diagnosis and contact TST positivity (55.0% for 
delay <60 days vs. 56.6% for delay ≥60 days). This study had significant limitations, 
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in that contacts from only 18% of the cases were enrolled (n = 266), and a further 
10% of the contacts enrolled were lost to follow-up between administering and 
reading the skin test. Also, the relatively high overall TST positivity in a high burden 
area and low numbers of young children (usually the best indicators of recent 
transmission) might have limited the ability to detect differences in recent 
transmission.  
 
In terms of TB transmission within health care facilities, again there are few 
empirical data on the role of delayed diagnosis. In one study in 17 hospitals in 
Canada, crude rates of TST conversion among health care workers were higher in 
hospitals where diagnostic delay was common (defined as more than half of TB 
patients undiagnosed within 24 hours or more than 30% of TB patients treated after 
one week or more). However, this association was not maintained after adjustment 
for overall TB admission rates.[98] 
2.1.5 Impact of diagnostic delay on initiation of antiretroviral therapy for HIV-
infected individuals 
It is now well established that outcomes are improved with early vs. delayed 
initiation of antiretroviral therapy during anti-tuberculosis treatment for HIV-
infected individuals with active TB disease.[99-102] Delays in TB diagnostic 
processes during the pre-ART period, regardless of the presence or absence of TB 
disease, could potentially lead to the delayed initiation of antiretroviral therapy and 
expose individuals to risks of other opportunistic infections and death. A 
mathematical model suggested that a six-week delay in ART initiation, independent 
of any TB-associated factors, would increase mortality by around 20%.[103] There 
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are few data from routine programmatic settings that describe the impact of TB 
diagnostic delays on ART initiation. One pilot programme in South Africa exploring 
rapid initiation of ART in pregnancy found that although most women (118/130, 
91%) initiated ART on the day that treatment eligibility was determined, waiting for 
TB culture results was the most common reason for delayed ART initiation (5/12, 
42% of those with delay of one week or more).[104]    
 
2.2 TB diagnostic default 
One of the major limitations of studies exploring TB diagnostic delay is that they 
tend to retrospectively evaluate delays for TB cases that start treatment. This has the 
potential to miss additional drop-out during the diagnostic process, which might also 
contribute to adverse outcomes and ongoing transmission. 
 
The need for submission of multiple sputum specimens to maximise the diagnostic 
yield of smear microscopy creates the potential for default during the sputum 
submission process. International guidelines, until recently, recommended that TB 
suspects provide sputum specimens for smear microscopy on two consecutive days. 
Patient drop-out during this diagnostic process, i.e. failure to return on the second 
day has been reported to be around 7% in studies from Malawi and South 
Africa,[105,106] but much higher at 42% in a study from urban Uganda.[107] In the 
most comprehensive study, at primary health care facilities in Uganda, where 
completion of sputum examination was defined as having at least one positive or at 
least two negative sputum smears, 22% of suspects defaulted prior to 
completion.[108]  Only one study has explicitly described the proportion of TB 
suspects that collected results of smear microscopy. In that study from a central 
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urban hospital in Malawi, 26% (119/453) did not collect their result; the proportion 
was not significantly different for smear-positive and smear-negative participants 
(29% vs. 26%).[105] 
 
Another way to explore default is to look at the proportion of patients with a 
confirmed diagnosis who do not start treatment, often termed primary default. The 
14 studies that have addressed this issue for smear-positive pulmonary TB in sub-
Saharan Africa are summarised in Table 2-2.[105,106,108-119] Most of these 
studies were also included in a systematic review and meta-analyses first published 
in November 2013, during the preparation of this thesis. [120] The highest rates of 
primary default were reported in two studies located in central urban hospitals (59% 
in Malawi and 38% in Ghana).[105,116] In the other studies, the proportions were 
lower but there was still substantial heterogeneity, with primary default ranging from 
5 to 27%. The pooled proportion for all studies, determined as a random effects 
weighted proportion, was 18.3% (95% CI 12.6-23.9). In one South African study 
that reported separately for smear-positive and culture-positive cases, default was 
substantially higher amongst the smear-negative, culture-positive cases (11% smear-
positive cases vs. 34% smear-negative, culture-positive cases).[119] One additional 
study reported overall default of 20.6% (95% CI 16.4-25.5) for bacteriologically-
confirmed cases (smear-positive and smear-negative, culture-positive cases) but did 
not report disaggregated data for the smear-negative/culture-positive cases.[121]  
 
Interpretation of the results from most of these quantitative studies is subject to the 
limitation that results were based on linkage of records in laboratory registers and 
treatment registers at the same facility and that precise outcomes for all suspects 
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could not be ascertained. However, in the few studies where tracing of defaulters 
was attempted, relatively few people were documented to be receiving treatment 
(23% of those traced in a large, multisite study and 16% of those traced in a smaller 
study, both in Malawi).[110,112] Substantial proportions of the unregistered smear-
positive cases were discovered to have died: in four studies, 35%, 44%, 63% and 
79% of those with outcomes ascertained had died.[109,110,112,119] One study from 
South Africa which used qualitative methods to explore reasons for primary 
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Table 2-2 Studies of TB diagnostic default from sub-Saharan Africa (smear-positive pulmonary TB cases) 
Study Country Location Year N Proportion not registered on 
treatment (95% CI) 
Kemp 1996[105] Malawi Single urban hospital NS 69 59.4 (47.6-70.2) 
Glynn 1998[109] Malawi Single rural district 1986-1994 682 5.9 (4.3-7.9) 
Nyirenda 1998[110]  Malawi 41 hospitals 1997 3482 14.4 (13.3-15.6) 
Creek 2000[111]  Botswana 15 facilities, single city 1997 127 14.9 (9.7-22.3) 
Squire 2005[112]  Malawi 32 facilities, single district 2000 157 14.6 (9.9-21.1) 
Dembele 2006[113] Burkina Faso 6 districts 2001 31 22.9 (4.5-29.5) 
Botha 2008a[106]  South Africa 13 facilities, single district 2004-5 367 17.4 (13.8-21.7) 
Botha 2008b[119] South Africa 11 facilities, single province 2005 227 10.6 (7.2-15.3) 
Chadambuka 2011[114] Zimbabwe 2 districts 2005 112 26.8 (19.4-35.7) 
Davis 2011[108] Uganda 5 primary health care clinics 2009 81 23.5 (15.5-33.8) 
Uchenna 2012[115] Nigeria 20 facilities, 5 states 2009 323 16.9 (13.0-21.2) 
Afutu 2012[116] Ghana Single urban hospital 2009 84 38.1 (28.4-48.8) 
Bristow 2013[117] South Africa 24 facilities, single province 2009 794 11.7 (9.7-14.1) 
Claassens 2013[118] South Africa 122 facilities, 5 provinces 2009 122* 25* 
CI, confidence interval; NS, not stated 
* Number of facilities (number of individuals not stated); proportion defined as mean across all facilities
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default in those that were alive but not on treatment found that health system factors 
were responsible in the majority of cases: this included results not being available 
and incorrect information being given at the clinic.[119] Similarly, in Malawi 
participants and families of those that had died reported delays in receiving results, 
false reassurance after negative test results, and unaffordable costs of hospital 
attendance. [112] 
 
2.3 Delay and default during diagnosis of drug-resistant TB 
With traditional culture-based diagnostic modalities, lengthy health system delays in 
diagnosis of drug-resistant tuberculosis are common. As shown in Figure 2-2, most 
research in this area has been conducted in South Africa, where most studies have 
documented delays of between 10 and 16 weeks from sputum collection to initiation 
of MDR-TB treatment.[46,122-131] In the national referral hospital in Tanzania 
between 2009 and 2011, the time from sputum collection to initiation of MDR-TB 
treatment was even longer at almost nine months, although this was during the early 
phase of setting up a national treatment programme.[132]  
 
The one South African site that has reported shorter delays and indeed has 
documented a trend of reducing delays has been the non-governmental organisation 
(NGO)-supported community-based programme in Khayelitsha, South Africa. In this 
programme, the time between sputum collection and initiation of MDR-TB/XDR-TB 
treatment reduced from a median of 54 days in 2008 to 27 days in 2011.[131] This 
programme utilised the line probe assay on culture isolates for detection of drug 
resistance throughout this period so the shorter delays may relate more to improved 
access to treatment and other structural health system factors as the community-
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based treatment programme expanded.[131] Further evidence of the benefit of 
decentralisation of drug-resistant TB management was shown in two studies from 
KwaZulu-Natal where delays were significantly shorter in decentralised compared to 
centralised treatment strategies (84 days vs 106 days and 72 days vs. 93 
days).[122,124]  
 
Given these long delays with drug-resistant TB and with the knowledge that, in one 
observational study from KwaZulu-Natal,[126] the median survival from sputum 
collection for MDR-TB cases was 60 days, it is not surprising that there is 
substantial attrition prior to treatment (Table 2-3). Over an eight year period (2002-
2010) in one district of Western Cape Province, South Africa, 34% (256/747) of 
laboratory-confirmed MDR-TB cases did not start appropriate drug-resistant TB 
treatment.[133] Similarly in 2011 in Gauteng province, South Africa, 37% of the 
laboratory-confirmed MDR-TB cases did not start treatment: 12% died and  25% 
were lost to follow-up prior to the initiation of appropriate treatment.[134] The 
NGO-supported programme in the Khayelitsha township of Cape Town again has 
reported better results, with only 14% of laboratory-confirmed MDR/XDR-TB cases 
between 2008 and 2011 not starting drug-resistant TB treatment, largely due to death 
(8% overall).[131]  
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Figure 2-2 Diagnostic delay for multidrug-resistant tuberculosis (studies from sub-Saharan Africa with culture-based diagnostics). All times are from sputum collection to 
MDR-TB treatment initiation unless otherwise stated 
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The impact of treatment delays on treatment outcomes for drug-resistant TB has not 
been well studied. Globally, treatment outcomes for MDR-TB are poor: meta-
analyses have estimated overall treatment success (defined as cure or treatment 
completion) of 54-62%.[135-137] In South Africa, treatment outcomes seem to be 
quite similar across different programmes, with treatment success in 44-49% of 
MDR-TB cases.[123,131,133,138,139] The only other study from sub-Saharan 
Africa to report final treatment outcomes for MDR-TB cases was an NGO-supported 
integrated TB/HIV programme in Lesotho, which demonstrated treatment success in 
62%.[140] Although studies have not formally explored the impact of pre-treatment 
delay on MDR-TB outcomes, there is evidence from Africa and other settings that 
sputum smear positivity increases the risk of mortality,[141,142] and that lung 
cavitation increases the risk of treatment failure.[142] 
 
2.4 Diagnostic strategies to reduce delays and default 
2.4.1 Alternative sputum collection strategies for microscopy 
To address the issue of patient drop-out during the diagnostic process, alternative 
strategies for sputum sampling have been explored. ‘Spot’ specimens are collected 
when a patient is at a health care facility whereas ‘morning’ specimens are collected 
in the early morning, often at home, on the basis that they tend to have a higher yield 
than specimens collected at other times.[143] A large cluster randomised trial 
conducted in Ethiopia, Nigeria, Nepal and Yemen compared the standard two-day 
‘spot-morning-spot’ scheme for collecting three specimens to an alternative strategy 
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of ‘spot-spot-morning’ (referred to as frontloading).[144] Sensitivity and specificity 
against the reference standard of solid culture were comparable under the two 
schemes. Diagnostic default was reduced by frontloading - a greater proportion of 
suspects provided the first two samples in the frontloading scheme than in the 
standard scheme (97.6% vs. 94.2%, p < 0.01).  
 
Separate analyses have also been conducted on single-country data from the same 
cluster randomised trial. For 243 suspects in Ethiopia, two sputum specimens 
collected on the first day had a similar yield (for diagnosis based on at least one 
positive smear) to two specimens collected on consecutive days (94.2% vs. 98.1%, p 
> 0.5).[145] For 224 suspects in Nigeria, two sputum specimens collected on the first 
day had similar sensitivity to the standard ‘spot-morning-spot’ approach (56.4% of 
culture-positives vs. 57.7%, p > 0.5).[146] These results were collated in a meta-
analysis and informed a change in WHO policy to recommend collection of two spot 
specimens from the same day.[147,148] 
 
A more recent study has taken this single-day approach further and compared the 
yield from two smears done from a single sputum specimen to two smears from two 
samples collected in a ‘spot-morning’ approach.[149] The sensitivity using standard 
light microscopy (with culture as the reference standard) was 55% from the single 
specimen and 56% from the two specimens. The use of light-emitting diode (LED) 
microscopy further improved the sensitivity of both approaches but there remained 
no significant difference between the one specimen and two specimen approaches 
(61% vs. 64%). 
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Table 2-3 Pre-treatment default for multidrug-resistant TB cases diagnosed through culture-based methods 
Study Country Location Year N Proportion not registered on 
treatment (95% CI) 
Comments 
Shean 2008 [133]  South Africa Western Cape 1992-2002 747 34.3 (31.0-37.8) 144 (19%) died/defaulted prior to treatment 
Ebonwu 2013 [134] South Africa Gauteng 2011 942 37.0 (34.0-40.2) 109 (12%) died prior to treatment 
Naidoo 2014* [130] South Africa Western Cape 2008-2011 414 9.4 (7.0-12.6)  
Cox 2014 [131] South Africa Khayelitsha 2008-2011 874 13.7 (11.6-16.2) 73 (8%) died prior to treatment 
CI, confidence interval 
* Also incorporated line probe assay testing directly on smear-positive sputum specimens 
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These approaches to simplify the diagnostic process have the potential to reduce 
default during the diagnostic process. However, there is no empirical evidence that 
such strategies lead to more TB cases initiating treatment in a timely fashion. A 
simple decision analysis model suggested that same-day sputum collection on its 
own would have relatively limited impact on treatment initiation, whereas the 
addition of same-day testing and result provision could potentially have a greater 
impact, through reduction in diagnostic default.[150] Despite the fact that sputum 
microscopy can be performed at peripheral levels of the health system and, at least in 
theory, can be performed on the same day as sputum collection, there have been no 
studies exploring the impact of same-day point-of-care microscopy.  
2.4.2 Point-of-care diagnostics 
In high HIV prevalence settings, chest X-ray is commonly used for diagnosis of 
smear-negative pulmonary tuberculosis. The impact of a digital X-ray service placed 
at an urban health centre in Zambia was evaluated with a ‘before-after’ study design 
using routine notification data.[151] Prior to the introduction of the point-of-care 
digital X-ray service, smear-negative patients suspected of having TB would be 
referred to a tertiary referral centre for chest X-ray. In the period after the 
introduction of the digital X-ray service at the health centre, there was a reduction in 
treatment delay (defined as treatment initiation ≥7 days from sputum submission) for 
all TB patients from 18.2% to 13.2% (adjusted odds ratio 0.6, 95% CI 0.4-0.9), 
without any increase in the proportion of X-rays performed.  Although there are 
limitations to diagnosis based on chest X-rays, in that microbiological confirmation 
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is not obtained, this provided some evidence of the potential impact of point-of-care 
diagnostic strategies. 
2.4.3 Traditional culture-based techniques 
Mycobacterial culture is considered the gold standard for the laboratory diagnosis of 
active M. tuberculosis disease. The introduction of culture into diagnostic algorithms 
has the potential to increase the diagnostic yield compared to microscopy alone, 
especially in HIV-infected individuals.[152-155] However, evidence for the 
programmatic impact of culture-based technologies is relatively weak.  
 
Nested within the TB/HIV in Rio (THRio) study of isoniazid preventive therapy, one 
study investigated the impact of culture within a screening algorithm in 217 HIV-
infected adults.[156] There were 33 cultures positive for M. tuberculosis and an 
additional 17 positive for non-tuberculous mycobacteria (NTM). Of the smear-
negative, culture-positive cases, 74% (17/23) started TB treatment but more than 
one-third of these (6/17) had started treatment on clinical grounds before the 
availability of the culture result. There were no details on precise timings of 
treatment in this study. A comparable number of individuals with a negative culture 
(16/167) were commenced on treatment on clinical grounds.[156] These cases might 
reflect inappropriate treatment of people without TB disease, although it is 
recognised that some cases of active pulmonary TB will have culture-negative 
disease and this study did not seek to determine the appropriateness of treatment in 
these cases.[157,158]  
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In a retrospective study of 150 sputum culture-positive and 150 culture-negative 
individuals from a tertiary hospital in southern India, the turnaround time for solid 
culture (Lowenstein-Jensen media) was 55 days and turnaround time for phenotypic 
drug susceptibility testing (DST) was 109 days.[159] Only two cases initiated 
treatment on the basis of the culture result; the majority of the culture-positive cases 
had already been commenced on treatment prior to availability of the culture result. 
Furthermore, although 25% (30/119) of those with DST results had evidence of first-
line anti-TB drug resistance, only four individuals had their treatment altered on the 
basis of the DST result.  
 
The one randomised controlled trial (RCT) to compare a diagnostic strategy of 
sputum smear microscopy against an intensified strategy of sputum smear 
microscopy plus liquid culture was performed in Tanzania.[160] This was a small 
study which in retrospect was underpowered, with only 47 patients analysed for the 
primary outcome of correct treatment at 8-week follow-up. There were also complex 
methodologies to evaluate the primary endpoint, as the presence or absence of TB 
disease incorporated not only microbiological results but also independent clinical 
assessment. Correct treatment was more likely at eight weeks with the intensified 
strategy than with standard strategy, although this did not reach statistical 
significance (100% vs. 88%, p = 0.14). All TB cases in both arms were on 
appropriate treatment; the difference was due to three participants without TB 
disease being on TB treatment at eight weeks in the standard arm. The small 
numbers and the fact that 36% of participants died or were lost to follow-up prior to 
eight weeks limit any major conclusions from the data.   
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The available evidence would therefore suggest that, although culture-based 
techniques improve diagnostic yield for tuberculosis, the real world impact of this on 
TB treatment may be limited, especially where treatment based on clinical and 
radiological grounds is common. Given the delays inherent with culture-based 
techniques, it is unsurprising that these do not reduce delays and default prior to 
treatment. Indeed there is some evidence (discussed in section 2.2) that default prior 
to treatment is higher for cases positive only on culture, suggesting that as the 
separation in time from specimen collection to result expands, the risk of default 
increases. It is plausible that the main programmatic impact of culture-based 
methods has been more restricted to enabling the detection and appropriate treatment 
of drug-resistant TB disease. 
2.4.4 Microscopic-observation drug susceptibility (MODS) assay 
The microscopic-observation drug susceptibility (MODS) assay is a low-cost and 
rapid culture method which involves direct observation by microscopy of M. 
tuberculosis growth in liquid culture medium and allows for direct drug 
susceptibility testing by observation of the growth of the organism in the presence of 
certain anti-TB drugs.[161,162] Numerous studies have demonstrated good 
diagnostic accuracy in a variety of different settings and have consistently shown 
that results can be obtained in significantly shorter time than with conventional 
culture and DST methods.[162-175] In a meta-analysis of nine studies, the mean 
turnaround time for MODS was 9.9 days.[176] One large study in Peru reported an 
initial time to detection of M. tuberculosis of seven days by MODS compared to 13 
days for liquid culture and 26 days for solid culture. Moreover, the overall time to 
detection of drug resistance was also seven days by MODS compared to 22 days by 
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the automated liquid culture system (MB/BacT) and 68 days by indirect DST on 
solid culture media (proportion method).[163] In a study from an area with high 
levels of drug-resistant TB in KwaZulu-Natal, time to diagnosis of MDR-TB was 
seven days by MODS compared to 70 days by liquid or solid culture with indirect 
DST.[174] Neither of these studies investigated the impact on actual diagnosis and 
treatment of TB and MDR-TB as results from the MODS assay were not used for 
patient management. 
 
In 2011, the World Health Organization recommended the use of MODS but only in 
specific conditions, namely in reference laboratories under strict laboratory 
protocols, and this was seen as an interim solution while capacity for liquid culture 
and genotypic methods expanded. [177] The limited approval was also based on the 
fact that conventional culture/DST would still be required to detect additional 
resistance (i.e. XDR-TB) and that biosafety level 2 facilities would be required, thus 
generally requiring use in centralised laboratories. The approval of MODS was 
largely on the basis of the diagnostic accuracy data and again there were limited data 
regarding impact on patient-relevant outcomes. One study in Peru did explore the 
impact of MODS, by determining outcomes for patients in a programme where 
physicians had access to MODS testing as part of routine patient care in addition to 
conventional culture methods.[178] In this study, 63 individuals had a positive 
MODS culture, and 14 (22%) of those had MDR-TB. MODS provided the first 
confirmation of TB diagnosis in 44 of 58 cases (76%) with complete clinical 
information and the first drug susceptibility information in 48 cases (83%). Although 
the MODS result should have led to a change in patient management in 24 cases, the 
appropriate change happened in only 16 of those cases (67%). Furthermore, lengthy 
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times to initiation of treatment (42 days from the positive MODS result) and to 
change of treatment in drug-resistant cases (48 days) offset any potential benefit 
from the rapid diagnosis. This illustrates the fact that theoretical benefits of 
diagnostics may not translate into positive impact when implemented in real world 
TB programmes.  
2.4.5 Line probe assays 
Line probe assays (LPA) are molecular diagnostic tests for the rapid detection of 
drug resistance that can be performed on smear-positive specimens or on culture 
isolates of M. tuberculosis. Line probe assays were recommended for 
implementation by the World Health Organization in 2008 on the basis of studies 
showing good diagnostic accuracy, comparable to culture-based phenotypic 
DST.[179] Several studies from different settings have since supported the evidence 
of good diagnostic performance.[180-190] Again, however, there are relatively few 
data describing the impact on patient-relevant outcomes.  
 
One pre- and post-implementation study in Delhi, India compared the use of solid 
culture and phenotypic DST (n = 51) to the LPA (Genotype MTBDRplus assay), 
used on smear-positive and culture-positive samples (n = 83).[191] In this study, the 
proportion of cases diagnosed with MDR-TB that initiated treatment increased from 
61% with culture/DST to 88% with the use of LPA. For those that commenced 
MDR-TB treatment, the median time from sputum collection to initiation of 
treatment was reduced from 157 days with solid culture & DST to 38 days with LPA 
(p < 0.001), predominantly due to a reduction in total laboratory time from 107 days 
to 5 days (p < 0.0001). With the use of LPA, the laboratory time only accounted for 
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13% of the overall time to treatment initiation and delays in submission of samples, 
reporting results, and initiating treatment became relatively more important.  
 
In a similar quasi-experimental pre- and post-LPA implementation study in Tbilisi, 
Georgia, 72 smear-positive MDR-TB cases diagnosed using culture & phenotypic 
DST were compared with 80 cases diagnosed using the Genotype MTBDRplus assay 
directly on sputum.[192] The group diagnosed after the introduction of LPA had a 
shorter time to commencing MDR-TB treatment (18.2 vs. 83.9 days, p <0.01), 
shorter time spent on a drug-susceptible TB ward (10.0 vs. 58.3 days, p <0.01), and a 
lower likelihood of receiving a first-line drug regimen, which could lead to amplified 
drug resistance (78% vs. 99%, p <0.01). There was also some evidence that 
treatment outcomes were improved following the implementation of the LPA, with a 
higher proportion of cases achieving sputum culture conversion after 24 weeks of 
treatment (86% vs. 63%, p = 0.01). The association between LPA use and sputum 
culture conversion was maintained after adjustment for age, prior history of TB and 
the presence of ofloxacin resistance (adjusted hazard ratio [aHR] 4.24, 95% CI 2.7-
6.8). 
 
In a study of 42 MDR-TB cases managed at a single centre in the United Kingdom 
over a 22-year period, the use of a line probe assay (INNO-LiPA) directly on smear-
positive sputum specimens, compared to conventional culture/DST, shortened the 
time to diagnosis of MDR-TB from 51 days to 9 days.[193] Another small study of 
MDR-TB suspects in Latvia, comparing outcomes after implementation of the 
INNO-LiPA assay (n = 23) to a historical cohort using liquid culture/DST (n = 48), 
found that the time to treatment initiation for rifampicin-resistant cases was shorter 
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with implementation of the LPA (median 14 days vs. 40 days).[194] There was no 
difference between the two groups in final treatment outcomes (cure achieved in 
52% in the LPA group vs. 60% in the liquid culture group), although the small 
number would have limited the power to detect any difference. 
 
In one before-after study from Northern Province in South Africa, although the 
introduction of the MTBDRplus assay shortened the laboratory turnaround time 
from a median of 52 days to 26 days, there was a fairly modest reduction in the 
overall time from sputum collection to MDR-TB treatment initiation (median 78 
days pre-implementation (IQR 52-93) vs. 62 days post-implementation (IQR 32-86), 
p = 0.05).[128] In a retrospective study from Western Cape, South Africa, also 
exploring outcomes prior to and following implementation of the Genotype 
MTBDRplus in routine practice, there was a somewhat greater reduction from 
median 80 days (IQR 62-100) to 55 days (IQR 38-78).[129]  
 
Collectively these studies highlighted that, especially with drug-resistant 
tuberculosis, other health system factors contribute substantially to the delays and 
that the impact of new diagnostics may depend to a great extent on the wider 
functioning of the health system.[195] 
 
2.5 Potential impact of new tuberculosis diagnostics 
It was postulated a few years ago that a test more sensitive than sputum microscopy 
for TB would be the diagnostic intervention which would alleviate the greatest 
burden of infectious disease in the developing world.[196] More specifically, one 
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mathematical model based on the four WHO regions with the highest number of TB 
deaths annually (Africa, Eastern Mediterranean, Southeast Asia and Western Pacific) 
suggested that a new rapid diagnostic test with 100% sensitivity and 100% 
specificity could prevent 359 000 TB deaths annually (approximately one quarter of 
all TB deaths), relative to smear microscopy, if implemented within existing health 
care infrastructure.[197] If the test was universally accessible through new delivery 
channels, requiring no infrastructure, then the impact could be even greater with 625 
000 deaths prevented annually (equivalent to 36% of all TB deaths based on 2004 
data). With this model, the impact of loss to follow-up within the diagnostic process 
was particularly marked, with a reduction in the lives saved by almost half with 20% 
loss to follow-up (failure to provide all samples or to return for results) under the 
universal access scenario.  
 
Other models have derived fairly consistent estimates of mortality reductions of 17-
23% from a more sensitive rapid TB diagnostic, despite exploring different 
epidemics and different timescales.[198-200] In one model the estimated reduction 
in mortality achievable by implementation of a new diagnostic test was equivalent in 
magnitude to that expected from a novel vaccine or an optimised 2-month treatment 
regimen for active disease.[198] One model based on the TB epidemic in Tanzania 
demonstrated that the impact of Xpert MTB/RIF on TB incidence would be greater if 
there was a reduction in diagnostic delays and default and if it improved access to 
care.[201] Another model has highlighted that improved diagnostic sensitivity in 
itself has the most significant impact on diagnostic delays, suggesting that a 10% 
increase in test sensitivity could lead to a 3-5 day reduction in diagnostic delay.[51]  
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2.6 Summary 
Delays in tuberculosis diagnosis are common in Africa and health system delays 
contribute as much if not more than patient delays, although this differs considerably 
depending on the setting and the diagnostic systems in place. Furthermore, a 
substantial proportion of individuals (around one in five) diagnosed with TB do not 
start treatment, although the reasons for this have not been fully elucidated. Although 
historically there has been a tendency to consider patient-related factors responsible 
for delays and default, the evidence suggests a major role for health system 
factors.[202,203] The problems of delays and default are inherent in diagnostic 
systems reliant on tests with poor sensitivity that are removed from the point at 
which patients access care. The problems of delay and default are magnified in the 
context of drug-resistant TB disease due to laboratory delays with culture-based 
diagnostics. Although there is limited direct evidence of the consequences of delay 
and default, it is highly plausible that they impact adversely on individual outcomes 
and contribute to ongoing TB transmission.  
 
Whilst diagnostic technologies and strategies have been developed with the potential 
to address the problems of delay and default, there is actually little empirical 
evidence of real world impact. This is at least partly due to the paucity of high 
quality diagnostic research studies. Mathematic modelling has highlighted that 
whilst a diagnostic test with better sensitivity than smear microscopy could have a 
significant impact on TB mortality and TB incidence, the impact would be greatest if 
used within a strategy whereby access to care was good and delays and default were 
minimised.   
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Chapter 3 Xpert MTB/RIF assay 
3.1 Overview 
The development of molecular tools, in particular the GeneXpert system and Xpert 
MTB/RIF assay, offers a new opportunity to tackle some of the problems associated 
with smear microscopy and culture-based diagnostic systems. It is based on a semi-
quantitative in-vitro polymerase chain reaction (PCR) and uses molecular beacon 
technology for the detection of M. tuberculosis complex and rifampicin resistance 
(through detection of mutations in rpoB gene).[204-210] It is an automated, closed 
cartridge system with results available within two hours. A key feature of the assay 
is the low bioaerosol infection risk which suggests that the test could be used outside 
the normal laboratory setting and without bio-safety facilities.[211] Further details of 
the system are given in Appendix A.  
 
3.2 Analytic performance 
Analytic studies were performed using the Xpert MTB/RIF assay on twenty sputum 
samples spiked with known quantities of M. tuberculosis.[44] The limit of detection 
(LOD) based on these studies was 131 colony forming units (cfu)/ml (95% CI 106.2-
176.4). This represents a LOD almost comparable to culture (10-100 cfu/ml) and 
significantly more sensitive than sputum smear microscopy (~10 000 cfu/ml).[212-
214] Additional studies with similarly spiked sputum samples found that the assay 
detected M. tuberculosis in all samples containing 103-107 cfu/ml and in five of six 
samples containing 100 cfu/ml.[215] The ability to detect genetically different M. 
tuberculosis strains has been tested and the assay detected all 79 distinct strains 
selected for testing.[44] Specificity was investigated using twenty different non-
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tuberculous mycobacterial (NTM) species and 89 other respiratory tract pathogens 
(bacteria, fungi and viruses). No significant cross-reaction was seen with the NTM 
species or with other respiratory tract pathogens.[44,215]    
 
3.3 Diagnostic accuracy for detection of Mycobacterium tuberculosis 
The diagnostic accuracy of the Xpert MTB/RIF assay has now been reported from a 
number of different studies in a variety of different settings. The performance of a 
single Xpert MTB/RIF assay for the detection of M. tuberculosis in sputum and 
other respiratory samples (such as fluid from bronchoalveolar lavage) is summarised 
in Tables 3-1 & 3-2 and Figures 3-1 to 3-4.[44-46,216-248] Excluded from these 
summaries are studies involving only paediatric populations[249-255]; studies 
involving only non-respiratory specimens (or where results for respiratory and non-
respiratory specimens were not reported separately)[256-269]; studies where 
specimens were pre-screened by smear microscopy or another PCR 
method[270,271]; and studies where culture was not the reference standard or where 
there was no formal reference standard.[272,273] In 27 prospective studies utilising 
fresh collected sputum samples and where full results were presented, the pooled 
sensitivity of a single Xpert compared to a reference standard of M. tuberculosis 
culture (calculated as a random effects weighted proportion) was 87% (95% CI 86-
88) and specificity was 98% (95% CI 98-98).[45,46,216-240] There was substantial 
heterogeneity in sensitivity between studies, partly reflecting the different study 
populations and the different specifications for the culture reference standard. The 
pooled sensitivity for smear-positive specimens (from 19 studies) was 98% (95% CI 
97-98) and for smear-negative specimens (from 20 studies) was 70% (95% CI 67-
73). 
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Table 3-1 Diagnostic accuracy of a single Xpert MTB/RIF test for detection of M. tuberculosis in fresh sputum or other respiratory specimens from prospectively 
enrolled TB suspects 
 
Study Location Specimens N Reference standard  Sensitivity  Specificity 
     Overall Smear 
positive 
Smear 
negative 
 
Boehme 2010[45] Multicentre Sputum 
 
1341 Liquid (x2) or solid 
(x2) culture 
92.2 
(675/732) 
98.2 
(551/561) 
72.5 
(124/171) 
99.2 
(604/609) 
Boehme 2011[46] Multicentre Sputum 3909 Culture‡ 90.3 
(933/1033) 
98.3 
(637/648) 
76.9 
(296/385) 
99.0 
(2846/2876) 
Bowles 2011[216] Netherlands Respiratory specimens 88 Liquid culture 93.8 
(60/64) 
100 
(40/40) 
83.3 
(20/24) 
95.8 
(23/24) 
Ioannidis 2011[217] Greece Respiratory  specimens 66 Liquid or solid culture 90.6 
(29/32) 
- - 94.1 
(32/34) 
Lawn 2011[218]* South Africa Sputum (including 
induced specimens) 
445 Liquid culture 73.3 
(55/75) 
100 
(21/21) 
63.0 
(34/54) 
99.2 
(367/370) 
Malbruny 2011[219] France Sputum 18 Liquid or solid culture 100 
(5/5) 
100 
(4/4) 
100 
(1/1) 
100 
(13/13) 
Scott 2011[220] South Africa Sputum 177 Liquid culture 86 - - 97 
Teo 2011[221] Singapore Respiratory specimens 122 Liquid or solid culture 90.3 
(56/62) 
100 
(43/43) 
68.4 
(13/19) 
91.7 
(55/60) 
Al-Ateah 2012[222] Saudi Arabia Respiratory specimens 172 Liquid or solid culture 95.5 
(42/44) 
- - 100 
(128/128) 
Balcells 2012[223]* Chile Sputum 160 Liquid or solid culture 91.7 
(11/12) 
100 
(8/8) 
75.0 
(3/4) 
99.3 
(147/148) 
Barnard 2012[224] South Africa Sputum 68 Liquid culture 71.2 
(37/52) 
90.5 
(19/21) 
58.1 
(18/31) 
100 
(16/16) 
 
 
 
 
59 
Study Location Specimens N Reference standard  Sensitivity  Specificity 
     Overall Smear 
positive 
Smear 
negative 
 
Carriquiry 2012[225]* Peru Sputum 131 Liquid or solid culture 97.8 
(44/45) 
100 
(31/31) 
92.9 
(13/14) 
97.7 
(84/86) 
Ntinginya 2012[226]† Tanzania Sputum 33 Liquid or solid culture 100 
(5/5) 
100 
(3/3) 
100 
(2/2) 
100 
(28/28) 
O’Grady 2012[227] Zambia Sputum 643 Liquid culture 86.1 
(173/201) 
96.2 
(102/106) 
74.7 
(71/95) 
95.7 
(420/442) 
Yoon 2012[228] Uganda Sputum 436 Liquid or solid culture 78.9 
(187/237) 
98.1 
(153/156) 
42.0 
(34/81) 
95.5 
(190/199) 
Al-Darraji 2013[229] Malaysia Sputum 125 Liquid culture 53.3 
(8/15) 
- - 100 
(110/110) 
Bates 2013[230] Zambia Sputum 94 Liquid culture 80.8 
(21/26) 
NR NR 97.1 
(66/68) 
Bunsow 2013[231] Spain Respiratory specimens 290 Liquid or solid culture 97.1 
(67/69) 
100 
(60/60) 
71.4 
(5/7) 
98,6 
(218/221) 
Hanrahan 2013[232] South Africa Sputum 551 Liquid culture 65.6 
(42/64) 
- - 99.6 
(487/489) 
Kurbatova 2013[233] Russia Sputum 226 Liquid or solid culture 95.3 
(102/107) 
100 
(91/91) 
68.8 
(11/16) 
86.0 
(104/121) 
Kwak 2013[234] South Korea Sputum 661 Liquid or solid culture 79.5 
(124/156) 
88.9 
(56/63) 
73.1 
(68/93) 
100§ 
(505/505) 
Park 2013[235] South Korea Respiratory specimens 320 Liquid or solid culture 67.9 
(19/28) 
66.7 
(10/15) 
69.2 
(9/13) 
97.9 
(286/292) 
Van Rie 2013[236] South Africa Sputum 158 Liquid culture 66.7 
(10/15) 
100 
(3/3) 
58.3 
(7/12) 
99.3 
(142/143) 
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Study Location Specimens N Reference standard  Sensitivity  Specificity 
     Overall Smear 
positive 
Smear 
negative 
 
Walusimbi 2013[237] Uganda Sputum 369 Liquid culture 48.8ǁ 
(21/43) 
- 48.8 
(21/43) 
95.1 
(310/326) 
Zmak 2013[238] Croatia Respiratory specimens 118 Liquid or solid culture 85.7 
(6/7) 
100 
(3/3) 
75.0 
(3/4) 
100 
(111/111) 
Sohn 2014[239] Canada Induced sputum 457 Liquid culture 45.8 
(11/24) 
85.7 
(6/7) 
29.4 
(5/17) 
99.8 
(432/433) 
Theron 2014[240] Multicentre Fresh sputum 729 Liquid culture 83.2 
(154/185) 
- - 95.1 
(517/544) 
* HIV-infected TB suspects only 
† Household contacts of index cases with smear-positive pulmonary TB; not clear if all symptomatic 
‡ Number and type of culture (liquid/solid) varied according to centre 
§ 20 Xpert positive/culture negative cases excluded from diagnostic accuracy estimations (due to clinical and radiological features of TB) 
ǁ Only smear-negative suspects included in study 
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Table 3-2 Diagnostic accuracy of a single Xpert MTB/RIF for the detection of M. tuberculosis in stored sputum or other respiratory specimens 
 
 
* Exact culture method not reported
Study Location Samples N Reference 
standard 
 Sensitivity  Specificity 
     Overall Smear 
positive 
Smear 
negative 
 
Helb 2010[44]  Vietnam Frozen sputum  107 Liquid or solid 
culture 
81.7 
(67/82) 
100 
(29/29) 
72 
(38/53) 
100 
(25/25) 
Armand 2011[241] France Frozen respiratory 
specimens 
117 Liquid or solid 
culture 
78.6 
(44/56) 
100 
(28/28) 
57.1 
(16/28) 
100 
(10/10) 
Marlowe 2011[242]  US Fresh and frozen 
respiratory specimens 
216 Culture* 89.2 
(116/130) 
97.7 
(85/87) 
72.1 
(31/43) 
95.3 
(82/86) 
Miller 2011[243] US Frozen respiratory 
specimens 
89 Liquid or solid 
culture 
93.1 
(27/29) 
100 
(24/24) 
60.0 
(3/5) 
96.7 
(58/60) 
Moure 2011[244] Spain Frozen respiratory 
specimens 
105 Liquid or solid 
culture 
78.2 
(61/78) 
- - 100 
(27/27) 
Rachow 2011[245] Tanzania Frozen sputum  259 Liquid or solid 
culture 
88.4 
(61/69) 
98.0 
(50/51) 
61.1 
(11/18) 
95.8 
(182/190) 
Theron 2011[246]  South Africa Frozen sputum 480 Liquid culture 78.7 
(111/141) 
94.7 
(89/94) 
46.8 
(22/47) 
94.4 
(320/339) 
Zeka 2011[247] Turkey Frozen respiratory 
specimens 
253 Liquid or solid 
culture 
86.2 
(50/58) 
100 
(27/27) 
74.2 
(23/31) 
99.4 
(194/195) 
Antonenka 2013[248] Germany Frozen respiratory 
specimens 
121 Liquid or solid 
culture 
74.6 
(50/67) 
94.1 
(16/17) 
68.0 
(34/50) 
96.1 
(51/53) 
Theron 2014[240] Multicentre Frozen sputum 1388 Liquid culture 83.2 
(292/351) 
- - 91.8 
(952/1037) 
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Figure 3-1 Sensitivity of a single Xpert MTB/RIF for detection of M. tuberculosis in prospectively 
enrolled TB suspects with culture as a reference 
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Figure 3-2 Specificity of a single Xpert MTB/RIF for detection of M. tuberculosis in prospectively 
enrolled TB suspects with culture as a reference 
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Figure 3-3 Sensitivity of a single Xpert MTB/RIF for detection of smear-positive M. tuberculosis in 
prospectively enrolled TB suspects with culture as a reference 
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Figure 3-4 Sensitivity of a single Xpert MTB/RIF for detection of smear-negative M. tuberculosis in 
prospectively enrolled TB suspects with culture as a reference 
 
 
 
 
The sensitivity and diagnostic yield of sputum smear microscopy are reduced in 
HIV-infected individuals.[274,275] Whether HIV infection also impacts on the 
performance of the Xpert MTB/RIF assay has been explored in eight studies (Table 
3-3).[45,46,220,227,228,230,240,246] There is some evidence from these studies of 
reduced sensitivity for detection of M. tuberculosis in HIV 
infection[45,46,230,240,246]; although two studies showed no difference in 
sensitivity,[220,228] and one study amongst hospital inpatients in Zambia 
demonstrated a modest increase in sensitivity amongst HIV-infected 
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participants.[227] There was also some evidence to suggest a small reduction in 
specificity amongst HIV-infected subjects.[220,228,230,240,246] There is 
conflicting evidence around the effect of CD4+ T-cell count on the sensitivity of 
Xpert MTB/RIF. Whilst two prospective studies reported higher sensitivity with 
lower CD4+ T-cell count,[218,276] one study using archived sputum specimens 
reported reduced sensitivity in those individuals with low CD4+ T-cell count (<200 
cells/µl vs. ≥200 cells/µl).[246] However, none of these diagnostic studies was 
powered specifically to detect differences in Xpert MTB/RIF performance by CD4+ 
T-cell count. 
 
3.4 Diagnostic accuracy for the detection of rifampicin resistance 
The Xpert MTB/RIF assay detects the presence of the common mutations in the 
rpoB gene that are found in >95% of rifampicin-resistant M. tuberculosis 
strains.[277] The performance of a single Xpert MTB/RIF test performed on fresh 
sputum samples for the detection of rifampicin resistance compared to a reference 
standard of phenotypic drug susceptibility testing (DST) and/or line probe assay 
(LPA) is shown in Table 3-4 and Figures 3-5 & 3-6. Across 15 studies, the pooled 
sensitivity of a single Xpert for the detection of rifampicin resistance was 93% (95% 
CI 90-95) and specificity was 98% (95% CI 97-98). It should be noted that the 
majority of studies, other than the two large multicentre studies and two other studies 
specifically in drug-resistant TB suspects, included fewer than 20 rifampicin-
resistant cases. 
 
The specificity of the assay with regards to rifampicin resistance has been of concern 
since the introduction of the Xpert assay.[278] The specificity documented in the 
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multicentre validation study of 98.1% was with a reference standard of phenotypic 
DST.[45] However, after taking rpoB gene sequencing results into account, 
specificity was reported as 100%, suggesting that the test had correctly identified the 
presence of rpoB mutations but that in some cases these were not associated with 
phenotypic rifampicin resistance. In the subsequent demonstration study, concerns 
about false-positive resistance results led to change in the software definitions during 
the study: resistance was defined on the basis of a difference in cycle threshold (∆Ct) 
between two probes of greater than 3.5 cycles and this was changed to 5 cycles. As a 
result, specificity improved from 96.2% (779/810) to 98.3% (796/810), although 
sensitivity was reduced as a result from 96.8% (242/250) to 94.4% (236/250). 
Subsequently, additional cartridge and software changes were made to improve the 
accuracy of the assay and new Xpert kits (version G4) were introduced in 
2012.[279,280]  
 
In the one study from India showing very low sensitivity for the detection of 
rifampicin resistance (64.4%) using the most recent Xpert MTB/RIF assay (version 
G4), the 21 discordant specimens (Xpert rifampicin susceptible/LPA rifampicin 
resistant) were examined further by phenotypic DST and genome sequencing.[281] 
In 20 specimens phenotypic DST confirmed rifampicin resistance, and in most of 
those (18/20) sequencing of the rpoB gene identified characteristic mutations 
associated with rifampicin resistance (L533P and S531L). It is not clear whether the 
false negative Xpert results were due to strain diversity and altered probe binding, 
technical assay issues, or possibly mixed populations of susceptible and resistant M. 
tuberculosis bacilli. It is noteworthy that the majority of study participants were on 
failing re-treatment regimens at the time of enrolment, raising the strong possibility 
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of mixed populations with evolving resistance in vivo. It has been documented that 
the assay only reliably detects the L533P mutation if 100% of the DNA population 
carries the mutation.[215] The problem of false negative Xpert rifampicin results for 
strains carrying the L533P mutation has also been reported elsewhere.[282]  
 
In two other studies, specimens showing discordance between Xpert result and 
phenotypic DST (Xpert resistant/phenotypic DST susceptible) were also examined 
by rpoB gene sequencing. In the one discordant case in the clinical validation study 
and in nine of 15 discordant cases in the multicentre validation study, common 
mutations associated with rifampicin resistance were identified through rpoB 
sequencing.  
 
It is now well documented that various genotypic and phenotypic DST methods can 
give discordant results for rifampicin resistance.[282-290] It is also documented that 
adverse clinical outcomes can occur with M. tuberculosis strains harbouring rpoB 
mutations but with phenotypic susceptibility to rifampicin.[284,290] The diagnostic 
accuracy of Xpert MTB/RIF for rifampicin resistance therefore needs to be 
interpreted in the context of the uncertainty over the reference standard and the true 
clinical significance of genotypic and phenotypic resistance. As molecular methods 
replace culture-based methods, there is a need for research to better understand how 
genotypic and phenotypic resistance predict treatment outcomes, for not only 
rifampicin but also other established and novel anti-TB drugs.[291] 
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Table 3-3 Diagnostic accuracy of Xpert MTB/RIF for detection of M. tuberculosis according to HIV infection status 
Study N* Sensitivity Specificity 
HIV-infected HIV-uninfected HIV-infected HIV-uninfected 
Boehme 2010[45] 392/584 93.9 98.4 - - 
Boehme 2011[46] 602/1088 82.4 
(173/210) 
90.7 
(304/335) 
99.2 
(389/392) 
99.3 
(748/753) 
Scott 2011[220] 124/26 84 83 96 100 
Theron 2011[246] 130/286 69.6 
(32/46) 
82.9 
(68/82) 
91.7 
(77/84) 
95.6 
(195/204) 
O’Grady 2012[227] 408/196 88.2 
(142/161) 
74.3 
(26/35) 
95.1 
(235/247) 
96.3 
(155/161) 
Yoon 2012[228] 328/107 78.7 
(144/183) 
79.6 
(43/54) 
94.5 
(137/145) 
100 
(53/53) 
Bates 2013[230] 62/22 80.1 
(17/21) 
100 
(3/3) 
95.1 
(39/41) 
100 
(19/19) 
Theron 2014a[240] 449/272 78.2 
(97/124) 
93.3 
(56/60) 
93.5 
(304/325) 
97.2 
(206/212) 
Theron 2014b[240] 835/537 78.9 
(186/236) 
92.1 
(105/114) 
  89.3 
(535/599) 
95.0 
(402/423) 
* Numbers are HIV-infected then HIV-uninfected participants 
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Table 3-4 Diagnostic accuracy of a single Xpert MTB/RIF for the detection of rifampicin resistance 
Study Location Samples N Reference standard Sensitivity Specificity 
Helb 2010[44] Uganda Frozen sputum 64 Phenotypic DST 100 
(9/9) 
98.2 
(54/55) 
Boehme 2010[45]  Multicentre Fresh sputum 720 Phenotypic DST 97.6 
(200/205) 
98.1 
(505/515) 
Boehme 2011[46]  Multicentre Fresh sputum 1060 Phenotypic DST ± LPA 94.4* 
(236/250) 
98.3* 
(796/810) 
Bowles 2011[216] The Netherlands Fresh and frozen respiratory 
specimens 
40 Phenotypic DST 100 
(8/8) 
100 
(32/32) 
Ioannidis 2011[217] Greece Fresh respiratory specimens 32 Phenotypic DST ± LPA 75.0 
(3/4) 
100 
(28/28) 
Lawn 2011[218] South Africa Fresh sputum 55 Phenotypic DST 100 
(4/4) 
94.1 
(48/51) 
Scott 2011[220] South Africa Fresh sputum 16 Phenotypic DST 100 
(4/4) 
66.7 
(8/12)† 
Barnard 2012 [224] South Africa Fresh sputum 36 LPA 100 
(3/3) 
100 
(33/33) 
Carriquiry 2012[225] Peru Fresh sputum 39 Phenotypic DST 100 
(6/6) 
90.9 
(30/33) 
O’Grady 2012[227] Zambia Fresh sputum 96 Phenotypic DST 81.3 
(13/16) 
97.5 
(78/80) 
Antonenka 2013[248] Germany Frozen respiratory specimens 50 Phenotypic DST 100 
(2/2) 
100 
(48/48) 
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Study Location Samples N Reference standard Sensitivity Specificity 
Kurbatova 2013[233] Russia Fresh sputum 100 Phenotypic DST 98.2 
(55/56) 
100 
(17/17) 
Kwak 2013[234] South Korea Fresh sputum 99 Phenotypic DST 88.9 
(8/9) 
100 
(90/90) 
Park 2013[235] South Korea Fresh respiratory specimens 19 Phenotypic DST 100 
(2/2) 
100 
(17/17) 
Rufai 2014[281] India Fresh sputum 137 LPA ± phenotypic DST 64.4 
(38/59) 
94.9 
(74/78) 
DST, drug susceptibility testing; LPA, line probe assay 
* After post hoc change to software definitions for rifampicin resistance
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Figure 3-5 Sensitivity of a single Xpert for detection of rifampicin resistance with phenotypic DST 
and/or line probe assay as a reference 
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Figure 3-6 Specificity of a single Xpert for detection of rifampicin resistance with phenotypic DST 
and/or line probe assay as a reference 
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3.5 Xpert MTB/RIF assay failure 
Studies of diagnostic accuracy tend to evaluate only subjects that have valid results 
from both the index test and reference test. As a result, estimates of diagnostic 
accuracy tend not to be affected by test failures. The Xpert MTB/RIF assay 
incorporates internal quality control mechanisms and the test can fail in three ways: 
‘error’, indicating a failure in the probe check control or a system component failure; 
‘invalid’, indicating that the sample processing control has failed, either due to 
incorrect sample processing or PCR inhibition; or ‘no result’, usually signifying 
power failure or other termination of test. The frequency of test failures could 
potentially impact on the impact of Xpert MTB/RIF in routine implementation.  
 
Table 3-5 shows the studies where the proportion of tests that failed to give a valid 
result has been reported. The reporting is not consistent, in that it is not always 
explicit whether repeat tests were allowed with the remaining sample/buffer mix. In 
the 15 studies summarised, the proportion with no valid results ranged from 0.6% to 
13.5%.[45,46,217,218,220,221,224,225,230,233,237,239,276,292,293] The highest 
proportions were reported in two large studies of routine Xpert 
implementation,[292,293] as well as a study from a large tertiary hospital in 
Canada.[239] In the study of Xpert implementation at decentralised microscopy 
centres in India, there was heterogeneity across the 18 sites, with the proportion of 
failed tests ranging from 3.9% to 14.2%.[293] Similarly in the multi-country TB 
REACH implementation project, the proportion of failed tests ranged from 5.9% to 
16.3% across the different sites.[292] In both of these large scale implementation 
projects, the majority of test failures (60-65%) were due to errors. Across all studies, 
the majority of specimens that underwent repeat testing yielded a valid result. The 
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observed heterogeneity in similar settings and the validity of repeat tests might 
suggest that operator-dependent factors were the most important contributors to the 
indeterminate results, although assay-related factors may also play a part.  
 
3.6 Impact of Xpert MTB/RIF on patient-relevant outcomes 
The most robust evidence around the impact of Xpert MTB/RIF comes from two 
clinical trials comparing Xpert to smear microscopy. The TB-NEAT study was a 
multicentre randomised control trial in South Africa, Zimbabwe, Zambia and 
Tanzania.[240] A total of 1502 individuals with symptoms suggestive of pulmonary 
TB disease at primary health care (PHC) facilities were randomly allocated to 
receive sputum smear microscopy (in all but one site performed on site at the PHC 
facility) or Xpert MTB/RIF (in all cases performed on site). Sputum culture was the 
reference standard for TB diagnosis in both arms. The trial was primarily designed to 
detect a difference in TB-related morbidity in culture-positive cases who had 
initiated TB treatment. Morbidity was measured using the TBscore, a scale based on 
the presence of TB symptoms and signs where a higher score on the scale 0-13 
indicates more morbidity [294]; and the Karnofsky performance status scale, a 
general indicator of wellbeing and functional status where 0 indicates death and 100 
indicates normal health with no complaints and no evidence of disease.[295,296]
 
 
 
 
76 
Table 3-5 Studies reporting frequency of Xpert MTB/RIF tests with no valid results 
Study Country Location/context Number of 
specimens tested 
Number with no 
valid result 
Proportion with no 
valid result (95% CI) 
Boehme 2010[45] Multi-country Multicentre validation study  5190 192 3.7 (3.2-4.3) 
Boehme 2011[46] Multi-country Multicentre demonstration study 5321 126 2.4 (2.0-2.8) 
Ioannidis 2011[217] Greece National reference laboratory 121 2 1.7 (0.5-5.8) 
Lawn 2011[218] South Africa Centralised hospital laboratory 908 5 0.6 (0.2-1.3) 
Scott 2011[220] South Africa Centralised hospital laboratory 205 12 5.9 (3.4-10.0) 
Teo 2011[221] Singapore Centralised hospital laboratory 131 9 6.9 (3.7-12.5) 
Barnard 2012[224] South Africa Centralised hospital laboratory 282 7 2.5 (1.2-5.0) 
Carriquiry 2012[225] Peru Centralised hospital laboratory 134 2 1.5 (0.4-5.3) 
Bates 2013[230] Zambia Centralised hospital laboratory 94 3 3.2 (1.1-9.0) 
Kurbatova 2013[233] Russia Centralised hospital laboratory 238 8 3.4 (1.7-6.5) 
Walusimbi 2013[237] Uganda Centralised hospital laboratory 430 19 4.4 (2.9-6.8) 
Sohn 2013[239] Canada Centralised hospital laboratory 502 44 8.8 (6.6-11.6) 
Balcha 2014[276] Ethiopia Centralised hospital laboratory 1536 95 6.2 (5.1-7.5) 
Cresswell 2014[292] Multi-country Various 47 973 5107 10.7 (10.4-10.9) 
Raizada 2014[293] India Decentralised microscopy centres 40 035 2878 7.2 (6.9-7.5) 
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There was no difference between the microscopy and Xpert groups in the TBscore at 
two months (median score 2 for both groups, p = 0.85) or six months (median score 
1 for both groups, p = 0.35). Similarly there was no difference in the Karnofsky 
performance status score at two months (median score 80 for microscopy group vs. 
90 for Xpert group, p = 0.23) or six months (median score 100 for both groups, p = 
0.85). Xpert detected a greater proportion of culture-positive cases than microscopy 
(83% vs. 50%) and a greater proportion of patients subsequently confirmed as 
culture positive started TB treatment on the same day of presentation in the Xpert 
arm (66% vs. 44%, p <0.001). In addition, a greater proportion of culture-positive 
cases had started treatment by day 56 in the Xpert arm (92% vs. 85%, p = 0.03), 
although the proportion of all participants on treatment by day 56 was similar in the 
two groups (43% in the Xpert group vs. 42% in the microscopy group). This finding 
reflected high rates of empirical treatment prior to or in the absence of 
microbiological confirmation of TB disease and this may have contributed to the 
lack of difference between the groups in TB-related morbidity.[240]  
 
The second trial was a pragmatic, cluster randomised trial nested within the national 
roll-out of Xpert MTB/RIF in South Africa.[297] Twenty clusters (each cluster 
consisted of two PHC clinics and an off-site laboratory) were allocated to Xpert or 
microscopy. Analysis included 4656 individuals investigated for TB. There was no 
difference in the primary outcome of mortality at 6 months: 3.9% in Xpert group vs. 
5.0% in microscopy group, risk ratio 0.86 (95% CI 0.56-1.28). There was a modest 
increase in diagnostic yield from the initial sputum specimen (9.2% with Xpert vs. 
7.8% with microscopy) but the proportion of those who tested positive who were not 
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on treatment by day 28 was similar in both groups (17.0% in Xpert group vs. 14.9% 
in microscopy group).[297] 
 
Another randomised controlled trial in Zimbabwe focused on the impact of Xpert for 
TB screening prior to ART. In this trial at a single large urban HIV treatment centre, 
424 HIV-infected adults eligible for ART (CD4+ T-cell count ≤350 cells/µl), were 
randomised to TB screening by fluorescence microscopy (FM) or Xpert MTB/RIF, 
regardless of the presence or absence of symptoms suggestive of TB.[298] The 
primary endpoint was a composite endpoint of the proportion that developed incident 
TB or died within three months of enrolment. There was no evidence of any 
difference in this composite endpoint: 12% with FM vs. 9% with Xpert (difference -
3%, 95% CI -9%-4%, p = 0.39). Xpert did not significantly increase the initial 
diagnostic yield (7% of participants had a positive test with FM vs. 9% with Xpert, p 
= 0.29). Of all TB cases diagnosed at baseline, the majority had negative index tests 
and a diagnosis based on clinical and radiographic features (69% with FM and 54% 
with Xpert) and this might again have affected the ability to detect a difference in 
outcomes between the two diagnostic strategies.[298]  
 
In the large Xpert MTB/RIF demonstration study, the system was positioned within 
primary health care facilities in six diverse settings.[46] The overall median time to 
receipt of Xpert results by clinicians was 1 day (IQR 0-2) and only 0.6% (9/1438) 
was lost or unreported. This contrasted with median time to receipt of culture results 
of 58 days (IQR 42-62), with 16.7% (848/5089) lost or unreported. Xpert shortened 
the time to treatment for culture-confirmed pulmonary TB cases: the median time to 
treatment during the Xpert implementation phase compared to the validation phase 
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(where treatment was based on smear and culture results) was 2 days vs. 4 days for 
smear-positive cases and 5 days vs. 56 days for smear-negative cases.[46] 
 
A before-after study compared Xpert MTB/RIF to the baseline diagnostic strategy of 
smear microscopy and culture in adults admitted to a tertiary hospital in Kampala, 
Uganda.[228] For culture-confirmed pulmonary TB cases, the median time to 
treatment was shorter under the Xpert strategy (median 0 days, IQR 0-2) than under 
the baseline smear microscopy and culture strategy (median 1 day, IQR 0-26). The 
ability to show only a slight difference was partly explained by the fact that around 
70% of culture-positive TB cases were smear positive and that turnaround of smear 
microscopy results was rapid. There was no difference in mortality at two months 
amongst all TB suspects (17% in baseline strategy vs. 17% in Xpert strategy) or 
amongst culture-confirmed TB cases (17% vs. 14%).[228]     
 
A series of studies have reported on the point-of-care implementation of Xpert 
MTB/RIF at a large primary health care clinic in Johannesburg, South 
Africa.[232,236,299] These studies demonstrated the feasibility of same-day 
treatment initiation, with over 80% commencing treatment on the same day and 96% 
of all Xpert-positive cases starting treatment. These studies also highlighted some 
human resource and operational challenges to implementing within a clinic 
environment, specifically that more staff were required and processes took longer 
than anticipated.[299] It was noteworthy that of the drug-susceptible cases diagnosed 
by Xpert, only 48% had a successful outcome (cure or completion) and the 
proportion who defaulted during treatment was particularly high at 23%, although 
there was no context given as to default rates prior to the implementation of 
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Xpert.[232] This does, however, raise the question as to whether rapid diagnosis and 
treatment initiation, particularly if earlier in disease progression when people are less 
symptomatic, could lead to higher default rates after the initiation of treatment. This 
is something that needs to be closely monitored in routine programmes as Xpert is 
introduced. 
 
In terms of the impact specifically for MDR-TB, one before-after study in ten 
primary health care facilities in Cape Town, South Africa compared outcomes with 
diagnostic algorithms incorporating either LPA (n = 414) or Xpert (n = 127).[130] 
There was no significant difference in pre-treatment default for MDR-TB cases (9% 
with LPA-based algorithm vs. 6% with Xpert-based algorithm) but the median time 
from sputum collection to initiation of MDR-TB treatment was reduced from 43 
days with the LPA-based algorithm to 17 days with the Xpert-based algorithm. In 
this study, there were differences in the algorithms other than the diagnostic test used 
and the individuals entering the diagnostic algorithm were not directly comparable 
across the two time periods. There was also the possibility that other changes in the 
health system occurred between the two time periods, although it was notable again 
that the laboratory turnaround time with Xpert (less than 24 hours) only comprised a 
small proportion of the overall time to treatment initiation.  
 
The first district in South Africa to achieve full coverage with Xpert MTB/RIF was 
the rural Sisonke district in KwaZulu-Natal. This was linked to a decentralised 
MDR-TB treatment model. Between October 2011 and October 2012, a total of 21 
650 Xpert tests were performed and 1409 Xpert-positive cases were diagnosed, 140 
(9.9%) of which were rifampicin resistant. 40% of rifampicin-susceptible cases 
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started treatment within two days and 67% within five days. 36% of rifampicin-
resistant cases started treatment within two days and 54% within five days.[300] 
 
Some of the limitations of placement of Xpert in centralised laboratories were 
highlighted in a study of 403 HIV-infected symptomatic TB suspects from an urban 
hospital in Durban. All participants had specimens sent for smear microscopy, 
culture and Xpert MTB/RIF. The total diagnostic time (time from sputum collection 
to receipt of results by a clinician) was longer for Xpert than for smear microscopy 
(median 6.4 days vs. 3.3 days, p <0.001). Of the 86 cases with a positive Xpert, only 
32 (37.2%) started treatment on the basis of the Xpert result, with most starting on 
the basis of an earlier positive smear or on clinical grounds.[301] Amongst the 
limitations of this study was the fact that this was performed during the first phase of 
Xpert roll-out within the National Health Laboratory Service (NHLS) in KwaZulu-
Natal and that smear microscopy was conversely performed in a private-sector 
laboratory with results electronically reported to the study site. 
 
3.7 Summary 
Xpert MTB/RIF is a molecular diagnostic test which can accurately identify M. 
tuberculosis directly from sputum specimens and which can detect the presence of 
mutations conferring rifampicin resistance. Xpert MTB/RIF is more sensitive than 
smear microscopy, although sensitivity is somewhat reduced in HIV infection. Assay 
failure does occur and seems to be more common in the setting of routine 
implementation than in earlier demonstration studies. Although Xpert has an 
increased diagnostic yield compared to smear microscopy, the magnitude of this in 
most clinical studies has been fairly modest and so far the evidence suggests that this 
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does not translate to significant impact on the mortality and morbidity of TB cases or 
of all those undergoing investigation. Use of Xpert outside existing laboratory 
structures as a point-of-care tool at primary health care level has been shown to be 
feasible but whether or not point-of-care placement impacts on patient-relevant 
outcomes has not yet been established. 
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Chapter 4 Trial methodology 
4.1 Aims and objectives 
The aim of the cluster-randomised trial was to evaluate the impact of point-of-care 
placement of Xpert MTB/RIF in a rural primary health care system with high levels 
of TB drug resistance and HIV infection. The primary objective was to test the 
hypothesis that timely initiation of appropriate TB treatment for culture-confirmed 
cases is improved with placement of the diagnostic system at the point of care 
(primary health care clinic) compared to placement at the district hospital laboratory. 
 
Secondary objectives included: 
 To evaluate the impact of Xpert MTB/RIF positioning on additional clinical 
outcomes (time to appropriate TB treatment, time to appropriate drug-
resistant TB treatment, time to ART initiation, all-cause mortality, and 
hospital admission) 
 To compare the diagnostic accuracy of Xpert MTB/RIF (sensitivity and 
specificity) under different positioning strategies. 
 
4.2 Trial setting 
The trial was conducted in Hlabisa health sub-district, uMkhanyakude district, 
northern KwaZulu-Natal province, South Africa and co-ordinated at the Africa 
Centre for Health and Population Studies (Figure 4-1). The Africa Centre is a 
Wellcome Trust-funded research institution affiliated to the University of KwaZulu-
Natal (www.africacentre.com). The Africa Centre carries out research on population 
and health issues affecting a rural community with a high burden of HIV and TB. 
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Population-based demographic and health surveys take place within the 
Demographic Surveillance Area, an area of 438 km2  with a population of 
approximately 85 000 people.[302] The centre also supports the local Department of 
Health to deliver integrated HIV & TB treatment and care through the primary health 
care (PHC) system in Hlabisa health sub-district (an area of 1430 km2 with a 
population of approximately 228 000). 
 
 
 
 
Figure 4-1 Map showing location of Hlabisa sub-district within South Africa 
 
 
KwaZulu-Natal province, South Africa can be considered to be the epicentre of the 
combined TB/HIV epidemic. Hlabisa health sub-district is a prime example of a 
rural district with a huge burden of disease and mortality attributable to HIV and TB. 
The majority of the community live in scattered homesteads that are not concentrated 
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into villages or compounds. The district (uMkhanyakude) is one of the most 
deprived in South Africa, with 43% unemployment and only 13% of the population 
having access to piped water inside dwellings.[303]  
 
A population-based HIV survey has demonstrated extremely high HIV 
seroprevalence in the area - overall prevalence 29% in the adult population (aged 15-
49 years) in 2011.[304] TB notification rates rose significantly in Hlabisa health sub-
district from the early 1990’s in association with the increase in HIV seroprevalence 
and peaked in 2008 at over 1700 per 100 000, at which point 76% of TB cases were 
co-infected with HIV.[305] Since then there has been evidence of a decline in TB 
notifications (largely related to a decline in smear-negative pulmonary TB) and in 
2011 the notification rate was 1050 per 100 000 with a smear-positive pulmonary TB 
notification rate of 390 per 100 000. Despite the decline, this remains amongst the 
highest TB notification rates in the world, rivalled only by the neighbouring 
Kingdom of Swaziland. HIV and TB were estimated together to be responsible for 
60% (7539/12 539) of all deaths in adults (age ≥15 years) between 2000 and 2010 in 
the Africa Centre Demographic Surveillance Area. Although there was evidence of a 
decline since 2003 in HIV/TB-related mortality, in 2010 HIV/TB continued to 
exceed all other causes of death combined for males aged 25-59 years and females 
aged 15-54 years.[17] 
 
TB has for a long time placed a substantial burden on the district hospital, and 
latterly on the primary health care system.[306-312] In 2011, TB was responsible for 
one in six inpatient episodes and case fatality rate for episodes involving TB (20.6 
deaths per 100 episodes) was more than double that for hospital episodes unrelated 
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to TB.[309] In HIV-infected individuals initiating ART at PHC clinics between 2004 
and 2008, 20% of males and 16% of females were receiving treatment for TB at the 
time of ART initiation.[312] In a cohort study nested within the larger HIV treatment 
and care programme, for adults who started ART between March 2010 and 
December 2011, TB was responsible for one in three deaths in the first year of 
ART.[311] The heavy burden of TB at district hospital and PHC level highlights the 
potential for TB transmission within the health system, which is of particular 
concern in the context of inadequate infection control in South African hospitals and 
clinics.[313-320]  
 
The emergence of drug-resistant TB in Hlabisa was described in the 1990s.[18] The 
epidemic of drug-resistant TB has latterly been characterised by some of the highest 
population rates of MDR-TB anywhere in the world (overall 57 per 100,000 for 
uMkhanyakude district in 2007, not disaggregated for new and previously treated 
cases) with only isolated cases of extensively drug-resistant TB (XDR-TB).[19] 
More recently with the introduction of Xpert, uMkhanyakude district has been 
shown to have the highest rate of rifampicin-resistant TB in the country (16.2% of all 
positive Xpert tests, again not disaggregated for new and previously treated cases, 
demonstrated rifampicin resistance).[303] Both of these estimates were not 
disaggregated for new cases and previously treated cases. The delivery of MDR-TB 
treatment was partly decentralised in 2008, which allowed earlier initiation of 
treatment than in the previous hospital-based system with some evidence of 
improved clinical outcomes on treatment.[122] However, almost 50% of laboratory-
confirmed cases had died or were untraceable by the time the culture/DST results 
were obtained.[122]  
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HIV and TB treatment and care are delivered at each of the 17 PHC clinics 
(including one situated at the district hospital) through decentralised collaborative 
programmes (Figure 4-2).[321]  Previous work in Hlabisa sub-district has revealed 
that TB patients have a mean travel time of two hours to and from the PHC clinic 
and a mean travel cost of ZAR 23 (approximately equivalent to £1.30).[322] This 
trial recruited patients from the largest PHC clinic (KwaMsane clinic), situated in a 
small urban township in the south of the sub-district. KwaMsane clinic investigates 
around 1800 people for TB each year and treats approximately 400 TB cases. 
KwaMsane clinic is situated approximately 55km by road from the district hospital. 
 
 
 
Figure 4-2 Map of Hlabisa sub-district showing location of primary health care clinics.  
Circles signify district hospital and KwaMsane clinic. Grey shaded area represents the Africa Centre 
Demographic Surveillance Area 
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4.3 Trial design 
The study was a cluster randomised trial of adult pulmonary TB and drug-resistant 
TB (DR-TB) suspects evaluating the impact of Xpert MTB/RIF positioning on 
clinical outcomes. The unit of randomisation was a time block (two-week period) – 
time periods were randomly allocated to placement of the Xpert MTB/RIF 
diagnostic system at either centralised sub-district level (district hospital laboratory) 
or at primary health care clinic level (point-of-care). A cluster therefore represented 
all individuals enrolled during a two-week period. Randomisation was done in 
permuted blocks of eight for clusters 1-32 and four for clusters 33-36 (due to the 
extension of the trial, see section. The unit of observation for all analyses was the 
individual participant. The trial schema is shown in Figure 4-3. 
 
The trial was designed as a pragmatic trial, in order to evaluate the effectiveness of a 
point-of-care diagnostic strategy under real-world conditions. Few trials are purely 
explanatory (exploring efficacy of an intervention) or pragmatic (exploring 
effectiveness) and this distinction is often conceptualised as a continuous spectrum 
rather than a dichotomy. The pragmatic-explanatory continuum indicator summary 
(PRECIS) tool can help to determine where on the continuum a trial might lie.[323-
325] This tool is based on ten key domains that determine the extent to which a trial 
is pragmatic or explanatory. Although this tool was not utilised in the design of the 
trial, it was used retrospectively to illustrate the pragmatism of the trial (Appendix 
B).  
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In many domains, the trial design was more towards the pragmatic end of the 
spectrum. Certainly the inclusion of all eligible individuals requiring investigation 
for pulmonary TB, or specifically drug-resistant TB, with minimal exclusion criteria 
was reflective of real-world practice. Also the follow-up schedule was reflective of 
the routine programme, with no additional visits specifically for the study, other than 
for outcome ascertainment.  
 
One of the key aspects of the trial that limited pragmatism was the fact that specific 
study personnel (nurse and research assistant) were placed at the primary health care 
clinic for the purposes of the study, and programme staff were not involved in 
directly implementing the trial procedures. This decision was taken because it was 
felt that the time taken for the individual informed consent process and data 
collection would infringe too much on the routine programme operations. Also, the 
study nurse followed standardised algorithms and management protocols with little 
room for flexibility, but that also reflected how the TB control programme operates 
in this setting. Another main limitation of the pragmatism was the fact that a single 
GeneXpert system was moved between the two locations (primary health care clinic 
and hospital laboratory) to comply with the randomisation schedule. This was due to 
the fact that resources only allowed purchase of a single system and that the system 
was only operational in one location at any one point, but nevertheless this was 
poorly representative of what would happen in a routine programme setting. Lastly, 
the need for continuous oversight of the trial meant that adherence of the study nurse 
to the trial protocol and standard operating procedures (SOPs) was closely 
monitored, probably more so than would be the case in a routine programme setting. 
However, this is unavoidable within the ethical and regulatory framework of clinical 
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trials, where the proper conduct of the trial and protection of trial participants are 
paramount. 
 
In summary, therefore, the trial was designed and implemented to be as pragmatic as 
possible, but failed to meet the criteria for a fully pragmatic approach.  
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Figure 4-3 Trial schema 
Clinic blocks 
(two-week time blocks at KwaMsane clinic)
N = 36
Age ≥18yrs; current cough; HIV infection 
and/or high risk of DR-TB
Point-of-care strategy (n =18)
Xpert testing at clinic by study nurse
Testing and management decision on 
same day where possible
Clinical endpoints
Follow-up at two months
Hospital laboratory strategy (n = 18)
Xpert testing at laboratory by trained 
laboratory technician
Transport of samples from clinic to lab 
and of results from lab to clinic by courier
Participants advised to return to clinic for 
results and further management
Clinical endpoints
Follow-up at two months
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4.4 Trial outcomes 
4.4.1 Primary outcome 
The primary outcome measure was the proportion of culture-confirmed pulmonary 
TB cases initiated on appropriate anti-TB treatment within 30 days of enrolment   
4.4.2 Secondary outcomes 
The clinical secondary outcome measures were separated into those among culture-
confirmed TB cases and those among TB and DR-TB suspects: 
 
Culture-confirmed pulmonary TB cases 
■ Time to initiation of appropriate TB treatment (days) for culture-confirmed 
pulmonary TB cases 
■ Time to initiation of appropriate DR-TB treatment  for pulmonary rifampicin-
resistant TB cases confirmed by culture and either line probe assay (LPA) or 
phenotypic drug susceptibility testing (DST) 
 
TB and MDR-TB suspects 
■ All-cause mortality in TB and DR-TB suspects at 60 days 
■ Proportion of TB suspects with at least one hospital admission within 60 days 
■ Time to initiation of antiretroviral therapy (ART) for HIV-infected TB and 
DR-TB suspects not yet receiving but eligible for ART 
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4.5 Trial population 
Adult pulmonary TB or drug-resistant pulmonary TB suspects were recruited at 
KwaMsane clinic (the largest PHC clinic in Hlabisa sub-district). Only individuals 
that were HIV-infected and/or had a high risk of drug-resistant TB were included , 
due to their high risk of mortality and prioritisation for Xpert MTB/RIF testing at the 
time of study design, according to WHO recommendations.[326] 
 
Inclusion criteria: 
■ Adult (≥18 years old) 
■ Current pulmonary TB symptoms (defined as cough of any duration) 
■ Confirmed HIV infection and/or high risk for drug-resistant TB (adapted 
from South African national guidelines and WHO guidelines for 
programmatic management of MDR-TB)[327,328]: 
o Failure of standard treatment or retreatment regimen 
o Smear non-conversion at month 2 or 3 of standard treatment regimen 
or retreatment regimen 
o Relapse or return after default 
o Any other previous TB treatment (at any time point) 
o Household exposure to known MDR/XDR-TB case 
o Health care workers 
o Prison inmate in previous 12 months 
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Exclusion criteria: 
■ Severely unwell requiring immediate admission to hospital 
■ Previous MDR/XDR-TB diagnosis or treatment (documented or self-
reported) 
■ Suspicion of extra-pulmonary TB only (absence of cough) 
■ Unable to give informed consent 
 
4.6 Randomisation 
The allocation schedule for random assignment of two-week time blocks was 
computer generated, using random permuted blocks of eight for blocks 1-32 and four 
for blocks 33-36. The computer-generated sequence for blocks 1-32 was produced 
by an independent biostatistician prior to the start of the trial; the sequence for blocks 
33-36 was produced in December 2012. Allocation for each clinic block was placed 
into sequentially numbered, opaque, sealed envelopes by the biostatistician; the 
envelope was opened on the Friday before the start of a new two-week block by the 
principal investigator and the allocated strategy for the next time block was 
communicated to study staff.   
 
4.7 Intervention 
The GeneXpert system is a 4-site, fully automated instrument integrating real-time 
amplification and detection of pathogens (Appendix A). The Xpert MTB/RIF assay 
employs a hemi-nested PCR of the rpoB core region of Mycobacterium tuberculosis 
(81 base pair region, also called rifampicin resistance-determining region (RRDR)). 
It uses five molecular beacons (different colours), each hybridising to a different 
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target segment within rpoB - binding does not occur if the sequence differs from 
wild type by even a single nucleotide substitution. The assay incorporates an internal 
control (Bacillus globigii spores). A positive test indicates two or more probes 
positive within two cycles of each other. Rifampicin resistance is reported if there is 
failure of one or more rpoB specific beacon to hybridise properly. A negative test 
indicates B. globigii signal but no M. tuberculosis signal. The assay produces a result 
of ‘invalid’ if there is neither a B. globigii nor a M. tuberculosis signal, indicating 
that the sample processing control has failed, either due to incorrect sample 
processing or PCR inhibition. An ‘error’ result indicates a failure in the probe check 
control or a system component failure. Finally, ‘no result’ usually signifies power 
failure or some other termination of test.   
 
The Xpert MTB/RIF assay was incorporated into diagnostic algorithms adapted from 
the WHO standardised diagnostic algorithms for HIV-infected individuals with 
suspected TB and individuals at high risk of drug-resistant TB (Figures 4-4 and 4-
5).[329]  
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Figure 4-4 Algorithm for management of Xpert MTB/RIF results for participants not currently on TB treatment 
Xpert MTB/RIF
MTB detected
RIF resistance not detected
Commence standard TB 
treatment (2HRZE/4HR)
MTB detected
RIF resistance detected
Repeat Xpert MTB/RIF on 
same specimen or 
additional specimen*
MTB detected
RIF resistance detected
Refer for DR-TB treatment
MTB detected
RIF resistance not detected
Commence standard TB 
treatment (2HRZE/4HR) & 
refer to medical officer
MTB not detected or 
error/invalid/no result
No TB treatment
Refer to medical officer
MTB not detected
Antibiotic therapy
Instruct participant to return 
after 14 days if remains 
symptomatic
If remains symptomatic, 
refer for chest X-ray and 
medical officer review
Error/invalid/no result
Repeat Xpert MTB/RIF*
DR-TB, drug-resistant TB; E, ethambutol; H, isoniazid; R, rifampicin; Z, pyrazinamide  
* Repeat test allowed on remaining sample/buffer mix or additional specimen (maximum one additional specimen allowed) 
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Figure 4-5 Algorithm for management of Xpert MTB/RIF results for participants currently on TB treatment 
Xpert MTB/RIF
MTB detected
RIF resistance not 
detected
Smear non-conversion at 
month 2 (standard 
regimen) or month 3 
(retreatment regimen)
Continue HRZE for extra 
month
Repeat AFB smear at end 
of month
Check for culture/DST 
results
Treatment failure after 
month 5 (standard 
regimen) or month 7 
(retreatment regimen)
Register as treatment 
failure
Refer to medical officer
MTB detected
RIF resistance 
detected
Repeat Xpert 
MTB/RIF on same 
specimen or additional 
specimen*
MTB detected
RIF resistance 
detected
Refer for DR-TB 
treatment
MTB detected
RIF resistance not 
detected
Continue current treatment
Refer to medical officer
MTB not detected or 
error/invalid/no result
Continue current treatment
Refer to medical officer
MTB not detected
Ensure that culture/DST 
specimen sent
Continue current treatment
Refer to medical officer
Error/invalid/no result
Repeat Xpert 
MTB/RIF*
AFB, acid-fast bacilli; DR-TB, drug-resistant TB; DST, drug susceptibility testing; E, ethambutol; H, isoniazid; R, rifampicin; Z, pyrazinamide 
* Repeat test allowed on remaining sample/buffer mix or additional specimen (maximum one additional specimen allowed) 
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4.8 Procedures 
4.8.1 Identification of participants 
Potential participants were identified by health care workers at the single PHC clinic. 
All subjects who presented to any area of the clinic with symptoms suggestive of 
pulmonary TB (cough ± fever/night sweats/weight loss) were given basic 
information about the trial and referred to the study nurse, who was situated at the 
clinic and who worked alongside the clinic TB nurses. The study enrolled 
participants between the hours of 0800 and 1630 on weekdays (Monday to Friday). 
The specific areas where subjects were identified were the TB clinic, HIV clinic, 
HIV counselling and testing services, antenatal care, and general primary health care 
services. A cough triage system was in operation throughout the study period, 
whereby all PHC attendees were asked about the presence of cough on arrival at the 
clinic. Individuals reporting cough were directed towards the TB area within the 
clinic. Throughout the study period, all HIV-infected adults attending for treatment 
or care were also screened for TB symptoms at every clinic visit in accordance with 
national guidelines.[330,331]  
4.8.2 Informed consent 
The study nurse checked the eligibility criteria and completed the form entitled 
‘Eligibility criteria’ (Appendix C). Subjects that met the eligibility criteria were 
provided information (verbal and written) about the study in isiZulu and/or English 
(Appendix D) and those that were willing to participate were taken through the 
informed consent process and were asked to sign the consent form. Agreement of 
99 
 
 
 
participants who were illiterate was indicated by thumbprint on the consent form and 
a literate witness signed on their behalf (Appendix E). 
4.8.3 Baseline evaluation 
The study nurse collected basic demographic information on the ‘Enrolment form’ 
(Appendix F); this included phone numbers (for the participant and for a nominated 
second contact) and physical address for the purposes of contacting for outcome 
evaluation. Information about current symptoms, previous TB history, HIV status, 
CD4+ T-cell count, viral load and antiretroviral therapy use was entered into the 
baseline case report form (CRF) (Appendix G) 
4.8.4 Sputum specimen collection 
Spontaneously expectorated sputum specimens were collected at the study clinic 
(two spot specimens per patient). Sputum collection occurred outside. Each sputum 
specimen was collected into a sterile, wide-mouthed specimen container with a 
tightly fitting screw top. Simple instructions on how to submit a good quality sputum 
specimen were given to each participant with the aid of a pictorial card with 
instructions in isiZulu, based on instructions shown previously to increase case 
detection.[332] Every effort was taken to prevent contamination of the exterior of the 
specimen container. Each specimen container was placed into an individual 
disposable watertight sealed plastic bag.  
 
The nurse instructed participants to wait one hour between producing the first and 
the second sputum specimen. The first sputum specimen was used for Xpert 
MTB/RIF testing and the second specimen for culture, line probe assay (LPA) ± 
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drug susceptibility testing (DST). Whilst awaiting testing or transport, sputum 
samples were stored at the clinic in a cooler box surrounded by frozen ice packs. 
 
After the first three months of the study, when it became clear that leakage of 
specimen containers during transit was a significant problem, each specimen 
container was sealed with plastic paraffin film before transport to the district hospital 
laboratory. This was performed for the specimens due for Xpert MTB/RIF testing 
and those sent for culture and DST.  
 
Sputum induction was not utilised for the study, even for those unable to 
expectorate, as it was not in use anywhere in the sub-district prior to or during the 
study.    
4.8.5 Sputum specimen testing 
A four-module GeneXpert machine with desktop computer was installed for each 
two-week time period at either the district hospital laboratory or the primary health 
care clinic according to the randomisation schedule. There was only one GeneXpert 
system for the trial and it was moved between the two locations when required, 
according to the randomisation. At both locations, Xpert MTB/RIF testing followed 
the manufacturer’s instructions.[333] Prior to 28 May 2012, Xpert version G3 
cartridges were used; from 28 May 2012 onwards, Xpert version G4 cartridges were 
used.[279] The change in cartridges was based on what was supplied by the 
distributor at the time of cartridge restocking.   
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For laboratory clusters, both sputum specimens were transported daily to the 
National Health Laboratory Service (NHLS) laboratory at the district hospital using 
the existing routine courier specimen transport system. Xpert MTB/RIF testing was 
performed by a laboratory technician and results were returned to the clinic using the 
routine transport system. Under the laboratory strategy, participants were requested 
to return to the clinic for results after three working days, based on the typical 
turnaround time for receipt of smear microscopy results at the clinic prior to the 
study.  
 
For point-of-care clusters, Xpert MTB/RIF was performed on site by the trained 
study nurse in a dedicated room within a park home (a prefabricated multi-room 
modular unit located outside the main clinic building). N95 respirator masks were 
used but no biosafety cabinet. Under the point-of-care strategy, participants were 
advised to wait for their result the same day. If they were unable or unwilling to wait 
at the clinic, they were advised to return the following day or any subsequent day. 
 
The Xpert MTB/RIF assay can generate three types of results other than positive and 
negative: error, invalid and no result. These results are associated with different 
problems with the sample and with the assay. In the event of any of these results, and 
if sufficient sample/buffer mix remained, a repeat Xpert MTB/RIF test was 
performed. If insufficient sample remained or if there was still no definitive result, a 
second sputum specimen was collected at the earliest convenience (usually when the 
patient collected the initial result). A second sputum specimen was also collected in 
the event of leakage of the initial specimen during transport from clinic to laboratory. 
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Second sputum specimens were tested under whichever strategy was operating at the 
time that the second specimen was collected.   
 
A repeat Xpert test was also recommended in the protocol in the event of a result 
demonstrating the presence of rifampicin-resistant M. tuberculosis. The repeat test 
could be performed with remaining sample/buffer mix from the original specimen or 
with a fresh specimen collected when the participant collected their result. This was 
included because of the concern about suboptimal specificity and the potential for 
false-positive rifampicin resistance results at the time of study design, so as to gather 
data on the reliability of repeat Xpert tests in differentiating true positive and false 
positive results.[46,278,334]  
 
Specimens for culture and drug susceptibility testing (DST) were forwarded via the 
routine motorised transport system to Hlabisa laboratory and then onwards to the 
provincial NHLS laboratory at Inkosi Albert Luthuli Hospital in Durban 
(approximately 260km by road). Mycobacterial growth indicator tubes (MGIT) were 
inoculated and incubated for up to 6 weeks. Identification of M. tuberculosis was 
confirmed from all positive cultures using niacin and nitrate and/or Rapid MPT64 
antigen assay (Standard Diagnostics, Inc. (SD), Yongin, Korea). The Genotype 
MTBDRplus assay (Hain Lifescience, Nehren, Germany) was performed on culture 
positive isolates to identify mutations associated with rifampicin and isoniazid 
resistance. Phenotypic DST for key first-line and second-line drugs (rifampicin, 
isoniazid, ofloxacin, and kanamycin) was performed using the 1% proportion 
method on Middlebrook 7H10 agar plates, only for isolates with rifampicin and/or 
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isoniazid resistance on LPA. Standard drug concentrations were used: 1 µg/ml 
rifampicin, 0.2 µg/ml isoniazid, 5 µg/ml kanamycin and 2 µg/ml ofloxacin. 
4.8.6 HIV testing 
All participants with unknown or negative HIV status were counselled and offered 
rapid HIV testing prior to enrolment.  This mirrored routine clinical practice at the 
clinic, where all TB suspects are offered HIV counselling and testing before sputum 
collection. All HIV-infected participants were referred for CD4+ T-cell count and 
HIV care and treatment as per routine clinic procedures. 
4.8.7 Additional investigations 
Other investigations (e.g. chest X-ray) and referrals were ordered at the discretion of 
the study nurse and other clinic staff and were according to national guidelines and 
local protocols. I supported the clinic by holding a weekly clinic as a medical officer, 
to which complex patients or suspects requiring further investigation could be 
referred. Additional samples were collected at the discretion of the medical officer if 
there were features suggestive of extrapulmonary TB (e.g. lymph node aspirate, 
pleural aspirate), but these specimens were submitted for laboratory testing as per 
routine protocols and did not undergo Xpert MTB/RIF testing. Otherwise, during the 
trial there were one to two medical officer visits per week, one specifically for 
initiation of antiretroviral therapy and the other for primary health care management 
(e.g. hypertension, diabetes, epilepsy). There were no X-ray facilities at the PHC 
clinic so a request for chest X-ray required referral to the district hospital. At the 
district hospital, a daily ‘cough clinic’ operated in concert with but physically 
separated from the main outpatient department where TB suspects with negative 
sputum microscopy or Xpert MTB/RIF results could be assessed by a medical 
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officer with a chest X-ray.[335] There was a private X-ray facility in the nearest 
town (~6km distance), where a chest X-ray cost ZAR 150 (approximately equivalent 
to £10). Participants were also free to access other public and private health 
practitioners and facilities. Only the public sector is allowed to stock and distribute 
anti-TB treatment in South Africa; it is not generally available in the private sector in 
South Africa. After diagnosing someone with TB, private doctors are meant to 
immediately refer the individual to a public health facility. 
4.8.8 Clinical management 
Clinical decisions were made on the basis of the Xpert MTB/RIF results and, where 
appropriate, other clinical and laboratory information. The standard treatment 
regimen (isoniazid [H], rifampicin [R], pyrazinamide [Z] and ethambutol [E]) could 
be initiated by the study nurse or TB nurse. All patients diagnosed with DR-TB were 
first seen by the medical officer and then referred to the provincial DR-TB centre, 
King Dinuzulu Hospital (formerly King George V Hospital) in Durban for specialist 
assessment and treatment initiation. Appointments at King Dinuzulu were booked by 
the medical officer after reviewing the patient. Generally, patients were admitted to 
the TB inpatient ward at Hlabisa Hospital two to three days before their scheduled 
appointment, travelled to and from Durban on an outpatient basis with Department 
of Health transport, and then stayed on the TB ward at Hlabisa Hospital for at least 
one month for supervision of treatment and monitoring for toxicity. Following the 
first month and if patients were clinically stable, treatment continued at home 
(injectable agents were given at the nearest PHC clinic or by mobile injection teams) 
and patients made monthly visits to King Dinuzulu Hospital for follow-up and 
pharmacy refill. Patients with XDR-TB or complicated MDR-TB (pregnant females, 
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renal failure, or liver failure) were generally admitted to King Dinuzulu Hospital for 
specialist inpatient management. 
 
Management of suspects who tested negative by Xpert MTB/RIF followed existing 
protocols for smear-negative TB suspects. Antibiotics were prescribed (amoxicillin 
500mg tds for five days or erythromycin 500mg qds for five days) and patients were 
advised to return if symptoms had not improved after 14 days. Patients who 
remained symptomatic following this course of antibiotics could be referred to the 
district hospital for chest X-ray and review by a medical officer. 
  
4.9 Outcome evaluation 
To ascertain the primary and secondary outcomes, all participants enrolled in the 
trial were invited to attend for clinic review with the study nurse two months after 
the enrolment visit; a specific date was given at the end of the enrolment visit 
although participants were told that they could attend any time from that date 
onwards. Participants who attended for follow-up were reimbursed with a ZAR 50 
food voucher (approximately equivalent to £3.30). Participants were also asked to 
consent to telephone follow-up and/or home visit in case clinic visit was not 
possible. A message was sent to their designated phone via short message service 
(SMS) to remind the participant if they did not attend on the given day.  
 
The study nurse was responsible for collecting the data relating to the primary and 
secondary outcomes at time of follow-up. Data was collected on the ‘Follow-up Case 
Report Form’ (Appendix H), in particular regarding TB treatment initiation and/or 
changes, hospital admissions, HIV testing, CD4+ T-cell count testing and ART 
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initiation (where appropriate). In the event that no contact was made with the patient 
or with the named contact persons, information was collated from clinic TB files and 
registers and the operational database for the HIV programme – permission to use 
this data was included in the informed consent process.  
 
4.10 Sample size calculation 
The baseline assumptions for the primary outcome analysis were that: 
■ Kwamsane clinic screened approximately 150 new TB suspects per month, 
120 of whom would meet eligibility criteria 
■ An estimated 25% of TB and DR-TB suspects would have a positive MGIT 
culture 
■ The sensitivity of a single Xpert MTB/RIF test compared to reference 
standard of single MGIT culture would be approximately 75% [218,246]  
■ An estimated 10% of Xpert MTB/RIF positive cases in the hospital 
laboratory arm would not return for or receive result as indicated  
■ An estimated 50-70% of Xpert MTB/RIF negative cases would be diagnosed 
by other means (e.g. chest X-ray) prior to 30 days but that this proportion 
would be lower in the laboratory arm 
 
The study was designed to detect a 10 percentage point increase in the proportion of 
culture-confirmed PTB cases initiated on appropriate treatment within 30 days (from 
85% in the laboratory arm). Sample size was calculated with the equation of Hayes 
and Bennett, using the coefficient of variation (κ).[336] With κ=0.05 and a mean 
cluster size of 12, it was estimated that 16 clusters and 188 culture-positive TB cases 
were needed in each arm to detect this difference with 95% confidence and 80% 
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power. It was assumed that 10% of individual participants would be lost to follow-up 
at time of outcome evaluation (60 days), so 208 culture-positive TB cases were 
needed in each arm. Based on the assumption that 25% of TB suspects would have a 
positive culture, this required enrolment of 1664 TB suspects, which equated to 
~85% of eligible suspects at KwaMsane clinic over the planned time period of the 
study (August 2011-December 2012). 
 
Although the original sample size was 32 clusters, the final sample size was 36 
clusters, as enrolment into the trial was extended due to the lower than expected 
culture positivity rate (see p114).  
 
In terms of the key secondary endpoints, all-cause mortality was measured in all 
participants, regardless of TB status. The sample size of 16 clusters per arm and 60 
participants per cluster gave approximately 80% power to detect a 33% change in 
mortality from a baseline of 12% in the district hospital arm with 95% confidence. In 
the absence of local data on mortality amongst people investigated for TB, the 
assumption for baseline mortality was based on previously published data reporting 
mortality in TB suspects,[73,337] and local data on mortality amongst TB and 
MDR-TB cases.[122]  
 
The coefficient of variation (κ) was small, but with time blocks as the unit of 
randomisation there was expected to be minimal variation between clusters. This 
value of κ corresponded to a range of proportions appropriately treated in the 
laboratory arm of 77-94% for individual clusters. There was no reliable data from 
previous cluster randomised trials to inform the value of κ. There have been few 
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published trials where the unit of randomisation is a time block rather than a 
geographical or organisational cluster. The trials that have been published did not 
use consistent methods for sample size calculation - some adjusted appropriately for 
cluster variation [338-340]; others arbitrarily inflated the sample size from that for an 
individual RCT [341]; and one based the sample size on the numbers available to 
participate.[342] 
 
4.11 Statistical analysis 
4.11.1 Participants and baseline characteristics 
A trial profile of participants was prepared as per the Consolidated Standards of 
Reporting Trials (CONSORT) guidelines, including the extension to cluster 
randomised trials.[343-345] The baseline demographic and clinical characteristics 
were presented in a table according to study arm. 
4.11.2 Baseline analysis 
Comparison of baseline characteristics was performed to characterise the study 
population and to identify baseline imbalances occurring due to chance between the 
study arms. No test of statistical significance was performed and confidence intervals 
and p values were not reported. The purpose of the comparison was to determine 
whether any baseline covariates needed to be adjusted for in the final analyses. The 
baseline analysis was performed for all participants and then separately for culture-
positive cases eligible for the primary outcome analysis. 
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4.11.3 Primary analysis 
4.11.3.1 Overview 
The primary analysis was the comparison of the proportion of culture-confirmed TB 
cases commenced on appropriate anti-TB treatment within 30 days of enrolment 
(binary outcome).  
4.11.3.2 Population for analysis 
This analysis was performed on an intention-to-treat basis. All individuals were 
analysed on the basis of the group to which they were randomised, regardless of the 
circumstances under which they received the intervention. The analysis included 
individuals with a positive culture (using the Mycobacterial growth indicator tube 
(MGIT) system) identified as Mycobacterium tuberculosis, but excluded cases on 
TB treatment at the time of enrolment (smear non-converters or failures still on 
treatment) that had a positive culture isolate susceptible to rifampicin and isoniazid. 
These participants were excluded because the appropriate management would 
involve continuation of the same treatment and therefore participants would reach 
the primary endpoint by default, without any specific action having been taken. 
4.11.3.3 Definitions for primary endpoint 
The definition of appropriate anti-TB treatment was based on the drug susceptibility 
pattern with reference to standard treatment guidelines (Table 4.1). Rifampicin and 
isoniazid resistance were defined on the basis of documented resistance with either 
phenotypic DST or LPA. The concordance between phenotypic DST and LPA 
results was described.  
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In practical terms, rifampicin mono-resistance was treated with a standardised MDR-
TB regimen (with the addition of isoniazid) whereas isoniazid mono-resistance was 
treated with standard first-line regimen for 6-9 months.[346] Although streptomycin 
was included as part of the standard re-treatment regimen in national guidelines at 
the time of study,[327] there was already a process of withdrawing its use even 
before the introduction of Xpert MTB/RIF. Therefore, the use of streptomycin in re-
treatment cases susceptible to rifampicin was not required to meet the definition of 
appropriate treatment. 
 
        
4.11.3.4 Statistical methods 
This binary outcome was analysed at an individual level, accounting for within-
cluster correlation. Regression modelling using generalised estimating equations 
with a binomial distribution function and a logit link was applied, specifying an 
exchangeable working correlation matrix. The odds ratio was reported with 95% 
confidence intervals and a p value from the Wald test. Where a major imbalance 
existed in any of the baseline individual-level covariates and the covariate could 
plausibly influence the outcome, a supplementary analysis was performed for the 
effects of the individual-level covariates. This was considered supportive to the 
primary analysis. 
4.11.3.5 Analysing for effect modification of primary outcome 
To determine whether the effect of Xpert MTB/RIF positioning differed for the 
subgroup of people at high risk of drug resistance, an interaction term was 
incorporated into the model to examine the evidence for effect modification. The 
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estimated difference in intervention effect between those with high risk of drug 
resistance versus those without risk of drug resistance was reported with 95% 
confidence intervals and a p value from the Wald test for the interaction.  
4.11.3.6 Missing data 
A complete case analysis was conducted (i.e. only including cases with post-baseline 
follow-up). There was no imputation for missing outcome data. Incomplete cases 
were described and their baseline characteristics were compared with those of the 
complete cases to determine the extent of any difference. 
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Table 4-1 Definitions of appropriate anti-TB regimen for primary and secondary endpoints 
Case definition Appropriate initial anti-TB drug regimen 
M. tuberculosis susceptible to rifampicin and isoniazid Isoniazid + rifampicin + pyrazinamide + ethambutol ± streptomycin* 
M. tuberculosis with mono-resistance to isoniazid Isoniazid + rifampicin + pyrazinamide + ethambutol ± streptomycin* 
M. tuberculosis with mono-resistance to rifampicin Standardised second-line regimenǁ ± isoniazid 
Multidrug-resistant M. tuberculosis  (MDR-TB)† Standardised second-line regimenǁ 
Extensively drug-resistant M. tuberculosis (XDR-TB)‡  Standardised XDR-TB regimen¶ 
M. tuberculosis with unknown drug susceptibility§ Isoniazid + rifampicin + pyrazinamide + ethambutol 
* At the time of the study, streptomycin was included as part of standard re-treatment regimen in national guidelines, although in practice was rarely prescribed 
† MDR-TB defined as resistance to rifampicin and isoniazid 
‡ XDR-TB defined as MDR plus resistance to ofloxacin and kanamycin 
§ Drug susceptibility test not performed or unsuccessful 
ǁ Standardised regimen according to national guidelines (kanamycin/amikacin + fluoroquinolone + ethionamide + cycloserine/terizidone ± pyrazinamide ± ethambutol)[346] 
¶ Standardised regimen according to national guidelines (capreomycin + fluoroquinolone + ethionamide + cycloserine/terizidone + PAS + clofazimine)[346] 
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4.11.3.7  Participants investigated under alternative strategy 
There were instances where individuals randomised to laboratory or clinic blocks 
were actually investigated under the alternative diagnostic strategy, either due to 
delay in specimen submission or a requirement for additional specimens. There were 
also instances where individuals underwent testing under both strategies, in the event 
of repeat testing occurring in a different time block. These occurrences were reported 
in the results section but all analyses were performed on an intention-to-treat basis. 
4.11.4 Secondary analyses 
4.11.4.1 Overview 
The secondary analyses of clinical outcomes included binary data and time-to-event 
data. The secondary outcomes are summarised in Table 4.2 and described below. 
4.11.4.2 Time to initiation of appropriate TB treatment for culture-confirmed 
pulmonary TB cases 
The population for this analysis was as per the primary outcome, i.e. individuals with 
a positive MGIT culture identified as Mycobacterium tuberculosis, excluding cases 
on TB treatment at the time of enrolment (smear non-converters or failures still on 
treatment) with a positive culture isolate susceptible to rifampicin and isoniazid. 
Time was measured in days from date of enrolment to date of treatment 
commencement. Follow-up time was right censored at time of death for participants 
who died prior to appropriate treatment and at 60 days for those who had not 
initiated appropriate anti-TB treatment. The definition of appropriate TB treatment 
was as per the primary outcome (Table 4.1). A complete case analysis was 
conducted, so individuals with no post-baseline follow-up were excluded. This time-
to-event outcome was measured at an individual level, accounting for within-cluster 
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correlation. Cause-specific Cox proportional hazards regression models were fitted 
with the shared frailty option to account for the cluster randomisation. Hazard ratios 
were presented with 95% confidence intervals. The proportional hazards assumption 
was examined graphically using the log-log plot and also using the score test based 
on scaled Schoenfeld residuals.[347]  
4.11.4.3 Time to initiation of appropriate DR-TB treatment for pulmonary 
rifampicin-resistant TB cases confirmed by culture and either line probe assay 
(LPA) or phenotypic drug susceptibility testing (DST) 
The population for this analysis was individuals with a positive MGIT identified as 
Mycobacterium tuberculosis and resistance to rifampicin ± isoniazid identified either 
on line probe assay or phenotypic drug susceptibility testing (rifampicin mono-
resistance or multidrug resistance (MDR)). Time was measured from date of 
enrolment to date of commencement of appropriate drug-resistant TB treatment. 
Follow-up time was censored at time of death for participants who died prior to 
appropriate DR-TB treatment and at 60 days for those who had not initiated 
appropriate DR-TB treatment. A complete case analysis was conducted, so 
individuals with no post-outcome follow-up were excluded. This time-to-event 
outcome was measured at an individual level, accounting for within-cluster 
correlation. Cox proportional hazard models were fitted with the shared frailty option 
to account for the cluster randomisation. Hazard ratios were presented with 95% 
confidence intervals. The proportional hazards assumption was examined graphically 
using the log-log plot and also using the score test based on scaled Schoenfeld 
residuals.[347] 
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Table 4-2 List of secondary outcomes with populations for analysis and exclusions 
Secondary outcome Population for analysis  Exclusions from analysis 
Time to initiation of appropriate TB treatment for culture-
confirmed pulmonary TB cases 
Individuals with a positive culture growth 
identified as Mycobacterium tuberculosis  
Individuals with missing outcome data 
Individuals on TB treatment at enrolment with a culture 
isolate susceptible to rifampicin and isoniazid 
Time to initiation of appropriate DR-TB treatment for 
rifampicin-resistant TB cases confirmed by culture and 
either LPA or phenotypic DST 
Individuals with rifampicin-resistant TB 
confirmed by culture and either LPA or 
phenotypic DST  
Individuals with missing outcome data 
All-cause mortality in TB and DR-TB suspects at 60 days All individuals enrolled Individuals with missing outcome data 
Proportion of TB suspects and DR-TB suspects with at least 
one hospital admission within 60 days 
All individuals enrolled Individuals with missing outcome data 
Time to initiation of antiretroviral therapy (ART) - for HIV-
infected TB and DR-TB suspects not yet receiving but 
eligible for ART 
HIV-infected individuals not receiving but 
eligible for ART based on CD4+ T-cell 
count ≤350 cells/µl, DR-TB or any TB 
after 1 Jun 2012 
Individuals with missing outcome data 
HIV-infected individuals with unknown ART eligibility 
HIV-infected individuals previously exposed to ART (except 
for prevention of mother-to-child transmission) 
ART, antiretroviral therapy; DR-TB, drug-resistant TB; DST, drug susceptibility testing’ LPA, line probe assay
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4.11.4.4 All-cause mortality in TB and DR-TB suspects at 60 days 
The population for this analysis was all enrolled individuals (i.e. all TB suspects and 
DR-TB suspects). A complete case analysis was conducted, so individuals with no 
post-baseline follow-up were excluded. Participants lost to follow-up were described 
and compared with those with known outcomes to determine the extent of any 
differences. Deaths recorded on the follow-up CRF or in programme registers were 
included for the endpoint. No specific information was collected about cause of 
death. This binary outcome was measured and analysed at an individual level, and 
the analysis accounted for within-cluster correlation. Regression modelling using 
generalised estimating equations with a binomial distribution function and a logit 
link were applied, specifying an exchangeable working correlation matrix. The odds 
ratio with 95% confidence intervals was reported with a p value from the Wald test.   
4.11.4.5 Proportion of TB suspects and DR-TB suspects with at least one hospital 
admission within 60 days 
The population for this analysis was all enrolled individuals (i.e. all TB suspects and 
DR-TB suspects). A complete case analysis was conducted, so individuals with no 
post-baseline follow-up were excluded. As the follow-up CRF did not contain 
information on dates of hospital admission and follow-up often occurred beyond 60 
days, it was necessary to cross-validate admissions with the district hospital 
information system. This outcome therefore only incorporated admissions to Hlabisa 
Hospital. This binary outcome was measured and analysed at an individual level, and 
the analysis accounted for within-cluster correlation. Regression modelling using 
generalised estimating equations with a binomial distribution function and a logit 
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link was applied, specifying an exchangeable working correlation matrix. The odds 
ratio with 95% confidence intervals was reported with a p value from the Wald test.   
4.11.4.6 Time to initiation of antiretroviral therapy (ART) - for HIV-infected TB 
suspects and DR-TB suspects not yet receiving but eligible for ART 
The population for this analysis was all individuals with documented HIV infection 
at enrolment who were antiretroviral therapy (ART) naïve and eligible for ART. 
Eligibility for ART was defined by CD4+ T-cell count ≤350 cells/µl (prior to or on 
the date of enrolment), rifampicin-resistant TB disease or any TB disease after 1 
June 2012. This was the date of implementation of the modified eligibility criterion 
recommending ART for all HIV-infected individuals with active TB disease. The 
presence of rifampicin-resistant TB disease or any TB disease after 1 June 2012 for 
the purposes of this analysis was based on the final Xpert MTB/RIF result, as this 
would in routine practice determine eligibility for ART.  
 
In the protocol and the statistical analysis plan, WHO clinical stage 4 disease was 
also included in the definition for ART eligibility. However, this was dropped for 
final analysis as information on clinical stage was not collected during the trial and 
was captured in the HIV programme database only when individuals started ART.  
 
Time was measured from date of enrolment to date of ART initiation. The date of 
ART initiation was based on documented date on follow-up CRF or, if the date was 
not recorded, from the HIV programme database. Follow-up time was censored at 
time of death for any participants that died prior to ART initiation. This time-to-
event outcome was measured at an individual level, accounting for within-cluster 
correlation. Cox proportional hazard models were fitted with the shared frailty option 
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to account for the cluster randomisation. Hazard ratios were presented with 95% 
confidence intervals. The proportional hazards assumption was examined graphically 
using the log-log plot and also using the score test based on scaled Schoenfeld 
residuals.[347] 
 
4.12 Economic evaluation and assessment of operational feasibility 
of point-of-care Xpert 
The trial protocol laid out a framework for an economic evaluation to explore the 
cost-effectiveness of point-of-care Xpert placement (Appendix Q). The intention was 
to perform a nested sub-study to collect information on patient and household costs 
incurred during the diagnostic process. Unfortunately, due to staffing and time 
constraints this was not possible. Similarly, an evaluation of the operational 
feasibility of point-of-care Xpert was planned, with certain key indicators to be 
assessed throughout the trial (Appendix Q). Due to staffing constraints and 
workload, information was collected on some, but not all, of these indicators thus 
giving an incomplete assessment of operational feasibility.    
 
 
4.13 Ethics approval and trial registration 
The trial was approved by the Ethics Committee of the London School of Hygiene 
and Tropical Medicine, reference 5926 (Appendix I), the Biomedical Research 
Ethics Committee of the University of KwaZulu-Natal, reference BF033/11 
(Appendix J), the and the Health Research Committee of the KwaZulu-Natal 
Department of Health, reference 084/11 (Appendix K). Approval for the study was 
also obtained from Hlabisa Hospital (Appendix L) and the Africa Centre for Health 
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& Population Studies Community Advisory Board (Appendix M). The trial was 
registered with Current Controlled Trials on 17 June 2011 [ISRCTN 18642314] 
(Appendix N) and with the South African National Clinical Trials Register on 10 
July 2011 [DOH-27-0711-3568] (Appendix O).   
 
4.14 Trial oversight 
The principal investigator was responsible for the conduct of the study, including 
study design, implementation, data collection, and data analysis. He was also 
responsible for co-ordination of local staff, liaison with Department of Health and 
National Health Laboratory Service, liaison with other relevant bodies, and 
protection of human subjects.  
 
The Trial Management Committee consisted of all the Investigators and was 
responsible for the overall management of the trial and decisions about continuation 
of the trial. Regular teleconferences were held throughout the trial. 
 
The Trial Steering Committee consisted of all the members of the Trial Management 
Committee plus three independent members (Professor David Moore [London 
School of Hygiene & Tropical Medicine], Professor Yunus Moosa [University of 
KwaZulu-Natal], and Dr Katherine Fielding [London School of Hygiene & Tropical 
Medicine]) and a representative from the funder (Wellcome Trust). The Steering 
Committee provided supervision for the trial and provided advice through the 
independent chairperson. The Steering Committee met six-monthly by 
teleconference.   
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Chapter 5 Trial results 
5.1 Participant flow 
A total of 36 two-week time blocks between 22 August 2011 and 01 March 2013 
were randomised to one of the two strategies for Xpert MTB/RIF positioning. In July 
2012, following the identification of a shortfall in the enrolment of culture-positive 
cases, the Trial Steering Committee recommended measures to enhance recruitment 
and to maximise the yield from sputum cultures. Despite implementation of these 
measures, enrolment remained below target. A decision was taken to extend the trial 
beyond the originally planned 32 clusters to maximise recruitment but the 
recruitment phase was not able to be extended beyond March 2013 due to time and 
financial constraints. 
 
1526 individuals were screened and 1297 (85.0%) were enrolled in the study. There 
were a further 16 exclusions (14 duplicate enrolments and two who were later found 
not to have met the eligibility criteria) leaving 1281 participants for analysis. Figure 
5.1 shows the flow of clusters and participants throughout the study. The reasons for 
exclusion are summarised in Table 5-1. 
 
The distribution of participants between the different groups (HIV-infected and risk 
of drug-resistant TB) was comparable across the trial arms (Table 5-2). Overall, 
more than 90% of participants were HIV-infected and just under half had one or 
more risk factors for drug-resistant TB.  
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Table 5-1 Reasons for individual exclusion 
Reason Laboratory Point-of-care 
Exclusion from study* 128 101 
Age <18 years 15 12 
No cough 69 49 
No documented HIV infection and no risk of drug 
resistance 
58 44 
Severely unwell requiring hospital admission 4 0 
Previous MDR/XDR-TB 1 4 
Suspicion of EPTB only 7 6 
Unable to give informed consent 4 3 
Exclusion from analysis 6 10 
Duplicate enrolment† 6 8 
On TB treatment at enrolment and not meeting 
correct criteria for risk of drug resistance‡ 
0 2 
* Individuals could have more than one reason for exclusion 
† For individuals enrolled twice, second enrolment excluded from analysis 
‡ On TB treatment without evidence of smear non-conversion or treatment failure: one individual 
presented with cough during treatment for TB meningitis, another individual presented with persistent 
cough three weeks into standard first-line treatment for smear-positive pulmonary TB 
 
 
Table 5-2 Distribution of participants between risk groups 
Risk group Laboratory 
(n = 640) 
Point-of-care 
(n = 641) 
HIV-infected only 351 (54.8) 353 (55.1) 
Risk of drug-resistant TB only 51 (8.0) 45 (7.0) 
HIV-infected & risk of drug-resistant TB 238 (37.2) 243 (37.9) 
 
 
There was significant variability in cluster size in terms of both TB and DR-TB 
suspects and culture-positive TB cases. The number of suspects per cluster ranged 
between 19 and 56 and the number of culture-positive cases per cluster ranged 
between zero and nine. The mean cluster size was well balanced across the two arms 
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in terms of suspects but the point-of-care arm had more culture-positive TB cases 
(91 cases, mean 5.1 per cluster) than the laboratory arm (68 cases, mean 3.8 per 
cluster). 
 
5.2 Baseline analysis 
The baseline demographic and clinical characteristics of the individual participants 
are shown in Table 5-3. The majority of suspects (76.3%) had at least one other 
symptom suggestive of TB (fever, night sweats or weight loss) besides the cardinal 
symptom of cough. The median duration of cough for all suspects was two weeks 
(interquartile range (IQR) 1-4). Almost 40% of suspects had at least one prior 
episode of TB. Of those, 390 (78.0%) had one previous TB episode, 81 (16.2%) had 
two previous TB episodes, and 29 (5.8%) had three or more previous TB episodes. 
The latest TB episode was within five years of enrolment for most participants with 
any previous TB (n = 306, 61.2%). 
 
The two arms were well balanced for most of the baseline characteristics. There was 
some evidence of imbalance for the CD4+ T-cell count in HIV-infected participants, 
with a higher median CD4+ T-cell count (280 cells/µl vs. 247 cells/µl) and lower 
proportion with CD4+ T-cell count <50  cells/µl (6.4% vs. 10.3%) in the laboratory 
arm. The proportion of HIV-infected participants on ART was comparable for the 
two groups. Most of the difference in CD4+ T-cell counts was attributable to those 
on ART (median CD4+T-cell count 327 cells/µl in laboratory arm vs. 293 cells/µl in 
point-of-care arm). CD4+ T-cell counts were similar across the arms for those not on 
ART (235 cells/µl in laboratory arm vs. 231 cells/µl in point-of-care arm). 
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Figure 5-1 Trial profile 
 
 
Clusters (2-week clinic blocks) 
randomised
N = 36
Clinic blocks allocated to 
laboratory strategy
n = 18
Individuals screened
n = 774
TB and DR-TB suspects 
enrolled
n = 646
TB and DR-TB suspects
n = 640
Mean per cluster 36 (range 19-56) 
Culture-confirmed TB cases
n = 68
Mean per cluster 3.8 (range 0-9)
Excluded from analysis
n = 6
Excluded (did not meet 
eligibility criteria)
n = 128
Clinic blocks allocated to point-
of-care strategy
n = 18
Individuals screened
n = 752
TB and DR-TB suspects 
enrolled
n = 651
TB and DR-TB suspects
n = 641
Mean per cluster 36 (range 20-55)
Culture-confirmed TB cases
n = 91
Mean per cluster 5.1 (range 2-9)
Excluded from analysis
n = 10
Excluded (did not meet 
eligibility criteria)
n = 101
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Table 5-3 Baseline characteristics of individual participants 
Variable  Laboratory 
(n = 640) 
Point-of-care
(n = 641) 
Sex Female (n, %) 393 (61.4) 422 (65.8) 
Age (years) Median (IQR) 36 (30-43) 36 (28-45) 
Body mass index (kg/m2) Median (IQR) 22.6 (20.2-26.5) 22.9 (20.1-27.0) 
Current symptoms Cough only (n, %) 157 (24.5) 147 (22.9) 
 Weight loss (n, %) 332 (51.9) 335 (52.3) 
 Fever (n, %) 269 (42.0) 256 (40.0) 
 Night sweats (n, %) 295 (46.2) 298 (46.7) 
Duration of cough (weeks)* Median (IQR) 2 (1-4) 3 (1-4) 
Current IPT use Yes (n, %) 8 (1.3) 11 (1.7) 
Risk of drug resistance None (n, %) 351 (54.8) 353 (55.1) 
 Treatment failure (n, %) 4 (0.6) 7 (1.1) 
 Smear non-conversion (n, %) 18 (2.8) 21 (3.3) 
 Previous TB treatment (n, %) 253 (39.5) 247 (38.5) 
 Household contact (n, %) 22 (3.4) 15 (2.3) 
 Health care worker (n, %) 12 (1.9) 9 (1.4) 
 Prison last 12 months (n, %) 7 (1.1) 10 (1.6) 
HIV infection  Positive (n, %) 589 (92.0) 596 (93.0) 
 Negative (n, %) 39 (6.1) 39 (6.1) 
 Never tested (n, %) 6 (0.9) 3 (0.5) 
 Not disclosed (n, %) 5 (0.8) 3 (0.5) 
 Missing (n, %) 1 (0.2) 0 
Antiretroviral therapy† Current (n, %) 238 (40.4) 222 (37.3) 
CD4+ T-cell count (cells/µl)†‡ Median (IQR) 280 (147-455) 247 (119-415) 
 ≤50 (n, %) 41 (6.4) 66 (10.3) 
 51-200 (n, %) 152 (23.8) 150 (23.4) 
 201-350 (n, %) 149 (23.3) 158 (24.6) 
 351-500 (n, %) 85 (13.3) 81 (12.6) 
 >500 (n, %) 108 (16.9) 92 (14.4) 
 Missing (n, %) 54 (8.4) 49 (7.6) 
IPT, isoniazid preventive therapy; IQR, interquartile range 
* Cough duration missing for 11 participants (laboratory, n = 3; point-of-care, n = 8) 
† Proportions are of HIV-infected participants 
‡ CD4+ T-cell count closest to enrolment date (up to 18 months prior to or 30 days after enrolment) 
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5.3 Diagnostic process 
5.3.1 Sputum specimen submission  
A total of 1235 suspects (96.4%) submitted two spontaneously expectorated initial 
sputum specimens. Of these, 1197 (96.9%) submitted their initial two sputum 
specimens on the day of enrolment, 26 (2.1%) submitted specimens the following 
day, and 12 (1.0%) submitted specimens on a later date. The proportion of suspects 
that submitted specimens did not differ by trial arm (laboratory 96.7% vs. point-of-
care 96.1%). There was also no evidence that the distribution of timing of specimen 
submission differed across the trial arms (Table 5-4). There were four occurrences of 
participants submitting the initial two sputum specimens during a different time 
block (cluster) and two of these crossed trial arms (one suspect was enrolled during 
laboratory block and submitted sputum specimens during point-of-care block; one 
suspect was enrolled during point-of-care block and submitted sputum specimens 
during laboratory block). 
5.3.2 Xpert MTB/RIF  
The results of Xpert MTB/RIF testing are shown in Table 5-5. Initial Xpert 
MTB/RIF tests yielded a valid result (positive or negative) in 553/619 (89.3%) in the 
laboratory strategy, compared to 596/616 (96.8%) in the POC strategy (p < 0.001). 
Allowing for repeat Xpert MTB/RIF tests using the remaining sputum/sample 
treatment reagent mix, a valid result was obtained in 571/619 (92.2%) in the 
laboratory strategy and 609/616 (98.9%) in the POC strategy (p < 0.001). The most 
obvious difference between the trial arms was with respect to the specimens not 
processed (in all cases due to specimen leakage during transit): 6.0% (37/619) of 
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initial specimens in the laboratory arm were not processed vs. 0.2% (1/616) in the 
point-of-care arm (p < 0.001). 
 
Including only results from the initial specimen, 9.9% (61/619) in the laboratory arm 
and 3.4% (21/616) in the point-of-care arm did not collect their Xpert result within 
60 days (p < 0.001).  
 
Of the 48 participants in the laboratory strategy without a valid result from the initial 
sputum specimen, 40 submitted a second specimen after a median of 5 days (IQR 4-
8); all but one of the repeat specimens yielded a valid Xpert result (seven positive 
and 32 negative). Of the seven participants in the POC strategy without a valid result 
from the initial sputum specimen, only one submitted a second specimen which 
produced a negative Xpert result. Overall, allowing for a maximum of two sputum 
specimens, a valid result was obtained for 610/619 (98.5%) in the laboratory strategy 
and 610/616 (99.0%) in the POC strategy (p = 0.441). 
 
When considering results of all Xpert tests performed, around one in six participants 
had a positive Xpert test (positive for detection of M. tuberculosis) and, of those, 
around one in six had rifampicin resistance detected. There was no evidence of any 
significant differences in Xpert results between trial arms. Overall, defining 
indeterminate Xpert results as any of ‘error’, ‘invalid’, or ‘no result’, 3.9% (49/1235) 
of first Xpert tests gave an indeterminate result, and this was slightly higher in the 
laboratory arm than in the point-of-care arm (4.7% vs. 3.1%, p = 0.146). After 
allowing for repeat Xpert tests on the first sputum specimen, 1.4% (17/1235) yielded 
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an indeterminate result, with minimal difference between trial arms (laboratory 1.8% 
vs. point-of-care 0.9%, p = 0.226).     
 
Table 5-4 Sputum submission and processing 
 Laboratory 
(n = 640) 
Point-of-care 
(n = 641) 
Sputum submission   
Submitted initial sputum specimens 619 616 
Day of enrolment 602 (97.3) 595 (96.6) 
One day after enrolment 10 (1.6) 16 (2.6) 
Two or more days after enrolment 7 (1.1) 5 (0.8) 
Submitted additional sputum specimen 40 (6.5) 1 (0.2) 
Xpert testing   
First sputum specimen tested 582 (94.0) 615 (99.8) 
Result from first sputum specimen 571 (92.2) 609 (98.9) 
Result from second sputum specimen 39 (6.1) 1 (0.2) 
Definitive Xpert result 610 (98.5) 610 (99.0) 
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Table 5-5 Xpert MTB/RIF results 
Xpert MTB/RIF result Laboratory
(n = 619) 
Point-of-care 
(n = 616) 
First Xpert test   
MTB DETECTED 97 (15.7) 107 (17.4) 
Rif Resistance NOT DETECTED 81 (13.1) 90 (14.6) 
Rif Resistance DETECTED 16 (2.6) 17 (2.8) 
MTB NOT DETECTED 456 (73.7) 489 (79.4) 
ERROR 9 (1.5) 10 (1.6) 
INVALID 16 (2.6) 9 (1.5) 
NO RESULT 4 (0.6) 0 
Not processed* 37 (6.0) 1 (0.2) 
First sputum specimen†   
MTB DETECTED 98 (15.8) 108 (17.5) 
Rif Resistance NOT DETECTED 82 (13.2) 91 (14.8) 
Rif Resistance DETECTED 16 (2.6) 17 (2.8) 
MTB NOT DETECTED 473 (76.4) 501 (81.3) 
ERROR 6 (1.0) 4 (0.6) 
INVALID 5 (0.8) 2 (0.3) 
NO RESULT 0 0 
Not processed* 37 (6.0) 1 (0.2) 
All Xpert tests‡   
MTB DETECTED 105 (17.0) 108 (17.5) 
Rif Resistance NOT DETECTED 87 (14.1) 91 (14.8) 
Rif Resistance DETECTED 18 (2.9) 17 (2.8) 
MTB NOT DETECTED 505 (81.6) 502 (81.5) 
ERROR 1 (0.2) 3 (0.5) 
INVALID 1 (0.2) 2 (0.3) 
NO RESULT 0 0 
Not processed a 7 (1.1) 1 (0.2) 
* Not processed was in all cases due to specimen leakage during transport 
† This allowed for repeat testing using residual specimen/buffer mix 
‡ A maximum of two sputum specimens could be submitted for Xpert MTB/RIF testing 
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Only 18/33 (54.5%) of those with an initial positive Xpert with rifampicin resistance 
detected submitted a second sputum specimen for Xpert testing as recommended in 
the protocol. In all but one instance, the second Xpert confirmed the initial result 
(positive with rifampicin resistance detected). In the one exception, an error was 
reported for the second specimen. The relatively low level of adherence to this aspect 
of the protocol may have been because repeat Xpert testing for rifampicin-resistant 
cases was not included in the national TB guidelines and national Xpert algorithm, 
which were implemented around the time that the trial started, and possibly also that 
the nurses gained confidence in the accuracy of Xpert as the trial progressed.   
5.3.3 Culture and drug susceptibility testing (DST) results 
A total of 1235 participants submitted a sputum specimen for culture and drug 
susceptibility testing (DST) according to the protocol. The results of the 
Mycobacterial Growth Indicator Tube (MGIT) culture are shown in Table 5-6. The 
most striking finding was that the overall yield from culture was actually lower than 
that from Xpert MTB/RIF with 12.9% (159/1235) of participants having a culture 
positive for M. tuberculosis, compared to 16.7% (206/1235) having a positive Xpert 
from the initial sputum specimen. Non-tuberculous mycobacteria were isolated in 
only 13 cases (1.1% of all suspects or 7.5% of positive cultures) and one case had a 
positive culture without definitive identification.  The lower yield from culture was 
at least partly explained by the substantial attrition during the laboratory processes. 
Overall 11.5% (142/1235) of specimens were not processed (in the majority because 
of specimen leakage in transport), 8.3% (103/1235) of cultures were contaminated, 
and in 2.9% (36/1235)  no culture result was returned to the clinic nor could be 
identified in the laboratory information system. Considering only results of 
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specimens that were processed and where a result could be identified, 15.0% 
(159/1057) of cultures were positive for M. tuberculosis.  
 
 
Table 5-6 Results of Mycobacterial Growth Indicator Tube (MGIT) culture 
Result Laboratory
(n = 619) 
Point-of-care 
(n = 616) 
Positive (M. tuberculosis) 68 (11.0) 91 (14.8) 
Positive (NTM) 7 (1.1) 6 (1.0) 
Positive (no identification) 1 (0.2) - 
Negative 402 (64.9) 379 (61.5) 
Contaminated 56 (9.0) 47 (7.6) 
Not processed 71 (11.5) 71 (11.5) 
Specimen leaked 63(10.2) 70 (11.4) 
Incorrect details* 2 (0.3) 0 
Processed for smear microscopy† 6 (1.0) 1 (0.2) 
No result 14 (2.3) 22 (3.6) 
NTM, non-tuberculous mycobacteria 
* Participant details on laboratory form and specimen container did not match 
† Specimen processed in error for smear microscopy instead of culture 
 
 
The baseline characteristics of the participants with an evaluable culture result, 
defined as positive for M. tuberculosis, positive for NTM, positive with no definitive 
identification or negative (n = 953), were compared with the characteristics of those 
without an evaluable result (n = 282). Those with an evaluable culture result were 
more likely to be HIV infected (93.6% vs. 89.0%, p = 0.010), more likely to be on 
ART if HIV-infected (40.7% vs. 33.9%, p = 0.049) and have higher baseline CD4+ 
T-cell count (median 277 cells/µl vs. 238 cells/µl, p = 0.053), but otherwise their 
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characteristics were similar to those of the participants without an evaluable result 
(Table 5-7). 
 
 
Table 5-7 Characteristics of participants with and without an evaluable culture result 
Variable  Evaluable 
culture result 
(n = 953) 
No evaluable 
culture result 
(n = 282) 
Sex Female (n, %) 619 (65.0) 169 (59.9) 
Age (years) Median (IQR) 36 (29-44) 36 (30-44) 
Body mass index (kg/m2) Median (IQR) 22.7 (20.2-26.8) 22.9 (20.1-26.5) 
Current symptoms Cough only (n, %) 218 (22.9) 67 (23.8) 
 Weight loss (n, %) 493 (51.7) 153 (54.3) 
 Fever (n, %) 395 (41.5) 116 (41.1) 
 Night sweats (n, %) 442 (46.5) 137 (48.9) 
Current TB treatment Yes (n, %) 37 (3.9) 11 (3.9) 
Previous TB treatment Yes (n, %) 368 (38.6) 121 (42.9) 
Current IPT use Yes (n, %) 15 (1.6) 1 (0.4) 
Risk of drug resistance Yes (n, %) 426 (44.7) 139 (49.3) 
HIV infection  Yes (n, %) 891 (93.6) 251 (89.0) 
Antiretroviral therapy* Current (n, %) 363/891 (40.7) 85/251 (33.9) 
CD4+ T-cell count (cells/µl)* Median (IQR) 277 (140-449) 238 (114-396) 
IPT, isoniazid preventive therapy; IQR, interquartile range 
* Proportions are of HIV-infected participants 
 
 
The results of drug susceptibility testing collated from line probe assay (LPA) and 
phenotypic DST are illustrated in Table 5-8. Concordance between line probe assay 
and phenotypic DST for rifampicin and isoniazid is presented in Table 5-9. 
Overall, 20.1% (32/159) of M. tuberculosis isolates were rifampicin resistant, the 
majority of which (29/32, 90.6%) were multidrug resistant. Isoniazid mono-
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resistance was rare, detected in only 1.9% (3/159) of M. tuberculosis isolates. 
Overall, rifampicin resistance was present in 9.7% (9/93) of culture-positive cases 
with no previous exposure to anti-TB treatment and 25.9% (14/54) of previously 
treated cases (Table 5-10).  
 
Table 5-8 Results of drug susceptibility testing (combined from line probe assay and phenotypic 
DST) 
 
Result Laboratory 
(n = 68) 
Point-of-care 
(n = 91) 
Rifampicin and isoniazid susceptible 51 (75.0) 72 (79.1) 
Isoniazid susceptible, rifampicin indeterminate* - 1 (1.1) 
Rifampicin mono resistance 2 (2.9) 1 (1.1) 
Isoniazid mono resistance 1 (1.5) 2 (2.2) 
Rifampicin + isoniazid resistance (MDR) 14 (20.6) 15 (16.5) 
Phenotypic DST was performed if line probe assay detected isoniazid and/or rifampicin resistance and 
if line probe assay results were indeterminate 
MDR, multidrug resistance 
* LPA reported as isoniazid susceptible, rifampicin inconclusive (phenotypic DST unsuccessful) 
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Table 5-9 Concordance between line probe assay and phenotypic DST for rifampicin & isoniazid 
Line probe assay 
result 
Phenotypic DST result 
Rifampicin  Isoniazid 
Susceptible Resistant Inconclusive  Susceptible Resistant Inconclusive 
Susceptible 3 1 0  3 2 0 
Resistant 2 26 0  0 29 0 
Inconclusive 1 3 1  1 1 0 
Figures in bold were defined as resistant for the purposes of analysis 
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Table 5-10 Rifampicin resistance according to history of TB treatment and trial arm 
 Laboratory 
(n = 68) 
Point-of-care 
(n = 91) 
Total 
New cases 3/37 (8.1%) 6/56 (10.7%) 9/93 (9.7%) 
With documented risk of drug resistance* 1/4 (25.0%) 1/4 (25.0%) 2/8 (25.0%) 
Without documented risk of drug resistance 2/33 (6.1%) 5/52 (9.6%) 7/85 (8.2%) 
Previously treated cases 9/27 (33.3%) 5/27 (18.5%) 14/54 (25.9%) 
Cases on treatment at enrolment† 4/4 (100%) 5/8 (62.5%) 9/12 (75.0%) 
All cases 16/69 (23.2%) 16/91 (17.6%) 32/160 (20.0%) 
* Two previously untreated rifampicin-resistant cases had household exposure to known drug-
resistant cases  
† Includes participants with treatment failure and sputum smear non-conversion 
 
5.3.4 Imbalance in culture positivity between trial arms 
The imbalance in culture positivity between the trials arms was unexpected given the 
trial design: as noted above, despite similar numbers of suspects, the point-of-care 
arm had a higher proportion of culture-positive TB cases (Table 5-11). The 
difference in proportion between the arms persisted after allowance for unevaluable 
culture results.  
 
Table 5-11 Proportion of participants with positive culture by trial arm 
 Laboratory Point-of-care 
All participants 68/640 (10.6) 91/641 (14.2) 
Participants who submitted sputum 68/619 (11.0) 91/616 (14.8) 
Participants with evaluable culture result* 68/478 (14.2) 91/475 (19.2) 
* Excluding contaminated cultures, those not processed, and those without valid result 
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There were no significant differences between the arms in presenting symptoms or 
duration of cough (Table 5-3). There was no difference in the proportion of 
participants that had already presented at least once previously to a health care 
facility with cough (34.1% in the laboratory arm vs. 36.4% in the point-of-care arm). 
The lower median CD4+ T-cell count (247 cells/µl vs. 280 cells/µl) and the higher 
proportion with CD4+ T-cell count <50 cells/µl (10.3% vs. 6.4%) in the point-of-
care arm could suggest some bias with sicker patients being enrolled during point-of-
care clusters, although as noted previously the difference between the arms in 
median CD4+ T-cell count was largely due to participants on ART and not untreated 
individuals. 
 
There was an uneven distribution of culture-positive cases across clusters (Figure 5-
2). There was some evidence of seasonality in the number of suspects enrolled, with 
more suspects enrolled during clusters in winter months (June-August). There was a 
difference in culture positivity between arms in the first eight clusters (7.5% in 
laboratory arm vs. 17.5% in POC arm), which could suggest differential enrolment 
of participants more likely to have TB into point-of-care clusters during the early 
phase of the trial. It could also be that there was a pool of cases that were 
undiagnosed prior to the start of the trial and that these cases were more likely to 
present during point-of-care blocks. Removing the first eight blocks, the overall 
proportion with a positive culture was more balanced between the two arms (12.3% 
in laboratory arm vs. 13.8% in POC arm).  
 
There was also evidence that the difference in culture positivity between arms was 
more marked for participants enrolling in the second week of a cluster block (Table 
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5-12), although there were no significant differences in culture yield across the arms 
depending on the day of the week enrolled (Table 5-13). The difference by week 
could suggest that community members or staff learnt when the diagnostic system 
was in operation at the clinic and that people strongly suspected to have TB were as 
a result more likely to present or be enrolled during the second week of a cluster.   
 
Table 5-12 Culture positivity by enrolment week of block 
Week Laboratory Point-of-care 
1 29/281 (10.3) 36/288 (12.5) 
2 39/320 (12.2) 55/306 (18.0) 
 
 
Table 5-13 Culture positivity by enrolment day (of either week during each block) 
Day Laboratory Point-of-care 
Monday 18/125 (14.4) 22/134 (16.4) 
Tuesday 20/141 (14.2) 24/133 (18.1) 
Wednesday 12/121 (9.9) 17/96 (15.0) 
Thursday 14/166 (8.4) 19/145 (11.6) 
Friday 4/48 (8.3) 9/50 (18.0) 
 
 
One aspect that could not be explored was whether there was differential adherence 
to the recommended one hour gap between collection of the two sputum specimens, 
as data on precise timing of specimen collection was not recorded. Lower adherence 
to this time gap in the laboratory arm, if participants were not waiting at the clinic, 
could plausibly have affected the mycobacterial yield in the second sputum 
specimens, which were systematically submitted for culture.  
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Figure 5-2 Frequency distribution of suspects and culture-positive cases by cluster 
Laboratory clusters – all suspects 
Point-of-care clusters – all suspects 
Laboratory clusters – culture-positive cases 
Point-of-care clusters – culture-positive cases 
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In summary, there was some evidence to suggest that there may have been some 
positive selection bias of people more likely to have TB into the point-of-care arm, 
although this could not be proven.  
 
5.4 Concordance between Xpert MTB/RIF and culture results 
The concordance between Xpert MTB/RIF result and MGIT culture result for all 
participants is displayed in Table 5-14. Only six of those that submitted sputum 
specimens (0.5%) had no result from either Xpert or culture. Of the 39 participants 
with positive Xpert and negative culture, 19 (48.7%) were on TB treatment at 
enrolment. In the majority of these cases (17/19), Xpert detected rifampicin 
susceptible M. tuberculosis and so may have detected non-viable bacilli.  
 
A further six of the remaining 20 participants with positive Xpert and negative 
culture had at least one previous episode of TB and in three of these cases the most 
recent episode of TB treatment had occurred within the year prior to enrolment (two 
were enrolled due to treatment failure) again raising the possibility that non-viable 
bacilli might have been detected by the Xpert assay. Nevertheless, the majority of 
those not on treatment with discordant Xpert positive/culture negative results had not 
previously received treatment and so the reason for the discordant results was not 
clear. Whilst the possibility of false positive Xpert detection of M. tuberculosis 
cannot be discounted, it is also plausible that differences between the two sputum 
specimens or technical issues with the cultures might have given rise to these 
discordant results. 
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Table 5-14 Overall concordance between Xpert MTB/RIF and culture results, all participants 
  MGIT culture result  
  Positive Negative No result* Total 
X
pe
rt 
re
su
lt†
 Positive 128 39 46 213 
Negative 30 734 243 1007 
No result 1 8 6 15 
 Total 159 781 295 1235 
* No result for MGIT culture included contaminated cultures and cultures positive for non-
tuberculous mycobacteria (as in these cases the presence or absence of M. tuberculosis cannot be 
definitively ascertained) 
† Xpert result defined as result of first valid test (on initial specimen or repeat specimen) 
 
5.5 Outcome data 
Outcome data were obtained for 919 (71.7%) participants and the proportion was not 
different between trial arms: laboratory arm (n = 461, 72.0%) vs. point-of-care arm 
(n = 458, 71.5%). Outcome ascertainment was prioritised for culture-positive cases 
and so follow-up data was available for all cases (159/159).  
 
The sources of outcome data for suspects and cases are shown in Table 5-15. 
Overall, 90.0% (827/919) of all outcome data came from contact with the 
participant; 81.5% (749/919) came from a participant follow-up visit at the clinic. 
These proportions were lower for cases: 76.7% (122/159) of outcome data for cases 
came from contact with the participant; 65.4% (104/159) came from a participant 
follow-up visit at the clinic. The proportions were lower because, where outcome 
data had not been collected from the participant or designated contact, information 
was collated from the clinic TB and HIV registers and this was done predominantly 
for culture-positive cases.  
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The median time to follow-up for all participants with outcome data ascertained from 
participant or nominated contact (n = 878) was 92 days (IQR 72-156). The time to 
follow-up was somewhat shorter for the 443 participants in the laboratory arm (86 
days, IQR 71-153) than for the 435 participants in the point-of-care arm (105 days, 
IQR 73-160). 
 
Table 5-15 Source of information for outcome data 
Source of data Laboratory Point-of-care 
All participants 461 458 
Participant clinic visit 389 (84.4) 360 (78.6) 
Participant phone call 32 (6.9) 46 (10.0) 
Nominated contact clinic visit 5 (1.1) 6 (1.3) 
Nominated contact phone call 10 (2.2) 19 (4.2) 
Home visit 7 (1.5) 4 (0.9) 
Clinic registers 17 (3.7) 18 (3.9) 
Other* 0 2 (0.4) 
Missing 1 (0.2) 3 (0.7) 
Culture-positive cases 68 91 
Participant clinic visit 52 (76.5) 52 (57.1) 
Participant phone call 4 (5.9) 14 (15.4) 
Nominated contact clinic visit 0 0 
Nominated contact phone call 0 7 (7.7) 
Home visit 0 0 
Clinic registers 12 (17.6) 15 (16.5) 
Other* 0 2 (2.2) 
Missing 0 1 (1.1) 
* Other included two reports of deaths: from TB tracing team (n = 1) and hospital staff (n = 1) 
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5.6 Primary outcome 
The primary outcome measure was the proportion of culture-confirmed pulmonary 
TB cases initiated on appropriate anti-TB treatment within 30 days of enrolment. For 
this analysis, three cases were excluded from the point-of-care arm as they were on 
TB treatment at enrolment and the M. tuberculosis culture isolate was susceptible to 
rifampicin and isoniazid. The population for analysis therefore included 156 culture-
confirmed pulmonary TB cases (68 in laboratory arm; 88 in point-of-care arm). The 
baseline characteristics of the culture-positive cases were balanced, except for a 
higher proportion of females and a higher proportion with risk of TB drug resistance 
in the point-of-care arm (Table 5-16). The median time to outcome evaluation was 
80 days (IQR 72-133) in the laboratory arm and 100 days (IQR 73-160) in the point-
of-care arm.  
 
The proportion of cases initiated on appropriate anti-TB treatment within 30 days of 
enrolment was 76.5% (52/68) in the laboratory arm and 79.5% (70/88) in the point-
of-care arm. In the primary analysis using generalised estimating equations with a 
binomial distribution function and a logit link, and allowing for within-cluster 
correlation, the odds ratio (OR) for initiating appropriate anti-TB treatment within 30 
days for the point-of-care arm compared to the laboratory arm was 1.13 (95% CI 
0.51-2.53, p = 0.76) (Table 5-17). The estimated value of the coefficient of variation 
(κ) was 0.11. 
 
As there was an imbalance in sex and baseline risk of drug resistance and these could 
plausibly affect the likelihood of starting appropriate anti-TB treatment within 30 
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days, the analysis was repeated, as specified a priori. This made no significant 
difference to the results (Table 5-17).  
 
For Xpert-positive/culture-positive cases, 51/57 (89.5%, 95% CI 78.9-95.1) in the 
laboratory arm and 65/68 (95.6%, 95% CI 87.8-98.5) in the POC arm started 
appropriate TB treatment within 30 days (Table 5-18). Overall, 215 participants 
started TB treatment within 60 days, 154 (71.6%) on the basis of a positive Xpert 
result and 14 (6.5%) on the basis of a positive culture. Three participants initiated 
anti-TB treatment within 30 days that was defined as inappropriate according to the 
drug susceptibility pattern (two in the laboratory arm and one in the point-of-care 
arm). In all three cases, this was due to discordant rifampicin resistance results: in 
two cases defined as MDR-TB by LPA and phenotypic DST, Xpert was reported as 
rifampicin susceptible and standard first-line anti-TB treatment was started; in the 
third case defined as isoniazid mono-resistant by LPA and phenotypic DST 
(rifampicin susceptible on both LPA and phenotypic DST), Xpert detected 
rifampicin resistance and MDR-TB treatment was initiated. Forty-five participants 
started treatment on clinical or radiological grounds, of whom only 7 (15.6%) had a 
subsequent positive culture identified as M. tuberculosis (Table 5-19). 
 
The majority (25/30, 83.3%) of Xpert negative/culture positive cases did not initiate 
appropriate TB treatment within 30 days and 50.0% (15/30) did not initiate 
appropriate treatment within 60 days. In the laboratory strategy, none of ten Xpert 
negative/culture positive cases started appropriate TB treatment within 30 days. Of 
the seven cases with fully susceptible TB, five (62.5%) started appropriate TB 
treatment on the basis of the positive culture (after 37, 55, 58, 86 and 92 days) and 
143 
 
 
 
two were not recorded as having started treatment. Of the three cases with 
rifampicin-resistant TB (all with MDR-TB), all three started drug-resistant TB 
treatment (after 51, 92, and 125 days); one of those cases had initially commenced 
first-line anti-TB treatment on the basis of the initial positive culture result before 
DST results. In the POC strategy, 5/20 (25.0%) of Xpert negative/culture positive 
cases commenced appropriate TB treatment within 30 days, four on the basis of 
chest X-ray and one on the basis of the positive culture (all five had fully susceptible 
TB). Of the remaining 12 cases with fully susceptible TB, two commenced treatment 
on the basis of chest X-ray (after 45 and 58 days), four commenced treatment on the 
basis of the positive culture (after 35, 40, 55, and 57 days), three participants died, 
and three were not recorded as having started TB treatment. Of the three cases with 
rifampicin-resistant TB (all with MDR-TB), one started drug-resistant TB treatment 
(after 125 days), one died after commencing first-line anti-TB treatment (on the basis 
of the positive culture results before DST results), and one was not recorded as 
having started any TB treatment. 
 
In summary, there was no evidence of an effect of Xpert positioning on the 
proportion of culture-positive pulmonary TB cases initiated on appropriate anti-TB 
treatment within 30 days.   
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Table 5-16 Baseline demographic and clinical characteristics for culture-confirmed pulmonary TB 
cases included in primary analysis 
 
Variable  Laboratory 
(n = 68) 
Point-of-care
(n = 88) 
Sex Female (n, %) 32 (47.1) 53 (60.2) 
Age (years) Median (IQR) 34 (28-41) 33 (27-41) 
Body mass index (kg/m2) Median (IQR) 20.5 (18.2-22.0) 21.0 (18.6-25.0) 
Current symptoms Cough only (n, %) 9 (13.2) 10 (11.4) 
 Weight loss (n, %) 53 (77.9) 67 (76.1) 
 Fever (n, %) 28 (41.2) 34 (38.6) 
 Night sweats (n, %) 39 (57.4) 50 (56.8) 
Duration of cough (weeks) Median (IQR) 3 (1-6) 3 (2-4) 
Current IPT use Yes (n, %) 1 (1.5) 1 (1.1) 
Risk of drug resistance None (n, %) 33 (48.5) 52 (59.1) 
 Treatment failure (n, %) 1 (1.5) 2 (2.3) 
 Smear non-conversion (n, %) 3 (4.4) 3 (3.4) 
 Previous TB treatment (n, %) 30 (44.1) 31 (35.2) 
 Household contact (n, %) 6 (8.8) 4 (4.6) 
 Health care worker (n, %) - - 
 Prison last 12 months (n, %) 1 (1.5) 2 (2.3) 
HIV infection  Positive (n, %) 64 (94.1) 87 (98.9) 
 Negative (n, %) 3 (4.4) 1 (1.1) 
 Never tested (n, %) 1 (1.5) - 
 Not disclosed (n, %) - - 
 Missing (n, %) - - 
Antiretroviral therapy* Current (n, %) 19 (29.7) 31 (35.6) 
CD4+ T-cell count (cells/µl)*† Median (IQR) 219 (98-371) 203 (99-328) 
 ≤50 (n, %) 6 (8.8) 10 (11.4) 
 51-200 (n, %) 21 (30.9) 29 (33.0) 
 201-350 (n, %) 14 (20.6) 24 (27.3) 
 351-500 (n, %) 12 (17.6) 8 (9.1) 
 >500 (n, %) 7 (10.3) 9 (10.2) 
 Missing (n, %) 8 (11.8) 8 (9.1) 
* Proportions are of HIV-infected participants 
† CD4+ T-cell count up to 18 months prior to or 30 days after enrolment  
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Table 5-17 Proportion of culture-confirmed pulmonary TB cases initiated on appropriate anti-TB treatment within 30 days, by trial arm  
  Proportion initiated on appropriate 
anti-TB treatment within 30 days 
 Unadjusted analysis  Adjusted analysis* 
  
% (95% CI) 
 
Odds ratio (95% CI) p value 
 
Adjusted odds ratio (95% CI) p value 
Laboratory 68 76.5 (64.6 – 85.9) 
 
1  
 
1  
Point-of-care 88 79.5 (70.9 – 88.1) 
 
1.13 (0.51-2.53) 0.76 
 
1.14 (0.50-2.57) 0.76 
CI, confidence interval 
* Adjusted for sex and baseline risk of TB drug resistance
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Table 5-18 Proportion of culture-confirmed pulmonary TB cases who started appropriate TB 
treatment within 30 and 60 days, according to Xpert MTB/RIF result 
 
Xpert result Laboratory Point-of-care 
30 days   
Xpert positive 51/57 (89.5%) 65/68 (95.6%) 
Xpert positive – rifampicin sensitive 42/45 (93.3%) 55/56 (98.2%) 
Xpert positive – rifampicin resistant 9/12 (75.0%) 10/12 (83.3%) 
Xpert negative 0/10 5/20 (25.0%)* 
Xpert no result 1/1 (100%)† - 
Total 52/68 (76.5%) 70/88 (79.6%) 
60 days   
Xpert positive 53/57 (93.0%) 65/68 (95.6%) 
Xpert positive – rifampicin sensitive 42/45 (93.3%) 55/56 (98.2%) 
Xpert positive – rifampicin resistant 11/12 (91.7%) 10/12 (83.3%) 
Xpert negative 4/10 (40.0%) 11/20 (55.0%) 
Xpert no result 1/1 (100%) - 
Total 58/68 (85.3%) 76/88 (86.4%) 
* Four subjects with negative Xpert started treatment on basis of chest X-ray (after 1, 8, 11, and 14 
days); one subject started treatment on basis of positive culture (after 30 days) 
† One subject with no Xpert result (specimen leaked) started treatment on basis of clinical features 
(after 1 day) 
 
 
 
 
 
 
 
 
 
 
147 
 
 
 
Table 5-19 Basis of TB diagnosis for participants who started TB treatment within 60 days 
Basis of diagnosis Laboratory Point-of-care 
Sputum Xpert 73 81 
Sputum culture 7 7 
Chest X-ray* 14 26 
Clinical features  2† 3‡ 
Not known 1 1 
Total 97 118 
Of the 45 participants who started treatment based on chest X-ray or clinical features, one had a 
positive Xpert, 40 had a negative Xpert, and 4 had no valid Xpert result 
* Included 1 case of pleural TB in point-of-care arm; all others notified as pulmonary TB 
† Included 1 pulmonary, l lymph node 
‡ Included 2 pulmonary, 1 lymph node 
 
 
5.7 Secondary outcomes 
5.7.1 Time to initiation of appropriate anti-TB treatment for culture-confirmed 
pulmonary TB cases 
The population for the analysis of time to appropriate anti-TB treatment was the 
same as for the primary analysis: 156 culture-confirmed pulmonary TB cases (68 in 
laboratory arm; 88 in point-of-care arm) contributed 2413 days follow-up (median 
5.5 days, IQR 1.0-22.5). Follow-up time was censored at the earlier of appropriate 
TB treatment initiation or 60 days. Six participants (all in the point-of-care arm) died 
prior to the initiation of appropriate anti-TB treatment (median time to death 27 days, 
IQR 17-35).  
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In the Cox regression model, the proportional hazards assumption was not met (p = 
0.012). An attempt was made to split the survival analysis at different time-points 
(seven and 14 days) but the proportional hazards assumption was still violated.  
 
Time to appropriate anti-TB treatment for the two groups was plotted as Kaplan-
Meier survival curves (Figure 5-3). Deaths were censored at 60 days.[348] The time 
to appropriate anti-TB treatment data for the two groups were compared using the 
log rank test (p = 0.026). The estimated median time to appropriate treatment was 7 
days (95% CI 6-10) in the laboratory arm and 1 day (95% CI 1-2) in the point-of-
care arm.    
 
Under the POC strategy, 34 cases commenced appropriate treatment on the day of 
enrolment, all on the basis of a positive Xpert without evidence of rifampicin 
resistance. This represented 50.0% (34/68) of Xpert-positive/culture-positive cases, 
or 38.6% (34/88) of all culture-positive cases eligible for the primary analysis. The 
distribution of time to appropriate anti-TB treatment is shown in Figures 5-4 and 5-5. 
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Figure 5-3 Kaplan-Meier curves for initiation of appropriate anti-TB treatment before death for 
culture-confirmed TB cases 
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Figure 5-4 Time to appropriate anti-TB treatment for culture-positive cases, laboratory arm (n = 58) 
 
 
Figure 5-5 Time to appropriate anti-TB treatment for culture-positive cases, point-of-care arm (n = 
76) 
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The number of clinic visits made before commencing appropriate anti-TB treatment 
was calculated for the culture-positive, rifampicin-susceptible cases that did 
commence treatment (n = 43 laboratory arm, n = 60 point-of-care arm). These were 
the cases that would be expected to be detected by Xpert and to commence anti-TB 
treatment at the clinic without referral. The results are displayed in Figure 5-6. 
  
 
Figure 5-6 Number of clinic visits required to commence appropriate anti-TB treatment (for culture-
positive, rifampicin-susceptible cases) 
 
 
5.7.2 Time to initiation of appropriate DR-TB treatment for pulmonary 
rifampicin-resistant cases confirmed by culture and drug susceptibility testing 
A total of 32 rifampicin-resistant cases (16 in laboratory arm, 16 in point-of-care 
arm) contributed 976 days follow-up (median 23.5 days, IQR 14.5-56.0). Two cases 
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died before the initiation of appropriate anti-TB treatment (both in the point-of-care 
arm).  
 
In the Cox regression model, the proportional hazards assumption was not met (p = 
0.014). Time to appropriate drug-resistant TB treatment for the two groups was 
plotted as Kaplan-Meier survival curves (Figure 5-4). Deaths were censored at 60 
days.[348] The time to appropriate drug-resistant TB treatment data for the two 
groups were compared using the log rank test (p = 0.467). The estimated median 
time to treatment initiation was 27 days (95% CI 22-51) in the laboratory arm and 17 
days (95% CI 10-60) in the point-of-care arm. 
 
Five rifampicin-resistant cases did not initiate appropriate treatment – two Xpert-
positive cases died after referral to the provincial drug-resistant TB unit but before 
starting drug-resistant TB treatment (14 and 17 days after enrolment); one Xpert-
negative, culture-positive case died before formal diagnosis and before referral to the 
provincial drug-resistant TB unit (66 days after enrolment); one declined referral to 
the provincial drug-resistant TB unit and disengaged from clinical care; and one was 
referred and seen at the provincial drug-resistant TB unit but was not commenced on 
treatment(due to negative Xpert and normal chest X-ray this participant was placed 
on a monitoring programme with continued evaluation of symptoms and periodic 
repeat sputum cultures). 
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Figure 5-7 Kaplan-Meier curves for time to initiation of appropriate drug-resistant TB treatment 
before death for rifampicin-resistant cases 
 
5.7.3 All-cause mortality in TB and DR-TB suspects at 60 days  
A total of 919 TB and DR-TB suspects with valid follow-up data were included in 
this analysis. The proportion with follow-up data was similar in the laboratory arm 
(461/640, 72.0%) and the point-of-care arm (458/919, 71.5%). Table 5-20 compares 
the characteristics of those included in the analysis with those of the 362 participants 
lost to follow-up and with unknown outcomes. The proportion of HIV-infected 
participants on ART was noticeably higher in those included in the analysis (42.5% 
vs. 29.2%, p < 0.001), perhaps because participants on ART were more likely to 
attend for study follow-up as they were attending regularly for routine care. 
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Otherwise there were no significant differences between those with known outcomes 
and those lost to follow-up.   
 
Overall, 24 (2.6%) participants died within 60 days of enrolment; more participants 
died in the point-of-care arm (n = 16, 3.5%) than in the laboratory arm (n = 8, 1.7%): 
OR 2.33, 95% CI 1.13-4.80, p = 0.022. This association was no longer significant 
after adjustment for baseline CD4+ T-cell count and culture result (Table 5-21). 
Overall, 0.9% (7/781) of those with a negative culture and 6.3% (10/159) of those 
with a positive culture died within 60 days. Of those with a positive culture, 5.5% 
(7/128) of those with a positive Xpert and 10.0% (3/30) of those with a negative 
Xpert died within 60 days.  
 
A summary of the clinical characteristics of the 24 participants who died within 60 
days is presented in Table 5-22. Most were HIV-infected (n = 22, 91.6%) and, of 
those, the majority were not yet on ART (n = 16, 72.7% of HIV-infected) and had a 
CD4+ T-cell count <200 cells/µl at enrolment (n = 14, 63.6%). Seven of the 16 not 
yet on ART were diagnosed with HIV in the 30 days prior to enrolment (three of 
those diagnosed on the day of enrolment). 
 
Over half of the participants who died within 60 days (n = 14, 58.3%) had 
microbiological evidence of pulmonary TB disease: seven participants Xpert 
positive/culture positive; three Xpert negative/culture positive; two Xpert 
positive/culture negative; and two Xpert positive with no culture result. All three 
Xpert negative/culture positive cases died before the initiation of TB treatment; all 
were HIV-infected not yet on ART and with low CD4+ T-cell counts (15 cells/µl, 90 
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cells/µl and 274 cells/µl) and only one started ART. Four of the 14 TB cases had 
rifampicin resistance detected by Xpert (two confirmed by culture and LPA/DST) 
and all four died before appropriate DR-TB was commenced (whilst awaiting initial 
appointment at provincial drug-resistant TB unit). One of the four was on first-line 
anti-TB treatment at enrolment and continued this up to the time of death but the 
other three had no anti-TB treatment prior to death.  
 
The temporal trend in deaths within 60 days was somewhat uneven as mortality 
declined over the course of the trial. 12 deaths (50.0%) occurred in the first 12 
clusters; 8 deaths (33.3%) occurred in the middle 12 clusters; and 4 deaths (16.7%) 
occurred in the last 12 clusters.  
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Table 5-20 Comparison of baseline characteristics for participants with outcome evaluated vs. those 
lost to follow-up 
 
Variable  Outcome 
evaluated 
(n = 919) 
Lost to follow-
up
(n = 362) 
Sex Female (n, %) 593 (64.5) 222 (61.3) 
Age (years) Median (IQR) 36 (29-44) 36 (28-45) 
Body mass index (kg/m2) Median (IQR) 22.7 (20.1-26.7) 22.7 (20.3-26.9) 
Current symptoms Cough only (n, %) 218 (23.7) 86 (23.8) 
 Weight loss (n, %) 475 (51.7) 192 (53.0) 
 Fever (n, %) 357 (38.9) 168 (46.4) 
 Night sweats (n, %) 430 (46.9) 163 (45.2) 
Current IPT use Yes (n, %) 15 (1.6) 4 (1.1) 
Risk of drug resistance None (n, %) 494 (53.8) 210 (58.0) 
 Treatment failure (n, %) 10 (1.1) 1 (0.3) 
 Smear non-conversion (n, %) 25 (2.7)  12 (3.3) 
 Previous TB treatment (n, %) 373 (40.6) 127 (35.1) 
 Household contact (n, %) 28 (3.1) 9 (2.5) 
 Health care worker (n, %) 17 (1.9) 4 (1.1) 
 Prison last 12 months (n, %) 9 (1.0) 8 (2.2) 
HIV infection  Positive (n, %) 856 (93.1) 329 (90.9) 
 Negative (n, %) 52 (5.7) 26 (7.2) 
 Never tested (n, %) 5 (0.5) 4 (1.1) 
 Not disclosed (n, %) 6 (0.7) 2 (0.6) 
 Missing (n, %) 0 1 (0.3) 
Antiretroviral therapy* Current (n, %) 364 (42.5) 96 (29.2) 
CD4+ T-cell count (cells/µl)* Median (IQR) 256 (134-428) 286 (141-446) 
 ≤50 (n, %) 80 (9.4) 27 (8.2) 
 51-200 (n, %) 225 (26.3) 77 (23.4) 
 201-350 (n, %) 223 (26.1) 84 (25.5) 
 351-500 (n, %) 117 (13.7) 49 (14.9) 
 >500 (n, %) 144 (16.8) 56 (17.0) 
 Missing 67 (7.8) 26 (10.9) 
* Proportions are of HIV-infected participants
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Table 5-21 Mortality within 60 days of enrolment, by trial arm 
  Mortality Unadjusted analysis  Adjusted analysis* 
 N % (95% CI) Odds ratio (95% CI) p value  Adjusted odds ratio (95% CI) p value 
Laboratory 461 1.7 (0.9-3.4) 1   1  
Point-of-care 458 3.5 (2.1-5.6) 2.33 (1.13-4.80) 0.022  1.92 (0.89-4.16) 0.096 
* Adjusted for M. tuberculosis culture result and CD4+ T-cell count 
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Table 5-22 Characteristics of participants who died within 60 days of enrolment 
Cluster Sex Age DR-TB risk HIV status On ART CD4+ T-
cell count 
Xpert result Culture result Notes 
Laboratory arm 
2 M 32 Previous TB Negative - - Negative No result  
11 F 30 No Positive No 66 Negative Negative  
14 M 53 Previous TB Positive Yes 102 Negative Contaminated  
20 M 43 No Positive No - - - Did not submit sputum 
21 M 63 No Positive No 92 Negative Negative  
21 F 45 No Positive No 162 Positive, RIFS Positive RIF/INH susceptible; died after 
initiation of appropriate TB Rx 
22 F 23 No Positive No 20 Positive, RIFR Not processed Died before initiation of DR-TB Rx 
30 F 33 No Positive No 61 Negative Negative  
Point-of-care arm 
1 M 28 Previous TB Positive Yes 67 Negative Negative  
1 F 29 No Positive Yes 433 Negative Negative  
1 M 31 No Positive No 16 Positive, RIFS Positive RIF/INH susceptible; died after 
initiation of appropriate TB Rx 
4 M 48 Previous TB Positive No - Positive, RIFS No result Died after initiation of appropriate TB 
Rx 
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Cluster Sex Age DR-TB risk HIV status On ART CD4+ T-
cell count 
Xpert result Culture result Notes 
4 M 40 Previous TB Positive No - Positive, RIFS Positive RIF/INH susceptible; died after 
initiation of appropriate TB Rx  
5 M 26 No Positive No 17 Negative No result  
7 M 29 No Positive No 274 Negative Positive RIF/INH susceptible; died before 
initiation of TB Rx  
9 M 48 No Positive Yes 257 Negative Not processed  
10 F 21 No Positive Yes 136 Positive, RIFS Positive RIF/INH susceptible; died after 
initiation of appropriate TB Rx 
12 F 33 SNC Positive No 461 Positive, RIFS Positive MDR on DST; died before initiation of 
DR-TB Rx 
15 F 53 No Positive Yes 203 Positive, RIFS Positive RIF/INH susceptible; died after 
initiation of appropriate TB Rx 
17 M 40 Previous TB Positive No 15 Negative Positive RIF/INH susceptible; died before 
initiation of TB Rx  
23 F 20 No Positive No 52 Positive, RIFR Positive MDR on DST; died before initiation of 
DR-TB Rx 
27 M 30 Previous TB Positive No 19 Positive, RIFR Negative Died before initiation of DR-TB Rx 
29 M 37 SNC Negative - - Positive, RIFS Negative Died on treatment (on Rx at initiation) 
34 M 49 No Positive No 90 Negative Positive RIF/INH susceptible; died before 
initiation of TB Rx 
ART, antiretroviral therapy; DR-TB, drug-resistant TB; DST, drug susceptibility testing; INH, isoniazid; MDR, multidrug resistance; R, resistant; RIF, rifampicin; Rx, 
treatment; S, sensitive; SNC, smear non-conversion
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5.7.4 Proportion of TB suspects and DR-TB suspects with at least one hospital 
admission within 60 days 
The 919 TB and DR-TB suspects with valid follow-up data were included in this 
analysis. In order to ascertain dates of hospital admission, details of participants who 
reported hospital admission were cross-validated with the district hospital 
information system. A similar proportion of participants in the two arms were 
admitted to hospital within 60 days of enrolment: 1·4% (95% CI 0.5-2.3) in 
laboratory arm vs. 2·2% (95% CI 1.0-3.3) in point-of-care arm (OR 1·60, 95% CI 
0·68-3·77, p = 0·286). 
 
5.7.5 Time to initiation of antiretroviral therapy (ART) for HIV-infected TB 
suspects and DR-TB suspects not yet receiving but eligible for ART  
Of the 689 ART-naïve HIV-infected participants, 452 (65.6%) were eligible for ART 
at enrolment based on CD4+ T-cell count ≤350 cells/µl prior to or on the day of 
enrolment, rifampicin-resistant TB or active TB disease following 1 June 2012 
(Figure 5-5). 321 of those (71.0% of those eligible) had follow-up data available and 
contributed 8911 days of follow-up (median 22 days, IQR 11-42). Those with 
follow-up data were more likely than those without follow-up data to have culture-
positive TB disease (23.4% vs. 0) but otherwise there were no significant 
differences. In particular, the median CD4+ T-cell count was similar for those with 
follow-up data and those without follow-up data (169 vs. 177 cells/µl, p = 0.943). 
 
The majority of individuals who were eligible did commence ART within 60 days of 
enrolment: 115/153 (75.2%) in the laboratory arm and 133/168 (79.2%) in the point-
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of-care arm. The time to ART initiation for the two trial arms is shown in Figure 5-6. 
The estimated median time to ART initiation was 24.1 days (95% CI 22.1-32.1) in 
the laboratory arm vs. 20.1 days (95% CI 17.1-22.1) in the point-of-care arm. The 
proportional hazards assumption was met (p = 0.514). There was no evidence that 
time to ART initiation was different in the point-of-care arm than in the laboratory 
arm (HR 1.22, 95% CI 0.91-1.64, p = 0.184).  
 
Overall, there were 83 participants eligible for ART, not on TB treatment at 
enrolment but with a positive Xpert test and with follow-up data available. Similar 
proportions in the laboratory arm (29/45, 64.4%) and the point-of-care arm (28/38, 
73.7%) had started ART within 60 days of enrolment. The median time to ART 
initiation for these TB cases was 23 days (IQR 21-34) in the laboratory arm (n = 29) 
vs. 17 days (IQR 14.5-23) in the point-of-care arm (n = 28). Similar proportions of 
these TB cases had started both TB treatment and ART by 30 days (61.9% in 
laboratory arm vs. 59.1% in POC arm). For those with the most advanced HIV 
disease (CD4+ T-cell count ≤200 cells/µl), a somewhat higher proportion in the POC 
arm (13/16, 81.3%) than in the laboratory arm (11/17, 64.7%) had commenced both 
TB treatment and ART by 30 days but this difference was not significant (p = 0.438).  
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Figure 5-8 Profile of ART-naive individuals eligible for ART and with follow-up data 
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Figure 5-9 Time to antiretroviral therapy (ART) initiation in HIV-infected suspects eligible for ART 
 
      
 
5.8 Post hoc analysis 
5.8.1 Initiation of appropriate anti-TB treatment at different time thresholds 
To explore the effect of different time thresholds (5 days, 7 days, and 14 days) for 
the primary endpoint of appropriate anti-TB treatment, post hoc analysis was 
performed.  Regression modelling using generalised estimating equations with a 
binomial distribution function and a logit link was applied. The odds ratio was 
reported with 95% confidence intervals and a p value from the Wald test. 
The results are presented in Table 5-23.  
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5.8.2 Initiation of appropriate anti-TB treatment according to Xpert MTB/RIF 
result 
 
Given the problem of significant number of unevaluable sputum cultures, the 
proportion of participants that initiated appropriate anti-TB treatment was explored 
using the result of the Xpert MTB/RIF assay as the determinant of the 
appropriateness of treatment. For this analysis, there were 213 participants with a 
positive Xpert MTB/RIF test. Similarly to the primary outcomes analysis, 
participants that were on treatment at enrolment and were identified as having 
rifampicin-susceptible TB by Xpert (n = 28) were excluded as continued treatment 
would by default be considered appropriate. A further 13 participants with no post-
baseline follow-up were excluded, leaving 172 participants (82 in the laboratory arm 
and 90 in the point-of-care arm).  
 
The proportion of cases initiated on appropriate anti-TB treatment within 30 days of 
enrolment was 91.5% (75/82) in the laboratory arm and 95.6% (86/90) in the point-
of-care arm. In an analysis using generalised estimating equations with a binomial 
distribution function and a logit link, and allowing for within-cluster correlation, 
there was no evidence of a difference between the two strategies (OR  2.20, 95% CI 
0.75-6.45, p = 0.15). This did not change after adjustment for the presence of 
rifampicin resistance (based on Xpert result). The presence of rifampicin resistance 
(based on Xpert result) was strongly associated with lower likelihood of initiating 
appropriate anti-TB treatment within 30 days (OR 0.16, 95% CI 0.05-0.53). 
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Table 5-23 Results from exploratory analyses with different time thresholds for initiation of appropriate anti-TB treatment 
Time threshold  Laboratory arm   Point-of-care arm Odds ratio (95% CI) p value 
 n % (95% CI)  n % (95% CI)   
5 days 22 32.4 (21.5-44.8)  56 63.6 (52.7-73.6) 3.62 (1.81-7.26) <0.001 
7 days 36 52.9 (40.4-65.2)  58 65.9 (55.0-75.7) 1.74 (0.94-3.21) 0.076 
14 days 42 61.8 (49.2-73.3)  66 75.0 (64.6-83.6) 1.88 (0.98-3.59) 0.057 
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Chapter 6 Diagnostic performance of Xpert MTB/RIF 
Reporting of the diagnostic performance of Xpert MTB/RIF for the detection of M. 
tuberculosis and for the detection of rifampicin resistance was done with reference to 
the Standards for the reporting of diagnostic accuracy studies (STARD) 
statement.[349,350] 
6.1 Diagnostic performance of Xpert MTB/RIF for detection of M. 
tuberculosis 
6.1.1 Methodology 
This analysis was based on individual-level data and made no allowance for 
correlation within clusters. Sensitivity, specificity, positive predictive value and 
negative predictive value were compared for the two trial arms. Estimation of 
accuracy of Xpert MTB/RIF for the detection of M. tuberculosis, against the 
reference standard of single MGIT culture, was based on individual participants with 
paired valid Xpert MTB/RIF and MGIT culture results. Valid Xpert results (the first 
valid result from either the initial or repeat sputum specimen) included M. 
tuberculosis detected or not detected. Indeterminate Xpert results (invalid, error or 
no result) were excluded. A valid MGIT culture was defined as positive for M. 
tuberculosis or negative. Contaminated cultures and positive cultures identified as 
non-tuberculous mycobacteria were excluded, as in these instances the presence or 
absence of M. tuberculosis cannot definitively be ascertained.  
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This was performed as an intention-to-treat analysis. There were two protocol 
violations where sputum was tested under the alternative strategy to the randomised 
allocation but this represented less than 0.2% of the participants. The analysis only 
included individuals not on TB treatment at the time of enrolment, so as to avoid 
bias from detection of non-viable bacilli with Xpert in those on TB treatment. 
Sensitivity, specificity, positive predictive value, and negative predictive value were 
reported with 95% confidence intervals. To determine whether there was any 
significant difference between the two arms for each of these estimates, the 
difference between proportions was calculated with 95% confidence intervals and a 
two-sample z test was used. 
 
The performance of the two different versions of the Xpert MTB/RIF cartridge (G3 
and G4) for the detection of M. tuberculosis was compared. 
6.1.2 Results 
893 participants had paired valid Xpert MTB/RIF and MGIT culture results (Figure 
6-1). In this sample, the prevalence of culture-positive TB was 16.4% (95% CI 14.1-
18.9). Overall sensitivity was 79.5% (95% CI 72.0-85.7), specificity 97.3% (95% CI 
95.9-98.4), positive predictive value 85.3% (95% CI 78.2-90.8), and negative 
predictive value 96.0% (95% CI 94.4-97.3).  
 
The prevalence of culture positive TB was higher in the point-of-care arm than in the 
laboratory arm. There was no evidence of any difference in diagnostic accuracy 
under the two positioning strategies (Table 6-1). 
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There was no significant difference in performance between the Xpert G3 and G4 
cartridge with regards to the detection of M. tuberculosis: sensitivity 79.2% (95% CI 
68.0-87.8) for G3 vs. 79.7% (95% CI 68.8-88.2) for G4 and specificity 97.6% (95% 
CI 95.5-98.9) for G3 vs. 97.1% (95% CI 94.8-98.5) for G4.  
 
The Xpert MTB/RIF gives a semi-quantitative result (high, medium, low, very low) 
as an estimate of the mycobacterial burden in the tested sputum specimen. This result 
is based on the cycle threshold of the first positive probe. The profile of semi-
quantitative results for the 174 participants with a positive Xpert is displayed in 
Figure 6-2. There was a fairly even distribution between three groups (medium, low, 
and very low) with fewer specimens yielding a semi-quantitative result of high. As 
shown in the figure, there was no substantial difference in the distribution between 
rifampicin-resistant results and rifampicin-sensitive results.  
 
The distribution of semi-quantitative results for culture-positive and culture-negative 
cases is shown in Figure 6-3. The majority (n =14, 70%) of those with a positive 
Xpert and negative culture had a semi-quantitative result of very low, which could 
suggest that in these cases Xpert detected a very small quantity of M. tuberculosis 
DNA but there were not enough viable bacilli present to grow in liquid culture.
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Figure 6-1 Flow diagram for diagnostic accuracy of Xpert MTB/RIF for detection of M. tuberculosis  
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Table 6-1 Diagnostic accuracy of Xpert MTB/RIF for the detection of M. tuberculosis, by arm 
 Laboratory 
(n = 449) 
% (95% CI) 
Point-of-care
(n = 444)
% (95% CI) 
Difference (95% CI) p value 
Prevalence culture positive TB 14.0 (11.1-17.6) 18.7 (15.3-22.6) - - 
Sensitivity 84.1 (72.7-92.1) 75.9 (65.3-84.6) 8.2 (-4.7-21.1) 0.223 
Specificity 96.9 (94.6-98.4) 97.8 (95.7-99.0) -0.9 (-3.2-1.4) 0.450 
Positive predictive value 81.5 (70.0-90.1) 88.7 (79.0-95.0) -7.2 (-19.2-4.8) 0.237 
Negative predictive value 97.4 (95.3-98.7) 94.6 (91.8-96.7) 2.8 (0-5.5) 0.052 
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Figure 6-2 Semi-quantitative Xpert results according to rifampicin susceptibility 
 
 
 
 
Figure 6-3 Semi-quantitative Xpert results according to culture positivity 
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In five instances of discordant Xpert positive/culture negative results, rifampicin 
resistance was also detected by Xpert. Four of these participants had no specific risk 
factors for DR-TB. Rifampicin-resistant TB was subsequently confirmed by culture 
and phenotypic DST in two of these cases, prior to starting DR-TB treatment. In a 
third case, Xpert MTB/RIF on a second sputum specimen gave the same result (M. 
tuberculosis detected and rifampicin resistance detected) although smear microscopy 
and culture were negative prior to commencing DR-TB treatment. The fourth case 
had a subsequent positive culture prior to DR-TB treatment but phenotypic DST of 
the culture isolate detected no resistance to rifampicin (or isoniazid). In the last of 
these five cases, no further sputum specimens were tested and the participant died 
before commencing DR-TB treatment (Table 6-2).  
 
Table 6-2 Details of participants with discordant Xpert positive/culture negative results and 
rifampicin resistance detected by Xpert 
 
DR-TB 
risk 
Assay Semi-
quantitative 
result 
Probe* Repeat Xpert Repeat culture Notes 
No G3 Very low E Pos, RIFR Neg x 2  
No G3 Very low E Pos, RIFR Pos MDR x 2  
No G4 Very low B - Pos MDR/Neg  
Yes G4 High E - - Died  
No G4 Very low D - Pos, RIFS INHS  
INH, isoniazid; MDR, multidrug resistance; Neg, negative; Pos, positive; R, resistant; RIF, rifampicin; 
S, sensitive 
* Specific probe detecting mutation 
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The sensitivity of Xpert MTB/RIF for the detection of M. tuberculosis was 
somewhat higher at low CD4+ T-cell counts, although specificity was similar at all 
CD4+ T-cell counts (Table 6-3). 
 
Table 6-3 Diagnostic accuracy of Xpert MTB/RIF for the detection of M. tuberculosis by CD4+ T-
cell count in HIV-infected participants 
 
CD4+ T-cell count  Laboratory POC Overall 
≤50 Sensitivity 5/5 (100) 
[47.8-100] 
8/10 (80.0) 
[44.4-97.5] 
13/15 (86.7) 
[59.5-98.3] 
 Specificity 18/18 (100) 
[81.5-100] 
35/39 (89.7) 
[75.8-97.1] 
53/57 (93.0) 
[83.0-98.1] 
51-200 Sensitivity 18/20 (90.0) 
[68.3-98.8] 
21/27 (77.8) 
[57.7-91.4] 
39/47 (83.0) 
[69.2-92.4] 
 Specificity 74/79 (93.7) 
[85.8-97.9] 
70/71 (98.6) 
[92.4-100] 
144/150 (96.0) 
[91.5-98.5] 
201-350 Sensitivity 11/14 (78.6) 
[49.2-95.3] 
17/22 (77.3) 
[54.6-92.2] 
28/36 (77.8) 
[60.8-89.9] 
 Specificity 93/94 (98.9) 
[94.2-100] 
90/91 (98.9) 
[94.0-100] 
183/185 (98.9) 
[96.1-99.9] 
351-500 Sensitivity 9/11 (81.8) 
[48.2-97.7] 
5/7 (71.4) 
[29.0-96.3] 
14/18 (77.8) 
[52.4-93.6] 
 Specificity 53/55 (96.4) 
[87.5-99.6] 
53/53 (100) 
[93.3-100] 
106/108 (98.1) 
[93.5-99.8] 
>500 Sensitivity 4/6 (66.7) 
[22.3-95.7] 
7/9 (77.8) 
[40.0-97.2] 
11/15 (73.3) 
[44.9-92.2] 
 Specificity 74/77 (96.1) 
[89.0-99.2] 
58/59 (98.3) 
[90.9-100] 
132/136 (97.1) 
[92.6-99.2] 
Figures in parentheses are percentages and figures in square brackets are 95% confidence intervals 
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6.2 Diagnostic performance of Xpert MTB/RIF for detection of 
rifampicin resistance 
6.2.1 Methodology 
This analysis was based on individual-level data and made no allowance for 
correlation within clusters. The reference standard was the result of line probe assay 
or phenotypic DST on the culture isolate (an isolate was considered resistant if 
resistance was identified on either LPA or phenotypic DST, but as shown in Table 5-
9 the majority of isolates were resistant on both tests). Estimation of sensitivity and 
specificity of Xpert MTB/RIF for the detection of rifampicin resistance was based on 
individual participants with M. tuberculosis detected by Xpert MTB/RIF and with a 
positive MGIT culture and valid drug susceptibility test (LPA or phenotypic DST) 
result. This included individuals on TB treatment at the time of enrolment (e.g. 
participants with smear non-conversion or treatment failure). Sensitivity, specificity, 
positive predictive value, and negative predictive value were reported with 95% 
confidence intervals. To determine whether there was any significant difference 
between the two arms for each of these estimates, the difference between proportions 
was calculated with 95% confidence intervals and a two-sample z test was used.  
 
6.2.2 Results 
127 participants had paired valid Xpert MTB/RIF and LPA/DST results (Figure 6-4). 
In this sample, the prevalence of rifampicin resistance was 20.5% (95% CI 14.4-
28.3). Overall sensitivity was 88.5% (95% CI 69.8-97.6), specificity 99.0% (95% CI 
94.6-100), positive predictive value 95.8% (95% CI 78.9-99.9), and negative 
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predictive value 97.1% (91.7-99.4). The diagnostic accuracy for the detection of 
rifampicin resistance was not significantly different between the two different Xpert 
positioning strategies (Table 6-4). 
 
Sensitivity for the detection of rifampicin resistance differed by Xpert MTB/RIF 
cartridge (G3 cartridge 75.0%, 95% CI 42.8-94.5 vs. G4 cartridge 100%, 95% CI 
76.8-100) although specificity did not (G3 cartridge 100%, 95% CI 93.0-100 vs. G4 
cartridge 98.0%, 95% CI 89.4-99.9). 
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Figure 6-4 Flow diagram for diagnostic accuracy of Xpert MTB/RIF for detection of rifampicin resistance 
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Table 6-4 Diagnostic accuracy of Xpert MTB/RIF for detection of rifampicin resistance, by arm 
 Laboratory
(n = 57)
% (95% CI) 
Point-of-care
(n = 70)
% (95% CI) 
Difference (95% CI) p value 
Prevalence rifampicin resistance 23.0 (13.0-35.8) 19.0 (10.0-29.7) - - 
Sensitivity 84.6 (54.6-98.1) 92.3 (64.0-99.8) -7.7 (-32.1-16.7) 0.539 
Specificity 97.7 (88.0-99.9) 100 (93.7-100) -2.3 (-6.7-2.1) 0.253 
Positive predictive value 91.7 (61.5-99.8) 100 (73.5-100) -8.3 (-24.0-7.3) 0.307 
Negative predictive value 95.6 (84.9-99.5) 98.3 (90.8-100) -2.7 (-9.6-4.2) 0.416 
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There were four participants with discordant results for rifampicin resistance: three 
with Xpert reported as rifampicin sensitive but LPA/DST on culture isolate reported 
as rifampicin resistant; and one with Xpert reported as rifampicin resistant but 
LPA/DST on culture isolate reported as rifampicin sensitive. The details for these 
participants are summarised in Table 6-5.  
 
All three of those with discordant Xpert rifampicin sensitive/culture rifampicin 
resistant results had risk factors for the presence of drug-resistant TB. One case had 
treatment failure of a standard first-line anti-TB regimen (2HRZE/4HR) for isoniazid 
mono-resistant disease. In this case it was noted that the difference in cycle threshold 
(ΔCt) of 3.6 would have given a rifampicin resistant result under the original assay 
definitions (before the definitions were changed to improve specificity of the 
assay).[278] In this case the clinical suspicion was that the patient harboured mixed 
populations of isoniazid mono-resistant and multidrug-resistant bacilli (as the ability 
of the Xpert assay to detect certain mutations in the presence of mixed populations is 
poor).[215]  
 
The one case with a discordant Xpert rifampicin resistant/culture rifampicin sensitive 
result had no specific risk factor for DR-TB. The Xpert assay detected rifampicin 
resistance due to probe E delay. The MGIT culture performed for the study was 
positive and line probe assay was reported as rifampicin and isoniazid sensitive. Two 
cultures sent prior to DR-TB treatment were positive and phenotypic DST for both 
was reported as resistant to isoniazid and kanamycin but sensitive to rifampicin.  
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Table 6-5 Details of participants with discordant rifampicin resistance results 
DR-TB risk Assay Xpert 
resistance 
result 
ΔCt LPA Phenotypic 
DST 
Repeat culture* 
Yes (treatment 
failure) 
G3 RIFS 3.6 RIFS INHR MDR MDR 
Yes (DR-TB 
contact) 
G3 RIFS 1.2 RIFI INHS MDR No result 
Yes (previous 
TB) 
G3 RIFS 1.6 No result MDR Negative 
No G4 RIFR 4.3† RIFS INHR INH 
monoresistance 
Polyresistant‡ 
∆Ct, difference in cycle threshold; I, inconclusive; R, resistant; S, sensitive 
* Repeat cultures performed subsequently, prior to commencing DR-TB treatment 
† Probe E delay 
‡ Two cultures positive with resistance to isoniazid and kanamycin but sensitivity to rifampicin on 
phenotypic DST  
 
 
6.3 Operational feasibility of point-of-care Xpert 
There were incomplete data on operational feasibility, as data collection did not take 
place for all the indicators outlined in the protocol. Data were collected on power 
supply, operating temperature for the GeneXpert system, and storage temperature for 
the Xpert MTB/RIF test kits (temperatures were only reliably collected at the PHC 
clinic). Data on Xpert indeterminate results were presented in section 5.3.2.  
 
6.3.1 Power supply 
There was one instance of interrupted power supply under the laboratory strategy. In 
this case the power supply was interrupted during a test run and the back-up 
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generator did not start. In this event, the system produced an output of ‘No result’ for 
all four tests on that run (see Table 5-5).  
 
Under the point-of-care strategy there were two instances of interrupted power 
supply. On both occasions, this occurred whilst no tests were running on the 
GeneXpert system. During these two episodes, the backup generator was started and 
power was maintained to allow continued operation of the GeneXpert system.  
 
6.3.2 Operating temperature for GeneXpert system 
The recommended temperature range for operation of the GeneXpert system is 15-
30°C. Daily minimum and maximum temperatures were recorded in the room 
dedicated to operation of the GeneXpert system. A total of 158 daily readings were 
recorded (equivalent to 87.8% of days in which the system was operational at the 
clinic). The median minimum and maximum temperatures were 16°C (IQR 13-15) 
and 28°C (22-31) respectively. On 51days (32.3%) the maximum temperature 
exceeded the upper limit of the recommended range (>30°C). 
 
6.3.3 Storage temperature for Xpert MTB/RIF kits 
The recommended temperature range for storage of Xpert MTB/RIF test kits is 2-
28°C. Daily minimum and maximum temperatures were recorded in the clinic room 
where test kits were stored (this was a separate room to that used for operation of the 
GeneXpert system). A total of 267 daily readings were recorded (equivalent to 
74.2% of days during the study period, as cartridges were stocked there throughout 
the trial). The median minimum and maximum temperatures were 14°C (IQR 13-15) 
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and 21°C (19-25). On 27 days (10.1%) the maximum temperature exceeded the 
upper limit of the recommended range (>28°C).  
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Chapter 7 Discussion 
7.1 Main findings 
As effective anti-TB treatment exists that in most cases can prevent mortality as well 
as rapidly reduce infectiousness, the key to reducing deaths and curbing TB 
transmission at a population level is early detection and initiation of appropriate anti-
TB treatment. This was the first study designed to test the hypothesis that timely 
initiation of appropriate anti-TB treatment would be improved through positioning of 
a molecular diagnostic system at the place at which patients access care (primary 
health care clinic) compared to within a centralised laboratory. Although it was not 
possible to demonstrate clear benefits with respect to the clinical endpoints selected 
for the study, there were important benefits from point-of-care placement and nurse-
performed Xpert in rural primary health care was demonstrated to be possible.  
 
Overall, 77% of culture-positive cases were initiated on appropriate anti-TB 
treatment within the 30-day threshold. Considering only those in whom Xpert 
detected M. tuberculosis, 92% started appropriate anti-TB treatment within 30 days. 
The majority of cases that did not start appropriate treatment within 30 days had 
therefore tested negative with Xpert. This highlights that test sensitivity remains 
critical for getting the right people onto treatment. Nevertheless, the reduced 
sensitivity of Xpert compared to liquid culture in the study needs to be 
contextualised as almost one in four culture specimens gave no valid result and the 
operational yield of Xpert (under both laboratory or point-of-care strategies) was 
actually greater than that of liquid culture. This emphasises that culture may be an 
imperfect gold standard in the setting of real world implementation.   
183 
 
 
 
 
7.1.1 Impact of point-of-care positioning on initiation of anti-TB treatment 
There was no significant difference in the proportion of culture-positive cases 
initiated on appropriate anti-TB treatment within 30 days. Under both diagnostic 
strategies, around three-quarters of cases started appropriate treatment within the 
designated timeframe. In both arms, the majority of cases detected by Xpert without 
evidence of rifampicin resistance commenced treatment in a timely fashion and 
point-of-care positioning allowed for earlier initiation of treatment for drug-
susceptible cases.  
 
The primary endpoint was chosen to evaluate whether the point-of-care strategy 
could reduce delays and primary default whilst maintaining comparable diagnostic 
accuracy to the laboratory setting. The assessment of the appropriateness of 
treatment within the outcome was felt to be important given concerns about the 
accuracy of Xpert for detection of rifampicin resistance and uncertainty as to 
whether Xpert would perform as well in the clinic setting. Also, at the time of study 
design there was relatively little evidence about the performance for detection of 
rifampicin resistance in settings with very high levels of drug resistance and in 
patient groups at high risk of drug resistance. In reality, the diagnostic performance 
in this study was good and there were only three cases where cases started what was 
deemed to be an inappropriate regimen, on the basis of discordance between the 
Xpert rifampicin resistance result and phenotypic DST result.  
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The majority of the culture-positive cases that did not start appropriate treatment by 
30 days had tested negative with Xpert. Whilst there was some evidence to suggest 
that more were diagnosed by other means (predominantly X-ray) in the point-of-care 
arm, the numbers were small and certainly insufficient to influence the overall 
outcome. Fewer cases than expected started treatment on an empirical basis within 
30 days – only four cases in the point-of-care arm and none in the laboratory arm. 
This may be because it was still relatively early in the disease course (median 
duration of cough was only three weeks) and that individuals did not initially seek 
alternative diagnostic methods after testing negative with Xpert. This confirms the 
importance of test sensitivity in reducing diagnostic delays, as previously suggested 
on the basis of mathematic modelling.[51] The developers of Xpert MTB/RIF have 
recently announced plans to improve sensitivity of the assay with the aim of 
achieving a limit of detection of approximately 10 cfu/ml, comparable to liquid 
culture.[351] If this improved sensitivity is realised, the impact on diagnostic delay 
will be of particular interest.      
 
In the absence of strong evidence to guide the time threshold for the primary 
endpoint, 30 days was chosen based on our considered opinion as to what would be 
clinically relevant. Although it is recognised that the reduction in the time to 
diagnosis is important for TB control,[352] the lack of data on critical time 
thresholds of importance for influencing individual prognosis and tuberculosis 
transmission does hamper the selection of appropriate endpoints for diagnostic 
clinical trials. Post hoc analysis suggested that significant differences between the 
two strategies could have been detected if the threshold for initiation of appropriate 
anti-TB treatment was much shorter (i.e. five days). However, whilst a shorter 
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threshold might have provided more power to detect a difference between the two 
strategies, it is not clear whether such a difference at that time point would have 
clinical or public health significance. 
 
The sample size calculation included the assumption that 10% of Xpert MTB/RIF 
positive cases in the laboratory arm would not return for or receive result as 
indicated but in the trial only 3% in the laboratory arm had not received the result by 
30 days. Although around 10% of participants overall in the laboratory arm were not 
documented to have received their result, this was mostly individuals with negative 
test results. This suggests either that subjects testing positive were more likely to 
return for their result or that the routine measures to recall those who tested positive 
and who did not initially return functioned well during the trial. It is also possible 
that the trial and the study personnel improved the performance of routine 
programmatic measures such as this. Data was not available on the levels of primary 
default at other clinics in the sub-district during the study period, although this could 
have provided a useful comparison.  
 
Although a greater proportion of participants in the laboratory arm than in the POC 
arm did not have a valid result from the first sputum specimen (8% vs. 1%), repeat 
Xpert tests on additional sputum specimens were allowed within the trial protocol. In 
the laboratory arm, three culture-positive cases without a valid Xpert result from the 
initial specimen (two leaked during transit, one invalid) had a positive Xpert with the 
subsequent specimen and started appropriate anti-TB treatment as a result. While the 
allowance for collection of additional sputum specimens might have limited the 
186 
 
 
 
power to detect a difference in the primary outcome between the strategies, it 
reflected standard practice in a routine TB programme. 
 
The point-of-care strategy provided a shorter time to commencement of appropriate 
anti-TB treatment. There was a difference in median time to appropriate anti-TB 
treatment of six days (1 day vs. 7 days).  The study was not designed to determine 
whether this might have an impact on individual morbidity, although this is probably 
unlikely as disease progression in five days would be expected to be limited. Point-
of-care positioning allowed same-day diagnosis and treatment initiation for 34 
participants. This represented half of the Xpert-positive/culture-positive cases in the 
POC arm or just over a third of all culture-positive cases. Most of those who did not 
receive same-day diagnosis and treatment under the point-of-care strategy 
commenced treatment the following day. This proportion that received same-day 
treatment initiation was lower than that in the TB-NEAT study, where 66% of 
culture-positive cases in the Xpert arm started anti-TB treatment on the day of 
sputum submission.[240] The proportion with rifampicin resistance was higher than 
in the TB-NEAT study and these cases all had delays to treatment initiation. The TB-
NEAT study predominantly involved large urban health care facilities whereas this 
study was performed at a rural primary health care clinic. Several factors may 
influence people’s willingness to wait for test results and logistically there were 
constraints in this study, with testing only performed during daytime working hours. 
It does suggest, however, that to achieve same-day treatment initiation for all 
individuals, a reduction in the two-hour turnaround for testing would be highly 
desirable.      
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Whether or not the shorter time to treatment could influence transmission is of 
particular interest. With untreated active TB disease in this context, there are risks of 
transmission in the community and within healthcare facilities. Nosocomial 
transmission of TB in South Africa has contributed to the failure of TB control, most 
notably with the explosive outbreak of extensively drug-resistant TB in Msinga sub-
district, KwaZulu-Natal in 2005-6.[20,21] Health care workers in South Africa 
remain at increased risk of TB infection and disease,[313,353-357] and specifically 
drug-resistant TB.[358,359] Health care facilities and health care workers remain 
poorly equipped to effect TB infection control.[313-320,360] In this context, the 
identification and treatment of individuals with active pulmonary TB disease 
becomes a priority, as appropriate anti-TB treatment rapidly renders patients non-
infectious, with both drug-susceptible and drug-resistant disease.[25,26] As the study 
included ambulant individuals and cases had a relatively short duration of symptoms, 
it would be expected that many would be active in the community and visiting 
congregate settings, including workplaces, church, schools and health care facilities. 
In this context, any reduction in the time to appropriate treatment could plausibly 
affect onward transmission.   
 
It was not possible to establish whether the time to appropriate treatment for drug-
resistant TB cases was shorter under the point-of-care strategy, primarily as there 
was insufficient power in this analysis. More generally though, any potential effect 
from Xpert positioning was offset by health system delays across the board for drug-
resistant TB cases. During preparation for the trial, it was anticipated that the local 
district hospital would become a fully decentralised DR-TB treatment site.[41] 
However, this did not happen according to anticipated timelines. The hospital 
188 
 
 
 
continued to function as a satellite unit, where care was co-ordinated by the 
provincial specialist DR-TB unit but aspects of care (e.g. initial inpatient treatment) 
were delivered at the district hospital.[122] During the trial, therefore, DR-TB cases 
still had to be referred for outpatient consultation to the provincial DR-TB unit in 
Durban for treatment initiation and the delay between referral and this initial visit 
was the main component of the overall delay. 
 
Furthermore, four patients with rifampicin resistance detected by Xpert died prior to 
the initiation of appropriate DR-TB treatment. All had been referred to the provincial 
DR-TB unit for treatment. Whether or not death would have been prevented with 
more rapid initiation of drug-resistant TB treatment in these cases is not clear – three 
of the four had advanced HIV disease (CD4+ T-cell count <100 cells/µl) and were 
not yet on ART. These deaths have to be put into the context of the situation prior to 
Xpert implementation, where up to 40% of MDR-TB cases died before laboratory 
diagnosis.[122] 
 
Despite these delays, the time to appropriate DR-TB compares favourably to the 
situation prior to the implementation of Xpert and the situation more broadly in the 
province. In the study area, median time from sputum collection to commencement 
of DR-TB treatment for 50 cases managed under the satellite model in 2008, and 
diagnosed using culture and phenotypic DST, was 84 days.[122] This was broadly 
similar to other public sector programmes in South Africa (Figure 2-2).[123-129] 
The overall median time of 23 days in this study with Xpert is therefore a substantial 
improvement. Our findings are similar to those from Cape Town, where the median 
time to MDR-TB treatment commencement under an Xpert-based algorithm was 17 
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days (95% CI 13-22).[130] In a retrospective study of routine implementation in 
Durban, 68% of rifampicin-resistant cases successfully traced had commenced 
treatment within 4 weeks. However, this represented fewer than half of all diagnosed 
cases, as there was a substantial number that were untraceable.[361] The South 
African National Strategic Plan 2012-2016 includes the target of five working days 
from suspicion of drug-resistant TB to starting appropriate treatment.[40] This was 
not achieved for any of the DR-TB cases in this study. There is some preliminary 
evidence that this is possible where Xpert has been implemented within a framework 
of decentralised MDR-TB treatment and care.[300]  
 
In order to facilitate the rapid initiation of treatment for drug-resistant cases, there 
are initiatives to capacitate nurses to initiate and monitor MDR-TB treatment.[362] 
These will need to be rapidly scaled up and supported if treatment targets are to be 
achieved.  The potential for nurses to have an expanded role in the diagnosis and 
treatment of TB, and specifically drug-resistant TB, could empower them, in similar 
ways to what has been seen with Nurse Initiated and Managed Antiretroviral 
Therapy (NIMART) in South Africa.[363,364] However, the empowerment that can 
be produced has to be balanced against the pressures of increased workload and 
responsibility.[363,364] There was certainly anecdotal evidence during the study that 
the nurses appreciated the potential for same-day TB diagnosis and treatment and 
enjoyed the expanded role of performing tests normally confined to the laboratory. 
However, this requires more formal study with larger numbers of nurses to see 
whether nurse-delivered diagnostic testing would be sustainable in the long term.          
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7.1.2 Mortality 
Overall mortality amongst all individuals investigated for TB and DR-TB was lower 
than expected (2.6% died within 60 days of enrolment). In unadjusted analysis, 
mortality was higher in the POC arm, but following adjustment for the presence of 
TB disease (M. tuberculosis culture positivity) and baseline CD4+ T-cell count, this 
association was no longer statistically significant. The presence of TB disease was 
the factor most strongly associated with mortality in this study population (6.3% of 
those with a positive culture for M. tuberculosis died within 60 days vs. 0.9% with a 
negative culture). This emphasises the importance of detecting and treating TB 
disease in a timely fashion. 
 
There was no evidence that the difference in mortality between the arms was due to 
poorer Xpert performance and missed diagnoses of TB and DR-TB under the point-
of-care strategy. The observed difference was partly explained by the imbalance in 
TB disease and CD4+ T-cell count. It is possible that there were other unmeasured 
clinical differences in participants that contributed to different mortality risks 
between the two arms. As noted during the exploration of the imbalance in culture 
positivity between the arms (section 5.3.4), it is possible that the physical presence 
of Xpert at the clinic promoted access to testing for more unwell individuals. One of 
the exclusion criteria for the study was being severely unwell and requiring 
admission to hospital. Four individuals were excluded from the study for this reason 
during laboratory blocks but none was during point-of-care blocks. It is plausible 
that the study team enrolled severely unwell individuals during point-of-care blocks 
because they knew a result would be obtained within two hours.  
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A limitation of the mortality endpoint was that it represented all-cause mortality and 
specific causes of death were not sought as part of the study. Although TB and HIV 
remain the most common causes of death in adults in the study area, other unrelated 
causes such as injury and trauma are also common in young adults.[365,366] 
Although there would be no reason to believe that deaths unrelated to TB and HIV 
would be systematically different between the two trial arms, the low overall 
mortality would mean that a small number of deaths could bias the mortality 
estimates.  
 
Mortality might have been underestimated in this study because of the relatively high 
rate of loss to follow-up (28% lost to follow-up at two months). It is well 
documented in HIV programmes that mortality can be high in those lost to follow-up 
and failure to account for this can lead to underestimation of mortality.[367-369] 
Having said that, it is also possible that mortality was overestimated given the fact 
that sputum culture positivity was the factor most strongly associated with mortality 
and loss to follow-up was biased towards culture-negative cases. Other baseline 
characteristics were broadly similar for those lost to follow-up and those whose 
outcomes were known. Although fewer of those lost to follow-up were on ART 
(29% vs. 43%), CD4+ T-cell counts were similar. Despite the incomplete outcome 
ascertainment, there was no difference in follow-up between the two arms and 
therefore the risk of bias was low.    
 
The study was also conducted through a period of rapidly shifting epidemiology of 
HIV. There had been rapid scale-up of HIV testing, through both the national HIV 
counselling and testing (HCT) campaign [370] and local initiatives for home and 
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mobile testing.[371] The trial took place following the change in CD4+ T-cell 
threshold for ART eligibility in HIV-infected adults to 350 cells/µl, which has led to 
earlier presentation for HIV care and treatment.[372] As a consequence, mortality 
has reduced not only in those accessing ART but more broadly at a population 
level.[372-374] The proportion of HIV-infected participants on ART at enrolment 
was similar to the population-level coverage in the area, suggesting that the study 
population was broadly representative of those living with HIV in the area.[304,375] 
The median CD4+ T-cell count of 263 cells/µl was lower than the median for HIV-
infected individuals in the population (374 cells/µl),[376] but this was not 
unexpected as those with lower CD4+ T-cell counts are more likely to be 
symptomatic and to be accessing health care. Most deaths in this study still occurred 
in persons with advanced HIV disease not yet on ART. This highlights the continued 
challenge to facilitate earlier access to HIV testing and more effective linkage to care 
and treatment.     
 
It is difficult to directly compare mortality across the clinical trials as study 
populations are not directly comparable and mortality endpoints might differ. In the 
XTEND and TB-NEAT studies recruiting individuals at primary health care clinics, 
overall mortality was measured at six months: 4.4% in XTEND and 8.1% in TB-
NEAT.[240,297] The XTEND study was performed in South Africa only, whereas 
the TB-NEAT study took place in South Africa, Zambia, Zimbabwe and Tanzania 
and there was some evidence that mortality was not uniform across the study 
sites.[240] The TB-NEAT study also reported two-month mortality in culture-
positive cases that commenced anti-TB treatment of 5.2%, which is comparable to 
the 6.1% two-month mortality in all culture-positive cases in our study. In the study 
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of Mupfumi et al., which enrolled only HIV-infected adults initiating ART at a large 
urban hospital in Zimbabwe, overall mortality was 7.9% at three months.[298] In a 
prospective study from a single primary health care clinic, overall mortality at six 
months was very low at 0.8%, although in this study the rate of loss to follow-up was 
high and it is possible that mortality might have been substantially 
underestimated.[232]  
 
The relatively low overall mortality underlines the point that amongst individuals 
with symptoms suggestive of TB, there is a considerable difference between those 
attending primary health care clinics and hospital inpatients. In the study of 
hospitalised patients with symptoms suggestive of TB in Uganda where Xpert was 
used for TB diagnosis, mortality was 17% at two months.[228] In a similar study in a 
large referral hospital in Uganda of sputum smear-negative TB suspects, mortality at 
two months was 32%.[377] The study populations in hospital-based studies 
generally include participants with more advanced TB and HIV disease; in the two 
Ugandan studies, median CD4+ T-cell count was 54 cells/µl and 46 cells/µl 
respectively.[228,377] There is unlikely to be a universal TB diagnostic strategy for 
use in both ambulatory primary health care attendees and hospitalised patients and 
trial designs and endpoints need to be specific to the context.    
7.1.3 Integrated antiretroviral therapy 
One of the postulated benefits of point-of-care Xpert was the potential for more 
prompt initiation of antiretroviral therapy for eligible HIV-infected patients. It was 
thought that more rapid identification or exclusion of TB disease might expedite 
progress through the pre-ART phase and enable earlier initiation of ART. The data 
did not support this hypothesis, as time to ART initiation was similar under the 
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point-of-care and laboratory strategies. Similarly for the subset of participants with 
rifampicin-susceptible TB detected by Xpert, there was no difference in time to ART 
initiation between study arms and no difference in the proportion that had started 
both TB treatment and ART by 30 days. 
 
The sub-population for this analysis was a heterogeneous group, as ART-naïve HIV-
infected participants were enrolled in the study at different time-points in the pre-
ART phase. Participants enrolled on the day of HIV testing, the day of CD4+ T-cell 
count testing, the day of CD4+ T-cell count result collection, the day of attendance at 
group counselling sessions prior to ART, the day of planned ART initiation, or any 
other day prior to ART if presenting specifically for TB investigation. Whilst data 
was not collected systematically on which of these categories each participant 
belonged to, there was no reason to believe that the distribution of participants would 
have varied between the study arms. 
7.1.4 Patterns of anti-TB drug resistance 
The majority of M. tuberculosis isolates in this study were rifampicin and isoniazid 
susceptible. However, almost one in four isolates had evidence of anti-TB drug 
resistance, the most common pattern being multidrug resistance (resistance to 
rifampicin and isoniazid). As the study population preferentially included people at 
high risk of anti-TB drug resistance, this should not be considered to be 
representative of population-level resistance patterns. Having said that, our finding 
that 16% of Xpert-positive specimens had documented rifampicin resistance is very 
similar to recent district-level data for all individuals tested by Xpert in 2013-
2014.[303] This might suggest that the drug resistance patterns are broadly 
representative of those in individuals being investigated for TB in the local area. 
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Rifampicin resistance was present in around one in four previously treated culture-
positive cases and one in ten cases with no previous exposure to anti-TB drugs. This 
provides evidence for the sustained transmission of drug-resistant TB in this 
community and underscores the need to develop effective strategies to interrupt TB 
transmission.  
 
One of the reasons that the Xpert MTB/RIF assay incorporates testing only for 
rifampicin resistance is that the presence of rifampicin resistance is considered a 
good proxy for multidrug resistance. In this study, 90% of rifampicin-resistant 
strains also had evidence of isoniazid resistance which is similar to provincial-level 
data.[378] Distinguishing between rifampicin mono-resistance and multidrug 
resistance may still be important and this highlights the need for further testing with 
culture and phenotypic DST when rifampicin resistance is detected by Xpert.  
 
Understanding the frequency of isoniazid mono-resistance arguably has more 
importance for the widespread roll-out of Xpert as a replacement for smear 
microscopy. There were only three cases of isoniazid mono-resistant TB (2% of 
culture-positive cases). With Xpert testing, in the absence of LPA or phenotypic 
DST, isoniazid resistance will not be identified and cases will be treated as having 
drug-susceptible disease with standard first-line anti-TB drug regimens. It is 
recognised that outcomes with standard first-line or re-treatment regimens (with the 
addition of streptomycin) are suboptimal in the presence of isoniazid mono-
resistance,[379,380] although the evidence base to inform best practice in this 
context is weak.[328] Preliminary evidence from mathematical modelling has 
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suggested that the inability to detect isoniazid resistance may have a limited impact 
on population-level impact and cost-effectiveness of Xpert.[381,382] Having said 
that, the prevalence of isoniazid resistance varies quite substantially across regions of 
the world,[383] and strengthened surveillance of anti-TB drug resistance will be 
critical as access to Xpert expands into different areas.      
 
No cases of extensively drug-resistant TB (XDR-TB) or even pre-XDR-TB 
(resistance to either fluoroquinolones or injectable second-line agents, but not both) 
were observed in this study. XDR-TB has spread throughout KwaZulu-Natal 
province and clinical cases were seen elsewhere in the sub-district during the course 
of the study.[22] The recent data from the province where half of the cases identified 
with rifampicin-resistant TB by Xpert did not have a sputum specimen submitted for 
confirmatory phenotypic DST with second-line sensitivities is of concern.[361] In 
this regard, further development of rapid diagnostics capable of expanded resistance 
testing is important and should be welcomed.[351] 
 
7.1.5 Diagnostic performance of Xpert MTB/RIF 
Prior to design of the trial, there was no published evidence about the use of Xpert 
MTB/RIF at primary health care level. It was therefore unknown whether the 
diagnostic technology would perform comparatively outside the normal laboratory 
infrastructure as within. In terms of diagnostic accuracy for the detection of M. 
tuberculosis, sensitivity and specificity were similar under both positioning 
strategies. Overall sensitivity of a single Xpert MTB/RIF was approximately 80%, 
which was slightly lower than the pooled sensitivity of 87% from 27 studies (Figure 
3-1), but similar to the sensitivity in two prospective studies in South Africa with 
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predominantly or exclusively HIV-infected subjects.[218,220] This suggests that the 
diagnostic system can deliver acceptable performance in this rural setting not only 
under normal laboratory conditions but also within a primary health care clinic when 
operated by a nurse. 
 
There was evidence that sensitivity was improved with low CD4+ T-cell counts in 
HIV-infected individuals, consistent with two other published studies.[218,276] 
However, none of these studies have been powered to specifically address the 
question of differential sensitivity by CD4+ T-cell count. The significance of this 
finding in our study is unclear in the absence of smear microscopy results and the 
lack of knowledge of radiological patterns of disease.  
 
While Xpert only detected four out of five culture-positive cases, the overall positive 
yield from Xpert actually exceeded that of culture. The positive yield of M. 
tuberculosis from a single sputum specimen for Xpert was 17.5% (216/1235) 
compared to 13.0% (160/1235) from a single culture. The main explanation for this 
was the high number of culture specimens that leaked in transit or were 
contaminated. While the study was not designed to detect differences between Xpert 
and culture, this illustrates some of the limitations of culture-based diagnostics 
especially where laboratories are far removed from the point of care. While culture 
may be considered the gold standard for laboratory detection of M. tuberculosis, it 
may be that it is a poor standard in routine operational settings. This also highlights 
the challenges for diagnostic evaluation where the reference standard may be 
inappropriate.[384]     
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The simultaneous detection of genotypic resistance to rifampicin is one of the key 
benefits of the Xpert MTB/RIF system. In the early phases of Xpert evaluation and 
implementation, concerns arose about suboptimal specificity for the detection of 
rifampicin resistance.[278,334] This study was performed in an area with high levels 
of drug resistance and specifically included subjects with high risk of drug-resistant 
TB disease. Overall specificity was somewhat higher than in the large published 
studies (99.0%) and there was only one false positive rifampicin resistance result. 
Even this case had documented polyresistance on subsequent phenotypic DST 
(resistance to isoniazid and kanamycin), which raises the possibility that rifampicin 
resistance-associated mutations were correctly detected by Xpert. Unfortunately it 
was not possible to perform sequencing of the rpoB gene to determine whether 
mutations associated with rifampicin resistance were indeed present. There is an 
increasing body of evidence describing discordant genotypic and phenotypic 
resistance for rifampicin.[283-290] There is also some evidence that treatment 
outcomes with standard first-line regimens are poorer where there is genotypic 
evidence of resistance but phenotypic susceptibility.[284,290] There remains much 
need of further research to determine whether genotypic or phenotypic resistance 
better predict treatment outcomes, not only for rifampicin but also for other anti-TB 
drugs, in order to better inform diagnostic and treatment strategies. 
 
Interestingly, sensitivity for the detection of rifampicin resistance was relatively low 
(88.5%) and there were three cases where Xpert detected no mutations but 
phenotypic DST suggested phenotypic rifampicin resistance. It was unfortunate that 
further laboratory work was not possible to investigate these discordant cases. All 
three cases had documented risk of drug resistance and two had previously received 
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anti-TB treatment. Only one case had further confirmation of phenotypic resistance 
before commencing drug-resistant TB treatment. One plausible explanation for these 
discordant cases would be the presence of mixed susceptible and resistant bacillary 
populations in an individual. It has been documented that for certain rpoB mutations 
(e.g. L533P), Xpert will only determine resistance if nearly all of the M. tuberculosis 
bacilli in the sample carry the resistance-conferring mutation.[215,385] The 
sensitivity of Xpert to detect rifampicin resistance has been shown to be reduced in 
the presence of confirmed mixed strain infections.[385] Further work is needed to 
determine the impact of mixed strain infections on Xpert-based diagnosis in different 
settings, especially as the prevalence of mixed strain infections has been reported to 
be as high as 30% in some studies.[386] There has been much discussion about the 
potential harm from false positive rifampicin resistance results, mainly through 
exposing individuals to potential toxicity from second-line TB drug regimens. 
However, false negative resistance results could impact more broadly at a population 
level, by allowing amplification of drug resistance and continued transmission of 
drug-resistant strains.[47] This is of particular concern in South Africa, where there 
is evidence of poor compliance to diagnostic algorithms, with only half of those with 
a positive Xpert demonstrating rifampicin resistance having a specimen submitted 
for culture and phenotypic DST.[361]  
 
It was noteworthy that these three discordant resistance results (sensitive by Xpert, 
resistant by phenotypic DST) were obtained with the earlier version of the Xpert 
MTB/RIF cartridge (G3). As a result, sensitivity for the detection of rifampicin 
resistance was better with the G4 cartridge than the G3 cartridge (100% vs. 75%). 
Although changes to the cartridge were primarily to reduce the rate of errors and 
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improve specificity (with regards to rifampicin resistance), there were some  
modifications, particularly with probe B, to improve the detection of rifampicin 
resistance.[279] While the improved accuracy with the G4 cartridge is therefore 
encouraging, the numbers of rifampicin-resistant cases was small and confirmation 
of improved sensitivity for the detection of rifampicin resistance is needed from 
larger studies and routine programmes. 
 
Approximately one in 25 initial Xpert tests produced either an error, invalid result or 
no result. This proportion was reduced to 1.4% following repeat tests on remaining 
sample/buffer mix. The proportion of indeterminate results with the first sputum 
specimen was similar under both strategies (1.8% with laboratory testing, 0.9% with 
point-of-care testing). This was towards the lower end of the range of assay failure 
rates reported previously (Table 3-5), even though most studies have been from 
hospital laboratories. There was no evidence that the failure rate changed over the 
course of the study or as operators became more familiar with test procedures. There 
were two nurses employed one after the other during the trial but there was no 
evidence that the diagnostic performance of Xpert differed between the two nurses. 
 
The nurses performing point-of-care testing and the laboratory technician dedicated 
to Xpert testing all received the same training in the procedures. However, there 
remained the possibility that operator performance could impact on Xpert results, 
especially as the nurse was performing point-of-care testing in between attending to 
patients. There was also the possibility that temperature or power supply issues 
would hamper Xpert performance at the primary health care clinic yet this was not 
observed. This suggests that in this setting, the clinic infrastructure was sufficient to 
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allow proper functioning of the diagnostic system and that the system is robust 
enough to operate in the clinic environment. 
 
7.1.6 Need for diagnostics to uncover other causes of respiratory symptoms 
This study focused on the diagnosis of pulmonary TB, yet it is notable that even in 
this high prevalence setting with high levels of HIV co-infection, the majority of 
individuals presenting with cough did not have pulmonary TB. Other forms of TB 
that can present with cough, such as pleural, pericardial and intrathoracic lymph 
node TB, were surprisingly infrequent in this study population. Although outcomes 
for those without pulmonary TB were generally good, with 60-day mortality less 
than 1% for those with a negative sputum culture, there may still be benefit in 
ascertaining other causes of respiratory symptoms. These benefits might include 
reduction in morbidity, avoidance of inappropriate anti-TB medication, and 
allowance for earlier initiation of antiretroviral therapy by identification of causes 
other than TB. One study of adult primary health care attendees in Zimbabwe 
determined the aetiology of cough of three weeks or longer duration using 
standardised investigations including sputum-based diagnostics and X-ray.[387] In 
this study, common causes of cough other than TB were pneumonia and non-
pneumonic lower respiratory tract infection, asthma, post-TB fibrotic lung disease 
and cardiac disease. In the context of ambulatory primary health care attendees, 
HIV-associated conditions such as Pneumocystis jiroveci pneumonia, cryptococcal 
lung disease, and Kaposi’s sarcoma were relatively rare.[387] Additional rapid 
diagnostics suitable for point-of-care detection of common bacterial and viral 
respiratory pathogens,[388] and development of point-of-care X-ray 
technologies,[151] might allow more accurate diagnosis and appropriate treatment of 
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a broader set of conditions. Sequelae of pulmonary TB disease are well recognised, 
in the form of fibrotic lung disease, bronchiectasis, chronic obstructive pulmonary 
disease (COPD), persistent cavitation, and pulmonary aspergilloma.[389] The 
burden of chronic lung disease might be expected to increase in coming years in 
southern Africa as a result of large numbers of HIV-associated TB cases since the 
1990s and increasing rates of long-term survival with antiretroviral therapy, 
interlinked with occupational and environmental exposures.[390,391] There is a 
need for surveillance to monitor the true burden and impact of chronic respiratory 
diseases in southern Africa.[392] Concurrently, research is needed to establish 
diagnostic and therapeutic strategies for chronic respiratory diseases.  
 
 
7.2 Limitations 
7.2.1 Statistical power for primary outcome 
The trial was underpowered to detect a significant difference in the primary 
outcome. This was due most importantly to the lower than anticipated proportion of 
culture-positive TB cases amongst those investigated for TB. For the initial sample 
size calculation, the assumption was that 25% of people being investigated for 
pulmonary TB would have a positive sputum culture but the actual figure was only 
13%. The assumption of 25% was based upon preliminary data for yield of sputum 
culture examinations in Hlabisa sub-district and in other South African studies. In 
the Xpert demonstration study, the yield of sputum culture at the Cape Town site 
was 24%.[46] In other South Africa studies using culture to investigate adults with 
symptoms suggestive of pulmonary TB, the yield of sputum culture was 
approximately 30%.[152,393] In the TB-NEAT study, the overall yield of sputum 
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culture was 24%, although this ranged from 18-38% across the different study 
sites.[240] 
 
There are likely to be a number of reasons for the lower than anticipated culture 
positivity observed during the study. There was substantial attrition in the processes 
leading to a culture result, with just over three-quarters (77%) of sputum specimens 
yielding a valid result. The first problem was leakage of sputum specimens during 
transit. Overall 11% of specimens for culture leaked during transit from the clinic to 
the provincial culture laboratory. Measures were taken during the study to limit 
specimen leakage – this included reinforcing instructions to participants and health 
care workers about the proper closure of specimen containers, use of different types 
of specimen container, and the routine use of plastic paraffin film to seal specimen 
containers prior to transport. However, the proportion of specimens that leaked 
remained similar throughout the study. The storage and transportation of specimens 
was done through the routine systems operated by the National Health Laboratory 
Service (NHLS) but this was complex, with initial transit from the clinic to the 
district hospital, and then onwards to the provincial reference laboratory.  
 
There is actually very limited information in the literature about leakage of sputum 
specimens during transit, even though this is recognised as an important logistic step 
in the framework of TB diagnosis.[195] In one study also from Hlabisa sub-district, 
2.4% (8/335) of sputum specimens leaked during transit from hospital laboratory to 
Durban.[394] In one other South African study, 3.7% of specimens collected at 
primary health care clinics for smear microscopy leaked in transit to a centralised 
laboratory.[106] In two studies exploring transport of sputum specimens to 
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centralised laboratories in India, 4.2% (51/1210) and 1.7% (3/175) leaked during 
transit.[395,396]  It was also noted recently as a significant problem during the South 
African national TB drug resistance survey, although the extent of the problem was 
not quantified.[397] There are no data provided by the NHLS quantifying the extent 
of the problem in the routine laboratory system. It is an important reminder that in 
laboratory studies focused on diagnostic test accuracy, loss of specimens due to 
leakage is unlikely to be documented and that evaluation of the true effectiveness of 
diagnostics needs to examine the entire process from initial presentation with 
symptoms to diagnosis and treatment. 
 
Contamination of sputum cultures occurs due to the overgrowth of bacteria in the 
liquid culture medium. The bacteria can be present in the sputum sample or can be 
introduced from the environment during laboratory procedures. The likelihood of 
contamination can be influenced by the quality of sputum specimens, quality and 
duration of storage, and laboratory decontamination procedures. The overall rate of 
contamination in this study was 8.3% (or 9.7% if excluding culture specimens with 
no valid result). This is comparable to the pooled proportion of 8.6% with the MGIT 
system in a meta-analysis including ten studies from high-income settings.[398] In 
South African studies, contamination with the MGIT system has varied from 3.0% to 
16.7% [218,220,246,393]; and in one study in the Zambian national reference 
laboratory the contamination rate was as high as 29.6%.[399] As results from 
sputum culture defined the study population and outcome, further measures could 
have been taken to optimise the yield of sputum culture. It may be that the use of 
both solid and liquid culture media would have increased the yield and reduced 
contamination rates. It is also likely that the collection of two sputum specimens for 
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culture would have improved the yield, although this would have brought additional 
logistical challenges and the provision of three spot sputum specimens may not have 
been possible for some participants.  
 
The lower than expected culture positivity could also be partly explained by the 
characteristics of the study population. The median duration of cough was two weeks 
for all those investigated and three weeks for culture-positive cases. Historically, 
individuals were defined as TB suspects and investigated in the presence of a cough 
for longer than two-three weeks, on the basis that most acute viral and bacterial 
respiratory tract infections would be expected to resolve within this timeframe. Now, 
in the context of HIV infection, investigations for TB are recommended for cough of 
any duration.[400] Given that this study was at primary health care level and 
included a mixture of passive and active case finding, it is possible that this was 
close to a true representative sample of clinic attendees with current cough and it is a 
reminder that the majority of people with cough do not have TB, even in a 
community with an extremely high burden of disease.      
7.2.2 Evaluation of feasibility and broader impact of the point-of-care strategy 
The initial design of the trial incorporated an assessment of the operational feasibility 
of both strategies. Unfortunately, data on all feasibility indicators were not collected. 
In particular, information was not collected on hands-on user time, user performance 
or user appraisal. In general, the diagnostic system operated well under both 
strategies with few interruptions in power supply and no requirement for system 
maintenance throughout the study (other than routine annual calibration of modules). 
At times the temperature exceeded the recommended maximum temperature both for 
operation of the GeneXpert system and for storage of cartridges at the primary health 
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care clinic yet there was no evidence that this adversely affected the performance of 
the system. 
 
One of the most reliable and easily measurable indicators of feasibility was the 
proportion of Xpert tests with an indeterminate result (error, invalid or no result). 
Encouragingly, there was no significant difference between the two trial arms in this 
indicator, and if anything the proportion was marginally lower under the point-of-
care nurse-operated strategy (3.1% of initial Xpert tests) than under the laboratory 
strategy (4.7%). Overall, this was similar to the proportions reported in other clinical 
studies, and lower than reported for routine programme implementation (see section 
3.5).  
 
The incomplete data on operational feasibility and the lack of economic evaluation 
limits the conclusions that can be drawn as to whether point-of-care Xpert could be 
implemented more widely. This also highlights the need to compile a comprehensive 
evidence base about the impact of a new diagnostic tool or strategy that goes beyond 
analysis of effectiveness. The Impact Assessment Framework (IAF) comprises five 
interconnected elements: effectiveness analysis, equity analysis, health systems 
analysis, scale-up analysis, policy analysis. [401]The main focus of the trial was the 
clinical impact of a point-of-care strategy but use of this framework to guide the 
research might have enabled collection of a broader set of data to inform policy 
decisions.    
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7.3 Trial design 
The cluster randomised trial incorporated an unusual design with clusters defined as 
participants enrolled during a two-week time block. This design allowed for 
randomisation to one or other diagnostic strategy and was considered logistically 
easier to implement than individual randomisation. Whilst there are examples of 
similar cluster randomised trials with time blocks in the literature, these are 
relatively rare.[144,338-342] In general, the main reasons for selecting a cluster 
randomised design are: where an intervention is to be applied to groups of 
individuals; where the population-level effect of an intervention is to be measured; or 
where there is a need to avoid contamination from individuals in the same 
community being randomised to different trial arms.[402] The intervention in this 
trial was delivered at the individual level and a design incorporating individual 
randomisation would theoretically have been possible and indeed would have been 
statistically the most efficient design. Both the TB-NEAT study and the study in 
Zimbabwe comparing Xpert to smear microscopy used individually randomised 
designs.[240,298] Implementing a trial with individual randomisation at the single 
primary health care clinic would have posed some logistical difficulties due to the 
need for the study team to switch between diagnostic strategies on the same day. For 
this reason it was considered appropriate to adopt a cluster randomised design.[402]    
 
Alternative designs to address the principal research hypothesis were also 
considered. If more resources had been available, a cluster randomised design with 
individual health care facilities as units of randomisation would have been possible. 
Alternatively, if inclusion of more health care facilities was possible, a stepped 
wedge design could have been used whereby all clinics would have commenced the 
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trial using the laboratory strategy and then would have adopted the point-of-care 
strategy at different time points. A stepped wedge design was used for the XTEND 
study comparing Xpert to smear microscopy in 20 laboratories across several 
districts in South Africa.[297] However, such a design would have created additional 
challenges for analysis and ultimately was not possible with the time and resources 
available. Finally, quasi-experimental designs, such as a non-randomised pre- and 
post-intervention study were considered.[403] These are generally the most common 
type of study used in diagnostic research and there are several examples in TB 
diagnostic research, both with the line probe assay,[128,129,191,192] and with Xpert 
MTB/RIF.[130,228,232] These may be logistically the easiest to design and 
implement. However, the lack of randomisation is the key weakness of such designs 
and inappropriate conclusions can be drawn on the basis of associations without 
evidence of a causal association. This type of design would have faced real 
challenges in this environment, particularly with the outcome of mortality, as 
significant reductions in mortality were documented in the area during the trial 
period.[372,373] 
 
The randomised design did provide well-balanced groups in the study. The only 
imbalance in baseline characteristics was in the CD4+ T-cell count of HIV-infected 
participants, which was marginally lower in the point-of-care arm than in the 
laboratory arm (247 cells/µl vs. 280 cells/µl). However, the imbalance between the 
arms in culture positivity was unexpected and could not be clearly explained from 
the data available. This does raise the possibility that there were some other 
systematic differences in participants that would also have had the potential to affect 
the outcomes.  
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An important concept for the design of cluster randomised trials is that of the 
between-cluster coefficient of variation (κ).[336] This is a measure of the variation 
between clusters in the main outcome of interest. In general, κ is usually ≤0.25 and 
many large community randomised trials in TB have used values of 0.20-
0.25.[24,404,405] For this trial, there were no prior data to inform an estimate of the 
coefficient of variation. Given that the clusters were defined by time blocks, limited 
variation between clusters was expected for the primary outcome and therefore a 
value of k = 0.05 was selected for the sample size calculation. This value of κ 
corresponded to a range of proportions appropriately treated in the laboratory arm of 
77-94% for individual clusters. The estimated value of κ based on the trial data was 
0.11. This should be a useful guide to future studies employing similar designs with 
clusters defined by blocks of time. 
 
The trial was designed to measure the time to appropriate treatment for all culture-
positive cases and specifically for rifampicin-resistant cases. This time to event data 
required survival analysis techniques, specifically Cox proportional hazards 
regression. Cox regression assumes that the ratio of hazards comparing the trial arms 
is constant over time. In practice, this might have been an unreasonable assumption 
as according to the trial design there was expected to be significant early difference 
in treatment initiation due to the anticipated earlier diagnosis under the point-of-care 
strategy. Indeed the same-day treatment initiation in the point-of-care arm meant that 
some individuals reached the endpoint on day zero, which creates problems for 
survival analysis. For the Cox regression models of time to appropriate anti-TB 
treatment and time to appropriate drug-resistant TB treatment the proportional 
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hazards assumption was not met. Therefore any hazard ratio from these analyses 
would have been unreliable and they were not reported. Kaplan-Meier survival 
curves were plotted and compared using the log rank test. Although there are other 
analysis methods that might be appropriate in the setting of non-proportional 
hazards,[406] discussion of these was beyond the scope of this thesis. 
  
7.4 Generalisability 
Many of the laboratory systems functioned relatively well during the study. Whilst 
aspects of the laboratory strategy incorporated routine systems, the use of Xpert 
within the laboratory was confined to testing samples from the trial and involved 
specific trial personnel and so might not have been truly representative of a real 
world laboratory setting. Participant numbers were such that the system was only 
testing around 20-30 specimens per week. Data from routine implementation of 
Xpert in KwaZulu-Natal show that the laboratory turnaround time of 48 hours was 
exceeded with almost one-third of samples.[361] Separate data also from KwaZulu-
Natal has detailed the delays in laboratory processes when Xpert was introduced into 
a single central hospital laboratory in Durban.[301] In the Durban study, the overall 
time from sputum collection to return of results to the health facility was 6.4 days, 
somewhat longer than the time in the laboratory arm in this study.[301]          
 
The majority of participants were HIV-infected. Around 40% of HIV-infected 
participants were on ART at the time of enrolment and many others were undergoing 
preparation prior to commencing ART. This was therefore a population already 
engaged in care and with reasons to return to the clinic other than for receipt of TB 
test results. Whether or not individuals with a documented risk of drug-resistant TB 
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are more likely to return for TB test results is not known, but it is plausible that 
concern about drug resistance or familiarity with clinic procedures from previous TB 
episodes might make people more likely to return. It is therefore possible that the 
study population, although selected because of prioritisation for Xpert testing,[326] 
might have different risk for diagnostic default from HIV-uninfected individuals 
without risk of drug-resistant TB. This could therefore have affected the ability to 
detect an advantage to the POC strategy and could also limit the generalisability of 
the findings to other settings with lower HIV prevalence and lower rates of drug-
resistant TB.  
 
7.5 Lessons for future diagnostic research 
There is relatively limited experience with clinical trials of diagnostic tests or 
strategies and the knowledge gained from this study should inform future diagnostic 
research. It is critical in diagnostic studies to decide whether the outcomes are to be 
measured in all those investigated or only in those found to have the disease, in this 
case TB. One of the main challenges of diagnostic trials is that a large number of 
suspects need to be enrolled in order to identify a suitable number of cases. In this 
study, given that the rate of culture positivity was almost half of that anticipated, 
enrolment of double the number of suspects would have been required to achieve the 
sample size for the primary outcome and this was not possible for logistical and 
financial reasons.         
 
Clinical trials for TB diagnostics are of growing importance as new technologies 
emerge to meet the recognised demand.[401,407,408]  Experience with diagnostic 
trials is more limited than with vaccine and drug trials, and the design, conduct and 
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analysis of such trials can be complex.[47,409] The design of clinical trials and 
selection of endpoints has been relatively consistent for TB vaccines,[410,411] and 
for anti-TB drugs.[412] In the few clinical trials involving Xpert, all have employed 
different primary and secondary endpoints, summarised in Table 7-1.[240,297,298] 
The different endpoints reflect some differences in study populations, interventions, 
and underlying hypotheses, and there are also differences in whether the primary 
outcome is measured amongst all participants investigated for TB or only amongst 
participants with TB disease. As clinical trials will increasingly be necessary to 
evaluate and compare the effectiveness of new TB diagnostics, it would be useful to 
seek consensus on appropriate designs and endpoints for clinical trials. 
 
The poor performance of culture and drug susceptibility testing created problems not 
only for the diagnostic accuracy analysis but also for the clinical outcomes as this 
was the gold standard diagnostic used to define the population for analysis and the 
primary endpoint itself. The problem of an imperfect gold standard is well 
recognised in diagnostic accuracy research and various solutions have been proposed 
to deal with this.[413-416] In future research beyond diagnostic accuracy studies, 
careful thought should be given as to the role of a reference standard and how 
imperfect reference tests might affect the evaluation of impact. 
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Table 7-1 Comparison of endpoints in randomised trials investigating impact of Xpert MTB/RIF 
 TB-NEAT [240] XTEND [297] Mupfumi et al. [298] This study 
Intervention Point-of-care Xpert Xpert Xpert Point-of-care Xpert 
Comparator  Point-of-care smear 
microscopy 
Smear microscopy Fluorescent microscopy Laboratory Xpert 
Randomisation Individual Cluster (health facilities) Individual Cluster (time blocks) 
Study population Adults with TB symptoms Adults with TB symptoms HIV-infected adults due to 
start ART (with or without 
TB symptoms) 
HIV-infected adults with TB 
symptoms and adults with 
suspected DR-TB 
Primary endpoint TB morbidity in culture-
positive cases who had 
commenced anti-TB 
treatment 
Mortality at 6 months in all 
participants 
Proportion diagnosed with 
TB or died within 3 months 
(composite endpoint) 
Proportion of culture-positive 
cases initiated on appropriate 
anti-TB treatment within 30 days 
Secondary endpoints Time to TB diagnosis 
Time to anti-TB treatment 
initiation 
Proportion of culture-positive 
cases not started on anti-TB 
treatment  
Proportion of culture-positive 
cases lost to follow-up 
Feasibility of point-of=-care 
Xpert 
Proportion with positive 
index test 
Proportion started on anti-TB 
treatment at 6 months 
Loss to follow-up 
- Time to appropriate anti-TB 
treatment for culture-positive 
cases 
Time to appropriate anti-TB 
treatment for culture-positive 
rifampicin-resistant cases 
Mortality at 60 days in all 
participants 
Time to ART initiation for HIV-
infected participants eligible for 
ART 
ART, antiretroviral therapy; DR-TB, drug-resistant TB
214 
 
 
 
An exploratory analysis was performed using only the Xpert result to define 
cases requiring treatment, regardless of culture result. The results were 
similar, with no evidence that the proportion of Xpert-positive cases 
initiated on appropriate anti-TB treatment within 30 days was different 
between the two strategies. If this analysis had been chosen as the primary 
analysis, it would not have combined the assessment of rapidity of diagnosis 
with accuracy of Xpert under the different positioning strategies. This was 
the rationale for using the results of culture/DST as the gold standard to 
define cases, as it was not known whether different diagnostic performance 
of Xpert under the two strategies might affect the outcomes selected for the 
study. In particular, at the time of study design, there was genuine concern 
about the problem of false positive rifampicin resistance results and whether 
this was due to a technical issue with the assay or whether this might be 
operator dependent. In reality, the performance of Xpert was similar under 
both strategies and there was only one false positive rifampicin resistance 
result so this therefore had no influence on the main outcomes.        One 
concern about using Xpert positivity to define cases in need of treatment 
was the possibility of false positive results for the detection of M. 
tuberculosis, particularly in the context of non-viable bacilli in previously 
treated individuals.[417] There were a few cases where this was a 
possibility but the majority of those not on treatment at enrolment with 
positive Xpert but negative culture had not previously received anti-TB 
treatment and so there must have been other explanations for the 
discordance. In the absence of data conclusively explaining the discordance 
and of prospective data on clinical outcomes without treatment in these 
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individuals, no conclusions can be drawn about whether such cases truly 
require treatment or not. 
 
  
7.6 Recommendations for implementation 
The evidence generated in this study suggests that Xpert MTB/RIF can be 
delivered at the point of care in a rural primary health care clinic and 
diagnostic accuracy comparable to laboratory implementation can be 
achieved. Whilst there were advantages to point-of-care placement, 
including earlier initiation of appropriate anti-TB treatment and reduced 
number of clinic visits prior to treatment, an effect on the proportion of 
culture-positive pulmonary TB cases initiated on appropriate anti-TB 
treatment within 30 days could not be demonstrated. Cost-effectiveness 
analyses have suggested that point-of-care placement of Xpert MTB/RIF at 
current prices would need to produce substantial clinical benefits to offset 
the increased costs associated with clinic deployment in South Africa.[418] 
Increased costs were at least partly due to loss of efficiency because of 
lower testing volumes at each implementation site. Further cost-
effectiveness analyses are needed, but it is likely that further significant 
price reductions would be required to justify routine decentralisation of 
Xpert MTB/RIF beyond district hospitals in the immediate future. However, 
an argument exists that where the primary health care infrastructure allows 
and where sufficient volumes of testing can be maintained then point-of-
care placement could bring important benefits.   
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7.7 Recommendations for future research 
It remains important that new TB diagnostic technologies and strategies are 
subjected to rigorous evaluation with patient-relevant outcomes in real 
world settings.[47,48,419] It is likely that developments in molecular 
technologies may bring competing systems to the market and there needs to 
be a solid framework to guide evaluation and implementation of such tools. 
It is important that studies are designed and appropriately powered to 
address hypotheses and to detect differences of clinical and public health 
significance.  
 
One of the critical gaps in knowledge relates to the impact of diagnostic 
strategies on TB transmission. Whilst mathematical modelling can address 
certain questions, our fundamental understanding of TB transmission 
remains poor. With advances in molecular epidemiology enabling better 
understanding of transmission, this presents an opportunity for integrated 
research to gain insight into the impact of different diagnostic strategies on 
transmission. Of particular interest in this regard would be the impact of 
different diagnostic strategies on nosocomial transmission within primary 
health care facilities and hospitals. Whilst this research focused on the 
primary health care setting and ambulatory TB suspects, there is a need to 
explore the impact of point-of-care strategies in an inpatient setting with 
hospitalised adults. In addition to determining the effect on clinical 
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outcomes, of particular interest would be whether near-patient testing can 
facilitate triage and isolation of patients and whether this could have an 
impact on nosocomial transmission.   
 
This study evaluated a single diagnostic test and used only sputum 
specimens to detect M. tuberculosis. It is possible that diagnostic algorithms 
involving a combination of diagnostic tests may offer the potential for 
improved detection of TB and improved outcomes. There is some evidence 
that urine-based testing, either with Xpert MTB/RIF or with tests to detect 
urinary lipoarabinomannan (LAM), may be complementary to sputum Xpert 
testing.[263,420] In particular, urine-based tests may be better at detecting 
individuals with disseminated or miliary disease that may be missed by 
sputum testing or that may be unable to expectorate sputum.[260,263] 
Whilst such combination testing may be more suited to the inpatient setting 
and hospitalised adults, there is also the potential to explore combined 
algorithms at primary health care level.  
 
Detection of tuberculosis remains the priority when investigating respiratory 
symptoms in high burden settings. However, it remains the case that the 
majority of people with respiratory symptoms do not have active TB 
disease. Again there is the need to explore whether other diagnostic tests 
(for example multiplex PCR for detection of bacterial and viral respiratory 
tract pathogens) could be used in combination with TB diagnostics at the 
point of care in order to better inform treatment decisions. There is also 
likely to be an increasing need to improve the detection and management of 
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chronic respiratory diseases within the framework of primary health care in 
Africa.  
 
7.8 Concluding remarks 
New TB diagnostic strategies are required to improve TB control in high 
burden settings, particularly in southern Africa with high levels of anti-TB 
drug resistance and HIV co-infection. In the study presented in this thesis, 
the impact of a point-of-care diagnostic strategy was explored for people at 
the highest risk of TB mortality in a rural area at the epicentre of the TB and 
HIV epidemics in South Africa. Whilst it was not possible to demonstrate 
benefit from the point-of-care strategy in terms of the primary outcome, 
important evidence was generated that should inform future diagnostic 
strategies and diagnostic research. Point-of-care placement allowed for 
earlier initiation of appropriate anti-TB treatment, in some cases same-day 
initiation, which could plausibly impact on TB transmission and reduce both 
patient and health system costs. Point-of-care placement also reduced 
attrition within the diagnostic process, with fewer specimens untested due to 
leakage in transit. This observation, coupled with high rates of leakage of 
culture specimens, highlighted the potential impact that could be achieved 
by relatively simple interventions, such as procurement of high quality 
specimen containers and ensuring correct closure of containers at clinic 
level.      
 
In this study the main reasons that culture-positive cases were not initiated 
on treatment within 30 days were missed diagnosis by Xpert (due to 
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suboptimal sensitivity) or the presence of drug-resistant TB and the resultant 
delay in accessing treatment at the specialist drug-resistant TB unit. Despite 
the suboptimal sensitivity of Xpert compared to the defined gold standard of 
culture, the diagnostic systems based around sputum culture in a centralised 
laboratory performed poorly, due to high rates of leakage during transit and 
relatively high contamination rate. As a result, the actual yield of Xpert 
under both strategies was greater than culture.  
 
Certainly with the evidence available now, future clinical trials of Xpert 
MTB/RIF should not need to use culture as a gold standard to define cases 
requiring treatment and clinical outcomes could be measured in cases as 
defined by Xpert result. However, as molecular technologies are developed 
with improved sensitivity, [421]but consequently with potential for reduced 
specificity, there may still be a need for culture as a gold standard in clinical 
trials exploring clinical impact. However, the selection of appropriate 
outcomes in future diagnostic research will depend on the specific question 
being addressed and the intervention being evaluated. 
 
Overall, the study highlights that improvements in the diagnostic cascade to 
get all TB cases on treatment in a timely fashion will require a combination 
of technological advances (tests with improved sensitivity), optimisation of 
simple systems such as sputum specimen collection and transport, and 
broader strengthening of health systems to limit delays between diagnosis 
and treatment.
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Appendix A  Details of the GeneXpert system and Xpert MTB/RIF assay 
 
The GeneXpert® diagnostic system is a self-contained device which integrates 
automated sample processing and real-time amplification and detection of infectious 
pathogens. The system was originally developed in the United States for the detection of 
agents of bioterrorism, particularly the causative agent of anthrax (Bacillus 
anthracis).[1]  A wide range of important infectious agents can now be detected using 
pathogen-specific cartridges within the same GeneXpert system: methicillin-resistant 
Staphylococcus aureus, vancomycin-resistant enterococci, Clostridium difficile, 
influenza, group B streptococci, Chlamydia trachomatis and Neisseria gonorrhea. An 
assay for the measurement of human immunodeficiency virus (HIV) viral load is 
currently in development.[2] 
 
The Xpert® MTB/RIF assay was developed collaboratively by three partner 
organisations: Cepheid, a commercial molecular diagnostics company; the Foundation 
for Innovative New Diagnostics (FIND), a non-profit organisation; and the University of 
Medicine and Dentistry of New Jersey (UMDNJ). The assay was based on the use of 
molecular beacon technology (Figure A-1),[3,4] which had been exploited for the rapid 
detection of drug-resistant M. tuberculosis.[5-7]  
 
 
 
 
Figure A-1 Molecular beacons as hybridization probes 
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Molecular beacons are designed to detect specific target DNA sequences and are highly 
specific, easily discriminating sequences that differ from one another by a single 
nucleotide substitution. The target sequences for the molecular beacon probes are 
contained within the 81bp core region of the rpoB gene, which encodes the RNA 
polymerase enzyme (Figure A-2). Mutations within this region are highly predictive of 
rifampicin resistance and ~96% of all rifampicin-resistant strains contain mutations in 
this region.[8] The use of this target sequence allows for the simultaneous detection of 
the pathogen (M. tuberculosis) and the most important form of drug resistance.  
 
 
 
Figure A-2 Core region of rpoB gene with target DNA sequence of the molecular beacon probes (A-E) 
 
Sample pre-treatment is minimal: treatment reagent (sodium hydroxide and isopropanol) 
is added to unprocessed sputum, which liquefies the sputum and inactivates M. 
tuberculosis (rapid killing by 6-7 log10). After 15 minutes incubation at room 
temperature, 2mls of digested sputum is transferred to the sample chamber of the 
cartridge (Figure A-3). These are the only manual steps required and all further steps are 
fully automated in the closed system.  
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Figure A-3 Manual steps for sample preparation 
 
The single-use Xpert MTB/RIF cartridges contain i) chambers for holding sample and 
reagents, ii) a valve body composed of a plunger and syringe barrel, iii) a rotary valve 
system for controlling the movements of fluids between chambers, iv) an area for 
capturing, concentrating, washing and lysing cells, v) lyophilized real-time PCR 
reagents and wash buffers and vi) an integrated PCR reaction tube that is automatically 
filled by the instrument (Figure A-3). The cartridge contains lypophilised Bacillus 
globigii spores, which function as an internal sample processing and PCR control. 
 
 
 
 
 
Figure A-4 Interior of an Xpert MTB/RIF cartridge 
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Each GeneXpert module incorporates a syringe drive, rotary drive and a sonic horn. The 
sonic horn delivers ultrasonic energy necessary to lyse the raw specimen and release 
nucleic acids contained within, while the combination of the syringe drive and rotary 
drive moves liquid between cartridge chambers in order to wash, purify and concentrate 
these nucleic acids. After the automated extraction is complete, the nucleic acid 
concentrate is moved into the cartridge reaction chamber where amplification and 
detection takes place.  
 
Mycobacterium tuberculosis is detected if at least two of the five probes (A-E) produce 
a positive signal with a cycle threshold (Ct) of ≤38 cycles and within two cycles of each 
other. Mycobacterium tuberculosis is not detected if there is a positive signal from the B. 
globigii control without a positive M. tuberculosis signal. If the B. globigii internal 
control fails then the test is reported as invalid.    
   
The definition of resistance in the original Xpert MTB/RIF assay (version G3) is based 
on the ΔCt (difference between highest and lowest Ct for the M. tuberculosis probes). 
Under the original assay algorithm, rifampicin resistance was defined with a ΔCt>3.5. 
Following early reports of suboptimal specificity for the detection of rifampicin 
resistance,[9-12] the algorithm was later changed (to improve specificity of the assay) 
such that resistance was then defined with ΔCt>5.[13] Subsequently, the cartridge and 
software were modified (version G4), particularly with regard to the probe B beacon 
sequence, to reduce false rifampin resistance results.[14,15]  
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S U P P L E M E N T A R T I C L E
Evaluation of Tuberculosis Diagnostics:
Establishing an Evidence Base Around the Public
Health Impact
Richard J. Lessells,1,2 Graham S. Cooke,2,3 Marie-Louise Newell,2,4 and Peter Godfrey-Faussett1
1Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom; 2Africa Centre for Health and Population
Studies, University of KwaZulu-Natal, Mtubatuba, KwaZulu-Natal, South Africa; 3Department of Infectious Diseases, Imperial College, London, and 4UCL
Institute of Child Health, London, United Kingdom
The limitations of existing tuberculosis diagnostic tools are significantly hampering tuberculosis control
efforts, most noticeably in areas with high prevalence of human immunodeficiency virus (HIV) infection and
antituberculosis drug resistance. However, renewed global interest in tuberculosis research has begun to bear
fruit, with several new diagnostic technologies progressing through the development pipeline. There are
significant challenges in building a sound evidence base to inform public health policies because most
diagnostic research focuses on the accuracy of individual tests, with often significant limitations in the design,
conduct, and reporting of diagnostic accuracy studies. Diagnostic accuracy studies may not be appropriate to
guide public health policies, and clinical trials may increasingly be required to determine the incremental value
and cost-effectiveness of new tools. The urgent need for new diagnostics should not distract from pursuing
rigorous scientific evaluation focused on public health impact.
Global control of the tuberculosis epidemic is a public
health priority [1, 2]. The targets for reduction in tu-
berculosis prevalence and mortality linked to the Mil-
lennium Development Goals and enshrined in the STOP
TB Global Plan 2006–2015 will not be achieved with
current interventions [3, 4]. There is an acute need for
improved tuberculosis diagnostics as one critical com-
ponent of the public health response to the tuberculosis
epidemic.
The rapid growth of the human immunodeficiency
virus (HIV) epidemic and the emergence of antitu-
berculosis drug resistance have highlighted the major
deficiencies in current diagnostic technologies both
for pathogen detection and for diagnosis of drug
resistance [5]. In most high-burden countries, sputum
smear microscopy remains the principal tool for di-
agnosing active disease; however, operationally, its sensi-
tivity for pulmonary tuberculosis can be as low as 20%
[6, 7]. Sputum culture and drug susceptibility testing are
available in certain settings, but their impact is limited by
the long duration and complexity of the laboratory pro-
cesses [8]. Additional challenges are faced in developing
diagnostics for extrapulmonary tuberculosis, pediatric
tuberculosis, and latent tuberculosis infection [9–11].
The STOP TB Global Plan 2006–2015 included the
target that, ‘‘by 2010, simple, robust, affordable tech-
nologies for use at peripheral levels of the health system
will enable rapid, sensitive detection of active tubercu-
losis at the first point of care’’ [4, p. 24]. Although this
has not been achieved, there have been developments in
the tuberculosis diagnostic field, and promising tech-
nologies have entered the clinical sphere [6, 12–15].
Most promising has been the Xpert MTB/RIF system,
an automated molecular test that simultaneously detects
Mycobacterium tuberculosis and mutations associated
with rifampicin resistance [16, 17]. It is hoped that the
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renewed global focus on tuberculosis will in the next few years
lead to the further proliferation of diagnostic technologies in
parallel with advances in therapeutics and vaccines.
It is the responsibility of the global scientific community to
correctly evaluate these new technologies so that proven effective
and cost-effective diagnostics can be adopted, thus generating
the greatest public health impact. The importance of diagnostic
research in the overall tuberculosis research agenda has been
highlighted by many different groups [2, 15, 18–22]. However,
huge gaps in funding for tuberculosis research and tuberculosis
control remain [1, 2, 23]; this should force us to rethink how
diagnostic research can be most effectively targeted and ratio-
nalized to inform public health policies.
This article focuses on the framework for evaluation of new
diagnostics: at the outset, we look at the potential benefits of
new diagnostics, and then we discuss different methodologies to
evaluate diagnostic performance with a view to their ultimate
implementation. Our focus throughout is on diagnostic tests for
detection of active tuberculosis disease and/or drug resistance in
high-burden countries.
POTENTIAL IMPACT OF NEW TUBERCULOSIS
DIAGNOSTICS
It has been hypothesized that a test more sensitive than sputum
microscopy for tuberculosis would be the diagnostic inter-
vention that would alleviate the greatest burden of infectious
disease in developing countries [24]. More specifically, one
mathematical model of the global tuberculosis epidemic sug-
gested that a new rapid diagnostic test with 100% sensitivity,
100% specificity, and 100% access could prevent 625 000 deaths
annually (equivalent to 36% of all tuberculosis-related deaths)
[25]. Other models have derived fairly consistent estimates of
mortality reductions of 17%–23% from a more sensitive rapid
tuberculosis diagnostic, despite exploring different epidemics
[26–28]. In one model, the estimated benefit in terms of mor-
tality from a new diagnostic test was equivalent in magnitude to
that expected from a novel vaccine or an optimized 2-month
treatment regimen for active disease [26]. This highlights 2 im-
portant points: (1) no single intervention will have the impact
required to meet tuberculosis control targets; thus, scaled-up
investment in research and implementation of diagnostics,
drugs, and vaccines will be required; and (2) because new di-
agnostics could have an equivalent impact to new drugs or
vaccines, evaluation of diagnostics should be as rigorous as
evaluation of drugs and vaccines.
EXISTING FRAMEWORK FOR TUBERCULOSIS
DIAGNOSTIC RESEARCH AND DEVELOPMENT
The fact that sputum smear microscopy remains the cornerstone
of tuberculosis diagnosis in most high-burden countries is
testament to the relative paucity of research and development in
the diagnostic arena and the failure to translate research findings
into policy. In medicine broadly, diagnostic research tends to be
performed in stepwise fashion, with basic science leading to
laboratory-based performance evaluation and then to clinical
studies (Figure 1) [29]. This structure inherently tends to ex-
clude the perspectives of end users in the conception and de-
velopment of diagnostics, although more recently in the
tuberculosis field, organizations have assisted this process by
defining the ideal specifications for a point-of-care test [30].
In the tuberculosis field, the process of diagnostic de-
velopment has rarely gone beyond diagnostic accuracy studies to
assess the impact in clinical practice on clinical decision making,
patient outcomes, and health system costs [13, 31, 32]. This is in
part explained by the fact that the regulatory framework for in
vitro diagnostic devices usually does not require evidence be-
yond performance data. Diagnostic accuracy studies are an
important part of the evaluation process. However, there is
much potential for bias in such studies, and diagnostic accu-
racy might vary widely between different clinical settings and
populations [33–36].
In the field of diagnostic accuracy research, there have been
certain key initiatives aimed at improving and standardizing
research methodologies and reporting: the guidelines for di-
agnostic evaluation produced by the TDR Diagnostics Evaluation
Expert Panel (DEEP) [37], the Quality Assessment of Diagnostic
Figure 1. Stepwise approach to evaluation of diagnostic technologies.
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Accuracy Studies (QUADAS) tool [38], and the Standards for
the Reporting of Diagnostic Accuracy Studies (STARD) ini-
tiative [39, 40]. The DEEP guidelines outline best practice in
the design and conduct of diagnostic evaluations, with focus on
performance characteristics and operational feasibility. QUA-
DAS is a quality assessment tool to be used specifically for the
assessment of diagnostic accuracy studies included in system-
atic reviews. The tool consists of 14 items (Figure 2); the ma-
jority involve sources of bias, with a few relating to variability
and quality of reporting. The objective of the STARD initiative
is to improve the quality of reporting of diagnostic accuracy
studies. The 25-item checklist (Figure 3) allows the reader to
judge the potential for bias (internal validity) and the gener-
alizability and applicability (external validity) of the study.
A systematic review that used both QUADAS and STARD
criteria to assess tuberculosis diagnostic accuracy studies pub-
lished during 2004–2006 showed significant deficiencies in
methodology and reporting of studies [41]. Unfortunately, more
widespread use of the STARD system has not been apparent in
recent years. As a further example, of the 10 published studies
evaluating the diagnostic accuracy of the Genotype MTBDRplus
assay (published during 2007–2010) [42–51], only one manu-
script explicitly mentions STARD [51]. Additional efforts are
required by researchers, research funders, journal editors, and
policy makers to encourage the use of these tools, with the aim
of improving the quality and validity of this element of the
evidence base.
THE NEED FOR HIGH-QUALITY EVIDENCE TO
INFORM PUBLIC HEALTH POLICIES
Public health policies and guidelines are now usually informed
by a systematic approach to judging the relevant evidence. In the
tuberculosis field, the World Health Organization (WHO) con-
venes expert groups to assess the available evidence for a specific
intervention (eg, diagnostic test), and this group then presents
their findings to the WHO Strategic and Technical Advisory
Group for Tuberculosis (STAG-TB) for consideration and en-
dorsement. The system to assess the evidence now adopted by
many organizations, including WHO, is the Grading of Recom-
mendations Assessment, Development, and Evaluation (GRADE)
system, which incorporates judgments on the quality of evidence
(high, moderate, low, or very low) and on the strength of any
recommendation (initially categorized as strong or weak; now
incorporates ‘‘conditional,’’ whereby national programs should
consider implementation based on their own situation) [52, 53].
The GRADE system is based around the concept of patient-
important outcomes, and as such, evidence from diagnostic
interventions creates additional challenges. Studies using in-
direct outcomes (eg, diagnostic accuracy studies) will usually
provide lower-quality evidence because of the uncertainty about
outcomes important to patients and the potential for bias [54].
It is important to be clear that the rating of low quality in this
context does not necessarily imply that studies were conducted
poorly, but that data from the study are not optimal for deriving
public health recommendations.
GOING BEYOND DIAGNOSTIC ACCURACY
STUDIES—THE NEED FOR IMPACT DATA
In the STOP TB New Diagnostics Working Group blueprint
for the evaluation of diagnostics, the next step after diagnostic
accuracy studies are demonstration studies, which include
patient outcomes (Figure 4) [55]. These demonstration studies
are designed to assess the scaled-up test performance and to
determine patient-level outcomes. This is the stage of the
evaluation process that should start to inform policy. It is
stated in this document that patient-important outcomes
should be assessed (eg, time to initiation of treatment, time to
smear and/or culture conversion, and treatment outcome) and
Figure 2. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool.
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that ‘‘these impact-related data should be compared to his-
torical data recorded prior to implementation of the new test in
routine clinical practice’’ [55, p. 62]. This use of historical data
is problematic as a method of assessing any health care in-
tervention and would not generally be accepted by regulatory
bodies in the field of drugs or vaccines [56]. It is difficult to be
Figure 3. Standards for the Reporting of Diagnostic Accuracy Studies (STARD) checklist.
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sure that any comparison is fair; there are potential sources of
bias, and consequently, the risk is that the value of the in-
tervention can be exaggerated.
Two organizations that have been instrumental in driving
forward development and evaluation of diagnostic technologies
for tuberculosis are the Foundation for Innovative New Diag-
nostics and the WHO TDR program (Special Programme for
Research and Training in Tropical Diseases). Demonstration
studies are key elements of their tuberculosis projects, which aim
to determine the feasibility, impact, and cost-effectiveness of the
diagnostic test under evaluation. The evidence from these studies
is a key element assessed by the expert groups and reported to
STAG-TB. If we take the example of the Genotype MTBDRplus
assay, preliminary data regarding patient-important outcomes
from the South African demonstration projects seemed rela-
tively disappointing because the median turnaround times did
not meet their predefined objective of 7 days; of the patients
with multidrug-resistant tuberculosis who were identified, only
28% were started on appropriate therapy on the basis of the test
result (42% had therapy delayed until results of conventional
drug susceptibility testing were available) [57]. Although these
results were based only on preliminary data analysis and are
understandable during implementation of a new technology,
there has, to our knowledge, been no further published evi-
dence from high-burden settings on patient-important outcomes.
However, the test has been introduced into routine practice in
some countries, and its use is now being scaled up [58].
It is generally considered that the optimal methodology for
assessing the clinical impact of any intervention, including di-
agnostics, is the randomized controlled trial (RCT) [59–61].
This is the methodology least prone to bias in estimating the
benefits and risks of any intervention. Data from RCTs can
additionally be used to perform economic evaluation, a step of
major importance for policy makers. The relative shortage of
RCTs in diagnostic research, in contrast to therapeutic and
vaccine research, is likely to be explained by a combination of
factors: lack of emphasis on this level of evidence by manu-
facturers and regulatory authorities, limited funding and poor
coordination of diagnostic research, and logistical and ethical
challenges. There are features specific to diagnostic trials that
complicate trial design and implementation. In a tuberculosis
diagnostic study, the population of interest might be persons
with suspected pulmonary tuberculosis (eg, individuals with
cough). Inevitably, the majority of participants will not have
tuberculosis; thus, the potential effect size on the total cohort
resulting from improved diagnosis is relatively small. However,
we have to include the entire cohort in a trial if we want to
capture comprehensive outcome data (to balance benefits and
harms).
To reveal the value of well-designed RCTs in diagnostic re-
search, it is worthwhile to stop studying tuberculosis and con-
sider malaria, another global health priority. Malaria rapid
diagnostic tests (RDTs) have been shown to have good di-
agnostic accuracy [62], and mathematical models have sug-
gested that implementation of RDTs could lead to significant
public health benefits in settings where malaria is endemic [63].
Trials were designed to assess the performance of the tests in
a field setting and to measure the impact on health care pro-
viders, therapeutic decisions, and patient outcomes [64–67].
Three of these trials showed that, despite good diagnostic ac-
curacy, there was no reduction in incorrect antimalarial treat-
ment with the use of RDTs [64–66]; of more concern, one trial
even showed a significant reduction in correct antimalarial
treatment [66]. These trials have provided vital information for
the further development and implementation of RDTs. The
results of these trials highlight the fact that a diagnostic test is
only ever a vehicle to guide therapies; it is never of therapeutic
benefit, and it is the treatment decision that will impact on
patient outcomes.
CONCEPTUALIZING CLINICAL TRIALS OF
TUBERCULOSIS DIAGNOSTICS
The first step in any trial is to determine the hypothesis that is to
be tested because this will inform the trial design. It is important
to consider the likely position of the new test in the diagnostic
Figure 4. The pathway for evaluation of new diagnostics (from the STOP TB New Diagnostic Working Group).
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process. In the case of a test for active pulmonary tuberculosis,
we need to decide how the test will be introduced in the existing
diagnostic structure, which includes sputum microscopy, spu-
tum culture, drug-susceptibility testing, and chest radiography.
It could be proposed as a replacement for$1 of these tests, as an
addition to these tests, or as a means of triage, for example, to
target sputum culture and/or drug-susceptibility testing. This
decision is in turn likely to depend on the proposed benefits of
the new test (eg, whether it is more rapid, more sensitive, more
specific, less technical, safer, or less expensive). Furthermore, we
need to consider the outcomes of interest, whether related to
benefit or harm; these may be appropriate or inappropriate
commencement of tuberculosis treatment, outcomes during
treatment (smear or culture conversion), final treatment out-
comes (cure or completion), and mortality.
One possible reason to explain the lack of RCTs in diagnostic
research is the perception that diagnostic tests carry minimal or
no risk. Although the test is unlikely to harm the patient, the
consequences of the test (eg, the therapeutic decision) may
confer harm, as shown in the example of RDTs of malaria. What
risks might we expect in a trial of a tuberculosis diagnostic?
Consider a hypothetical trial comparing clinical outcomes be-
tween a rapid molecular tuberculosis test and the standard-
of-care diagnostic pathway (Figure 5). At a basic level, this trial
will tell us whether the benefits from earlier correct diagnosis
or exclusion of tuberculosis outweigh the risks from incorrect
classification of disease (false-negative or false-positive results).
The benefits would seem to be self-evident but need to be
quantified. The risks are more complicated and will be context
specific. False-negative diagnoses will result in appropriate
treatment being withheld, with potential for poorer outcomes.
False-positive diagnoses also carry risk, however, because alter-
native diagnoses may not be considered and, therefore, not
treated, and patients may be exposed to potentially toxic ther-
apy. For diagnosis of drug resistance, the risks from incorrect
classification are even more complicated. False-negative results
of genotypic testing may lead to inappropriate treatment with
first-line regimens, with consequent adverse outcomes, in-
cluding amplification of drug resistance. False-positive results
may lead to inappropriate treatment with multidrug-resistant
tuberculosis regimens, with lower efficacy against sensitive
strains and with risks of severe toxicity.
These examples highlight another challenge with tubercu-
losis diagnostic research (and common to much diagnostic
research), which is the lack of a perfect gold standard with
which to compare new tests. If our new test is potentially more
sensitive than the existing test (as might be the case with mo-
lecular tests, compared with sputum culture), this will affect
any analysis. The lack of a gold standard often requires a con-
struct gold standard that comprises information from the ref-
erence test with additional clinical information and follow-up
information [68]. Of further concern, discrepancies between
phenotypic and genotypic drug-susceptibility results can be
extremely difficult to interpret, and it is not always clear which
is the more reliable measure of drug resistance [69]. In many
ways, these issues reinforce the need for well-designed clinical
trials because thorough interpretation of the tests may only be
possible with meticulously collected baseline and follow-up
clinical data.
PRACTICAL TRIAL DESIGNS
If the outcomes of interest are individual-level outcomes (eg,
treatment initiation and mortality), a clinical trial with individual
randomization would be the logical and statistically most effi-
cient design. However, because there will be information re-
garding the diagnostic performance from the laboratory-based
evaluation, the question arises, if the test is shown to have
comparable accuracy to an existing test but has other advan-
tages (ie, more rapid and/or less invasive), is it ethical to
conduct an RCT with individual randomization? Critical to this
decision is whether there is equipoise regarding the clinical
outcome. Equipoise with regard to clinical outcomes of a di-
agnostic strategy arises, for example, when the consequences of
misdiagnosis are severe (eg, HIV-infected patients who receive
a misdiagnosis of tuberculosis who are dying of another
HIV-related illness) or when failure to diagnose does not lead
to mistreatment or poorer outcomes (eg, patients prescribed
tuberculosis treatment regardless of the test result).
Individual randomization may, however, present consider-
able logistical challenges in certain health care settings, and for
this reason, cluster randomized designs may be considered with
Figure 5. Potential impact of false-positive and false-negative tubercu-
losis diagnoses in a hypothetical trial comparing a rapid molecular test
to tuberculosis culture.
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health care units (eg, hospitals, clinics, and mobile teams) as
clusters. Cluster randomized designs are increasingly used in
public health research. The principal reasons for considering
such a design are as follows: if the intervention is to be delivered
to groups rather than individuals, if the outcome is to be mea-
sured at a population level, or to avoid contamination by in-
dividuals in the same community who are randomized to
different trial arms [70]. However, there is also an acceptance
that cluster randomization may also be appropriate in settings
where it offers greater logistical convenience, compared with an
individually randomized trial, although cluster RCTs generally
require larger sample sizes and have added challenges in design,
analysis, and ethics [70–72].
A further modification of the cluster randomized design is the
phased implementation or stepped-wedge design [70, 73]. The
key features of this design are that all clusters receive the in-
tervention by the end of the trial, and the order in which the
clusters receive the intervention is decided at random. This is
particularly appropriate when there is preexisting evidence that
the intervention may have a beneficial effect and when assigning
clusters to the control arm for the duration of the trial might be
ethically unacceptable. This might be particularly suited to
evaluation of certain diagnostic technologies, for which there is
evidence from initial diagnostic accuracy studies that suggests
beneficial effect.
If randomization is not deemed to be appropriate or feas-
ible, alternative prospective trial designs, often termed quasi-
experimental designs, may still be able to generate evidence on
the effectiveness of diagnostics [74]. An example would be the
pre- and postimplementation study in which outcomes are
measured during a pre-intervention phase and subsequently
during a postintervention phase. Although the lack of ran-
domization threatens the internal validity (no firm conclusion
can be made with regard to the effect of the intervention unless
the effect size is large), there may conversely be a gain in external
validity (improved generalizability of findings if fewer patients
are excluded than in conventional RCTs).
Retrospective studies may be the only methodology to obtain
outcome data in circumstances in which a diagnostic is widely
implemented on the basis of performance characteristics. Such
pre- and postimplementation analyses have been used in high-
resource settings to estimate the impact of molecular resistance
testing on detection and treatment of multidrug-resistant tu-
berculosis [75, 76].
Whether a clinical trial is justified in the evaluation of diag-
nostics will ultimately depend on the balance between the
benefit to be gained by accurately establishing the impact of
a new tool and the costs of running a large clinical trial and
potentially delaying full-scale implementation of an effective
intervention. These decisions are not straightforward, and col-
laboration between scientists and policy makers is vital to de-
termine when diagnostic trials are necessary.
CONCLUSIONS
Recent developments in tuberculosis diagnostics have led to
much optimism, but we still lack the tools that meet the needs of
patients in high-burden countries. The next 10–20 years will
hopefully see further developments in diagnostic technology.
We need to ensure that the framework for evaluating diagnostic
tools is best suited to ensuring that the tools with the greatest
public health impact and cost-effectiveness are implemented
and that those with minimal impact are developed further or are
discarded. Diagnostic accuracy studies are an important early
step in the evaluation process but do not produce sufficient
evidence to inform public health policies. Well-designed pro-
spective studies (including RCTs) should be integrated in the
research pathway to provide reliable information on therapeutic
impact, patient outcomes, and cost-effectiveness. This new era
of tuberculosis diagnostics should be accompanied by a new era
for diagnostic research focused clearly on the evaluation of
public health impact.
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Impact of a novel molecular TB diagnostic system
in patients at high risk of TB mortality in rural
South Africa (Uchwepheshe): study protocol for a
cluster randomised trial
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Abstract
Background: Tuberculosis control in sub-Saharan Africa has long been hampered by poor diagnostics and weak
health systems. New molecular diagnostics, such as the Xpert® MTB/RIF assay, have the potential to improve patient
outcomes. We present a cluster randomised trial designed to evaluate whether the positioning of this diagnostic
system within the health system has an impact on important patient-level outcomes.
Methods/Design: This pragmatic cluster randomised clinical trial compared two positioning strategies for the Xpert
MTB/RIF system: centralised laboratory versus primary health care clinic. The cluster (unit of randomisation) is a 2-
week time block at the trial clinic. Adult pulmonary tuberculosis suspects with confirmed human immunodeficiency
virus infection and/or at high risk of multidrug-resistant tuberculosis are enrolled from the primary health care clinic.
The primary outcome measure is the proportion of culture-confirmed pulmonary tuberculosis cases initiated on
appropriate treatment within 30 days of initial clinic visit. Univariate logistic regression will be performed as the
primary analysis using generalised estimating equations with a binomial distribution function and a logit link.
Conclusion: Diagnostic research tends to focus only on performance of diagnostic tests rather than on patient-
important outcomes. This trial has been designed to improve the quality of evidence around diagnostic strategies
and to inform the scale-up of new tuberculosis diagnostics within public health systems in high-burden settings.
Trial registration: Current Controlled Trials ISRCTN18642314; South African National Clinical Trials Registry DOH-27-
0711-3568.
Keywords: Tuberculosis, Multidrug-resistant tuberculosis, HIV, Molecular diagnostics, Point-of-care systems,
Clinical trial
Background
Control of the tuberculosis (TB) epidemic in sub-
Saharan Africa is a major public health challenge [1,2].
The epidemic has been exacerbated by the co-existent
explosive human immunodeficiency virus (HIV) epi-
demic and the emergence of drug-resistant Mycobacter-
ium tuberculosis strains leading to high mortality rates
[2,3]. Enshrined in Millennium Development Goal 6
and the Stop TB Partnership Global Plan 2006–2015
are the targets to reduce TB prevalence and TB mortal-
ity rates by 50% (compared to 1990) by 2015 and to
eliminate TB as a public health problem by 2050 [4,5].
At current rates of progress these targets will not be
achieved in sub-Saharan Africa. New interventions and
improved strategies for delivery of interventions are ur-
gently required.
TB control at present relies primarily on the diagnosis
and treatment of individuals with active TB disease. Early
case detection and initiation of appropriate antituberculous
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therapy is necessary not only to reduce mortality but
also to interrupt transmission. TB microscopy (still the
most common diagnostic method in use worldwide) is
poorly equipped to control the current TB epidemic in
sub-Saharan Africa given its poor sensitivity, particu-
larly in HIV co-infection, and inability to detect drug re-
sistance [6]. Additionally, the placement of diagnostics
in centralised facilities distant from where patients seek
care contributes to significant delays [7,8] and default
[9-13] before initiation of treatment. The impact of this
is illustrated most starkly in multidrug-resistant TB
(MDR-TB), where delays in culture and drug suscepti-
bility testing (DST) techniques mean that 50% of pa-
tients have died by the time their culture/DST result is
available [14,15].
The development of novel molecular tools, in particu-
lar the Xpert® MTB/RIF assay, offers new opportunities
to tackle these problems. This is a fully automated,
closed cartridge diagnostic system that utilises hemi-
nested polymerase chain reaction (PCR) and molecular
beacon technology to detect the presence of Mycobacter-
ium tuberculosis and rifampicin-resistant mutations dir-
ectly from clinical samples in less than 2 h [16-18].
The World Health Organization (WHO) recommended
the system be implemented in high-burden settings on the
basis of initial data from validation and demonstration
studies [19-21]. Many countries are now moving ahead
with implementation and there is a need for research to
address key questions in the early phase of implementa-
tion so as to inform future scale-up [21]. One critical
question relates to the optimal positioning of the diagnos-
tic system within different health systems, and this is the
focus of the research study.
The primary objective is to test the hypothesis that
timely initiation of appropriate TB treatment when the
diagnostic system is positioned at the primary health
care clinic (point of care) is different from when the
diagnostic system is positioned centrally at the district
hospital laboratory. Secondary objectives are:
 To evaluate the impact of Xpert MTB/RIF
positioning on additional clinical outcomes
(mortality, hospital admission, time to initiation of
antiretroviral therapy)
 To explore the cost-effectiveness of Xpert MTB/RIF
implementation at primary health care clinic level
 To compare the operational feasibility of Xpert
MTB/RIF placement at the primary health care
clinic level and district hospital laboratory level.
Methods/Design
Setting
The trial is being conducted in Hlabisa health sub-
district, uMkhanyakude district, northern KwaZulu-
Natal, South Africa (Figure 1). This area has an ex-
tremely high dual burden of TB and HIV: the TB notifi-
cation rate for the sub-district in 2010 was 1,130/
100,000; HIV seroprevalence in the adult population
(≥15 years) within the Africa Centre surveillance area
was 24.1% in 2010; in 2008, 76% of TB cases were asso-
ciated with HIV infection [22]. In the years 2000–2006
HIV and TB accounted for 71.5% of deaths in young
adults (25–49 years) in the Africa Centre surveillance
area [23]. HIV and TB treatment and care are deliv-
ered at 17 primary health care (PHC) clinics through
decentralised collaborative programmes. Participants
are recruited from the largest PHC clinic that is situ-
ated within a small urban township in the south of the
sub-district, approximately 60 km by road from the dis-
trict hospital.
Study design
The study is a pragmatic cluster randomised clinical trial
comparing two positioning strategies for the Xpert
MTB/RIF system: positioning at centralised laboratory
level (district hospital laboratory) versus positioning at
primary health care clinic level (point of care). The clus-
ter (unit of randomisation) is a 2-week time block at the
primary health care clinic (clinic blocks), and clusters
are randomly assigned to the district hospital laboratory
strategy or point-of-care strategy. The trial schema is
shown in Figure 2.
Participants
Adult (≥18 years) pulmonary TB suspects with con-
firmed HIV infection and/or at high risk of MDR-TB are
included after giving informed consent. These criteria
were defined because of the high risk for mortality in
these groups and prioritisation for Xpert MTB/RIF test-
ing, in line with the WHO recommendations [20]. A TB
suspect is defined for the purposes of the trial as an indi-
vidual with a current cough (of any duration) with or
without other symptoms. High risk of MDR-TB is de-
fined according to national and international guidelines
and incorporates the following categories: failure of the
standard treatment regimen (2HRZE/4HR), failure of the
re-treatment regimen (2HRZES/1HRZE/5HRE), acid-fast
bacilli (AFB) smear non-conversion at month 2 or 3 of
the standard or re-treatment regimen, relapse or return
after default, any other previous TB (4 or more weeks of
TB treatment), household contact with a known MDR-
TB case, prison inmate within the last 12 months and
health care worker [24,25]. Participants are excluded
if they report a previous diagnosis of MDR-TB or exten-
sively drug-resistant TB (XDR-TB), are severely unwell
requiring admission to hospital, or are unable to give in-
formed consent. Participants are recruited between the
times of 0800 and 1630, Monday to Friday.
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Interventions
All participants provide two spontaneously expectorated
sputum specimens on the day of enrolment (spot speci-
mens). The first sputum specimen is submitted for Xpert
MTB/RIF testing. The second specimen is submitted for
Mycobacterial Growth Indicator Tube (MGIT) culture,
line probe assay (LPA) ± phenotypic drug susceptibility
testing (DST). In both strategies, the specimen for cul-
ture/LPA/DST is transported daily (in the afternoon) to
the National Health Laboratory Service (NHLS) labora-
tory at the district hospital and then onwards to the pro-
vincial NHLS referral laboratory. The results of this are
used to define TB cases and to define the primary out-
come measure.
District hospital laboratory strategy
Sputum specimens are transported on a daily basis to the
National Health Laboratory Service (NHLS) laboratory at
the district hospital using the routine sample transport
system. Xpert MTB/RIF testing is performed by a trained
laboratory technician at the earliest convenience (within
24 h of the specimen being received in the laboratory) and
printed results are returned to the clinic using the same
routine transport system. Under this strategy, participants
are requested to return for results after 72 h.
Point-of-care (POC) strategy
The diagnostic system is located at the primary health care
in a dedicated room close to the TB clinic (Figure 3).
Figure 1 Maps showing location of (a) the study site and (b) primary health care clinic (trial clinic) and district hospital.
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Figure 2 Trial schema.
Figure 3 Professional nurse operating the Xpert MTB/RIF system at the primary health care clinic.
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Xpert MTB/RIF testing is performed immediately by the
study nurse, on the same day where possible. Participants
are invited to wait for the result (approximately 2 h) or, if
they are unable to wait or it is towards the end of the
working day, they are advised to return the following day.
Outcome measures
The observational unit for all analyses is the individual
participant. The primary outcome for the study is the
proportion of culture-confirmed pulmonary TB cases
initiated on appropriate TB treatment within 30 days of
initial clinic visit (appropriate treatment defined
according to results of LPA ± phenotypic DST on the
culture isolate).
Secondary outcomes at an individual level are the fol-
lowing, with all time-to-event analyses using the initial
clinic visit as time zero:
 All-cause mortality in TB suspects and MDR-TB
suspects at 60 days
 Time to initiation of appropriate TB treatment
(days) for culture-confirmed pulmonary TB cases
 Time to initiation of MDR-TB treatment (for MDR-
TB cases confirmed by culture/LPA/DST)
 Proportion of TB suspects and MDR-TB suspects
with at least one hospital attendance within 60 days
 Time to initiation of antiretroviral therapy (ART) for
HIV-infected TB suspects and MDR-TB suspects
not yet receiving but eligible for ART
 Sensitivity and specificity of Xpert MTB/RIF
▪ for M. tuberculosis detection (compared to
reference standard of single MGIT culture)
▪ for detection of rifampicin resistance (compared
to reference standard of phenotypic DST ± LPA)
Sample size
The study was designed to detect an increase from 85%
to 95% in the proportion of culture-confirmed pulmon-
ary TB cases initiated on appropriate treatment within
30 days. Sample size was calculated with the equation of
Hayes and Bennett, using the coefficient of variation (κ)
[26]. With κ = 0.05 and a cluster size of 12 culture-
positive cases, we would need 16 clusters and 188
culture-positive TB cases in each arm to detect this dif-
ference with 95% confidence and 80% power. We as-
sumed 10% of individual participants would be lost to
follow-up at 60 days, so we would need 208 culture-
positive TB cases in each arm. Based on the assumption
that 25% of TB suspects would have a positive MGIT
culture, we would require enrolment of 1,664 TB sus-
pects. The total sample size will therefore be 32 clusters
and 1,664 individual participants.
The coefficient of variation (κ) is small, but as the clus-
ters are clinic time blocks rather than geographic areas or
health care facilities, minimal variation is expected be-
tween clusters. This value of κ corresponds to a range of
proportions appropriately treated within 30 days in the
district hospital laboratory arm of 77-94%.
For the secondary endpoint of all-cause mortality
within 60 days, the analysis will incorporate all partici-
pants (all suspects), regardless of presence or absence of
TB disease. The sample size of 32 clusters and 60 partic-
ipants per cluster gives approximately 80% power to de-
tect a 33% reduction in mortality from 12% in the
district hospital laboratory arm to 8% in the point-of-
care arm, with 95% confidence.
Randomisation
The allocation schedule for random assignment of 2-
week time blocks was computer generated, using ran-
dom permuted blocks of eight. Allocation for each clinic
block was placed into sealed envelopes by the statisti-
cian; the principal investigator opens the envelope on
the Friday before the start of a new 2-week block and
communicates the allocation for the next 2 weeks to
study staff.
Implementation
Health care workers at the primary health care clinic
identify potential participants. All individuals reporting
cough are referred to the study nurse. Eligibility criteria
are checked by the nurse, and subjects meeting the in-
clusion criteria are provided spoken and written infor-
mation about the study in isiZulu and/or English; those
willing to participate are taken through the informed
consent process and are asked to provide a signature or
thumbprint on the consent form.
A baseline assessment is performed by the study
nurse. Demographic information, current symptoms,
previous TB history, risk factors for drug resistance,
HIV status, and history of ART use are documented on
a case report form.
With both strategies, clinical decisions are made by
the study nurse on the basis of the Xpert MTB/RIF re-
sult and according to pre-defined algorithms. TB pa-
tients without resistance to rifampicin are commenced
on standard anti-TB therapy (4HRZE/2HR) by the study
nurse. All patients with rifampicin-resistant TB are
reported to the trial physician on the same day and are
subsequently referred to the specialist drug-resistant TB
treatment centre in Durban. Management of suspects
with a negative Xpert MTB/RIF follows existing proto-
cols for smear-negative TB suspects: oral antibiotics are
prescribed and patients are advised to return if symp-
toms do not improve after 14 days. Patients who remain
symptomatic following this course of antibiotics can be
referred to the district hospital for chest X-ray and phys-
ician review. Results from MGIT culture and DST are
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returned through the routine laboratory system and are
used to guide clinical management where appropriate.
Outcome evaluation
To ascertain the primary and secondary outcomes, at
enrolment all participants are allocated a review date 2
months from the enrolment visit. Participants are invited
to attend clinic for review but are also invited to consent
to telephonic follow-up and/or home visit in case clinic
visit is not possible. Additional contact details are pro-
vided for at least one other family member (or other per-
son designated by participant) at enrolment, wherever
possible. Participants are told that, when attending
the clinic for the follow-up visit, they will be reim-
bursed with a ZAR 50 grocery voucher (approximately
equivalent to USD 6). Outcome data pertaining to TB
treatment initiation, additional investigations, hospital
attendances and admissions, and ART initiation (where
appropriate) are collected on a case report form by the
study nurse. In the event that no contact is made with
patient or with named contact persons, follow-up in-
formation is collected from the clinic TB registers and
the operational HIV programme database – permission
to use these data is also included in the informed con-
sent process.
Statistical analysis
Analysis of baseline characteristics will be performed to
characterise the study population and to identify base-
line imbalances between the study arms in order to de-
cide whether any covariates need to be adjusted for in
the final analyses. The baseline data will include: age,
sex, body mass index (BMI), history of previous TB, HIV
infection status, CD4+ cell count, and use of antiretro-
viral therapy and isoniazid preventive therapy.
All final analyses will be intention-to-treat analyses
performed at the individual level taking account of
within-cluster correlation. The definition of TB cases for
the primary outcome will be based on MGIT culture
positivity. The proportion of TB cases initiated on ap-
propriate TB treatment within 30 days will be based
on whether the appropriate treatment regimen was
commenced within 30 days of the initial clinic visit—
appropriate regimens are defined according to drug
susceptibility pattern and with reference to national
guidelines (Table 1) [27]. The primary analysis will in-
clude only TB cases not on TB treatment at the time of
enrolment, i.e. excluding smear non-converters or fail-
ures still on treatment. The primary outcome is a binary
variable (initiation of appropriate treatment or not) so uni-
variate logistic regression will be performed as the primary
analysis using generalised estimating equations (GEE) with
a binomial distribution function and a logit link [28]. The
odds ratio will be reported with 95% confidence intervals
and a p-value from the Wald test. This method will allow
for the correlation between observations (within clusters)
without needing to specify a distributional assumption for
the correlations. In addition, important individual-level
characteristics that are unbalanced between arms will be
included in the model as covariates. For the secondary
outcomes with binary variables, GEE models will also be
fitted with a binomial distribution function and a logit
link. For the secondary outcomes with time-to-event mea-
sures, Cox proportional hazard models will be fitted with
the shared frailty option to account for the cluster ran-
domisation [29]. Hazard ratios will be presented with 95%
confidence intervals.
The diagnostic performance of Xpert MTB/RIF will be
compared between the two arms. Estimation of sensitiv-
ity and specificity of Xpert MTB/RIF for the detection of
M. tuberculosis against the reference standard of single
MGIT culture will be based on complete case analysis
(participants with paired valid Xpert MTB/RIF and
MGIT culture results) and will only include individuals
not on TB treatment at the time of enrolment. Estima-
tion of sensitivity and specificity of Xpert MTB/RIF for
the detection of rifampicin resistance against the refer-
ence standard of genotypic ± phenotypic DST on the
culture isolate will be based on participants with M.
tuberculosis detected by Xpert MTB/RIF and with a
positive MGIT culture and valid drug susceptibility test
(LPA ± phenotypic DST) results. This will include indi-
viduals on TB treatment at the time of enrolment (e.g.
participants with AFB smear non-conversion or treat-
ment failure).
Economic evaluation
In addition to evaluating the effectiveness of point-
of-care positioning of Xpert MTB/RIF, data from the
trial will be combined with those from a costing ana-
lysis to explore the cost-effectiveness of point-of-care
placement. Health system costs will be obtained
through monitoring of study expenditure and inter-
views with health service management. Collection of
data relating to patient and household costs will be
nested within the trial—this will involve additional
data collected from a subset of patients at baseline
and at the 2-month follow-up to determine direct
and indirect costs incurred during the diagnostic
process. The framework for costing analysis is
presented in Table 2. The health system costs and
patient costs will be combined with the outcome
data to generate an average incremental cost per TB
case appropriately treated.
Operational feasibility
The study will also compare the operational feasibility
of Xpert MTB/RIF implementation at the hospital
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laboratory and at the primary health care clinic. This en-
compasses an assessment of the performance and ro-
bustness of the system, as well as evaluation of the
practicality of operating the system at the laboratory and
at the clinic. The key indicators to be assessed are
displayed in Table 3. Data on these indicators will be
collected throughout the trial.
Ethical considerations
The study has been approved by the Biomedical Re-
search Ethics Committee of the University of KwaZulu-
Natal (BF033/11), the Ethics Committee of the London
School of Hygiene and Tropical Medicine (5926), and
the Health Research Committee of the KwaZulu-Natal
Department of Health (HRKM084/11). Permission for
the study was granted by Hlabisa Hospital and by the
Community Advisory Board of the Africa Centre for
Health and Population Studies.
Given that the units of randomisation are time blocks,
it is not possible for individuals to consent to random-
isation. Individual consent for participation remains im-
portant given that the intervention is delivered to
individuals and that individual-level data are collected at
enrolment and at follow-up.
There are TB suspects who are not eligible for this
study and therefore will not have access to Xpert MTB/
RIF testing within the study (suspects who are neither
HIV-infected nor at high risk for MDR-TB). The justifi-
cation for this is that these groups were a lower priority
for this intervention given the much lower mortality
rates and these suspects continue to receive diagnostic
evaluation including sputum microscopy ± culture/LPA/
DST according to national guidelines. At the time of
study design it was predicted that, were Xpert MTB/RIF
to be implemented in South Africa, the WHO recom-
mendations would be followed (use in HIV-infected and
those at high risk of MDR-TB). Although the national
roll-out plan went beyond this in incorporating its use
for all TB suspects, Xpert MTB/RIF has not yet been
installed in Hlabisa sub-district and is therefore not yet
available in the sub-district outside the trial.
Discussion
Evaluation of diagnostic tools provides different chal-
lenges than those of therapeutic interventions. Diagnos-
tic accuracy studies are usually the starting point for
evaluation of new technologies, yet to inform public
health policies and implementation it is crucial to evalu-
ate patient-important outcomes [30]. The ultimate
Table 2 Components of cost analysis
Health service costs Patient and household costs
Direct costs associated
with diagnostic services
Direct costs
Fixed Transport
Building space Transport to/from clinic
(patient ± carer)
Utilities Transport to/from hospital
(patient ± carer)
GeneXpert machine Non-transport
Staff training Medication
Internal/external QC OPD attendance
GeneXpert calibration X-rays
Variable GP consultation
Xpert MTB/RIF tests Traditional healer consultation
Consumables (gloves, N95 masks)
Specimen transport
Staff work time (based on time analysis)
GeneXpert maintenance
Direct costs associated
with medical services
Indirect costs
First-line TB therapy Lost time (salary) at work
(patient ± carer)
MDR-TB therapy
Hospital admission
OPD attendance
Clinic attendance
Table 1 Definitions of appropriate initial anti-TB drug regimen for primary outcome measurement
Case definition* Appropriate initial anti-TB drug regimen
M. tuberculosis susceptible to rifampicin and isoniazid Isoniazid + rifampicin + pyrazinamide + ethambutol
M. tuberculosis with mono-resistance to isoniazid Isoniazid + rifampicin + pyrazinamide + ethambutol
M. tuberculosis with mono-resistance to rifampicin Standardised second-line regimen§ with isoniazid
Multidrug-resistant M. tuberculosis (MDR-TB)† Standardised second-line regimen§
Extensively drug-resistant M. tuberculosis (XDR-TB)† Standardised XDR-TB regimenǁ
* Case definition based on results of MGIT culture + line probe assay + phenotypic DST.
† MDR-TB defined as resistance to rifampicin and isoniazid.
† XDR-TB defined as MDR plus resistance to ofloxacin and kanamycin.
§Standardised regimen according to national guidelines (kanamycin/amikacin + fluoroquinolone + ethionamide + cycloserine/terizidone ± pyrazinamide ±
ethambutol) [27].
ǁStandardised regimen according to national guidelines (capreomycin + fluoroquinolone + ethionamide + cycloserine/terizidone + PAS + clofazimine) [27].
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impact of a new diagnostic test should be measured by
its capacity to generate beneficial outcomes. A
randomised trial is the most rigorous design to evaluate
clinical outcomes from a diagnostic intervention. Indi-
vidual randomisation was considered logistically challen-
ging and potentially disruptive in the context of a busy
clinic and laboratory system, although this would have
been the most efficient statistical design [28]. Cluster
randomisation by health care facility was not possible
given the limited resources. Therefore cluster random-
isation by time block was the preferred study design to
maximise internal validity and to minimise disruption to
clinic services. Other trial designs were considered (non-
randomised controlled trial with allocation by day/week/
month or controlled before and after study) but were felt
to be inferior in addressing the research hypothesis,
mainly because of the potential for bias and therefore
loss of internal validity. There have been few published
trials where the unit of randomisation is a time block ra-
ther than a geographical or organisational cluster. The
trials that have been published have not used consistent
methods for sample size calculation—some have ad-
justed appropriately for cluster variation [31-33] whereas
others have arbitrarily inflated the sample size from that
for an individual RCT [34] and others have based the
sample size on the numbers available to participate [35].
Blinding of patients or of health care workers is not
feasible in this pragmatic diagnostic trial because alloca-
tion to trial arms involves different actions by the patient
and the clinical staff. As a result of this, the outcomes
are as objective as possible to limit potential bias from
differential ascertainment of outcomes in the two arms.
The possibility of differential recruitment into the trial
arms exists but will be minimised by standardised refer-
ral criteria for the clinic health care workers; recruitment
will be monitored by reviewing the clinic records to as-
certain what proportion of patients with cough were re-
ferred to the study during each 2-week block. This will
be reported if there is a major imbalance in recruitment
to the two trial arms. There is a further risk of selection
bias if there is differential non-participation. The propor-
tions of eligible subjects consenting by trial arm will be
monitored and will be reported accurately at the con-
clusion of the trial. There is some risk of contamination
between the arms if, over time with point-of-care test-
ing, the health workers see the importance and the ef-
fect of receiving the test result in a timely fashion and
this then improves their ability to encourage all sus-
pects to return and receive their result. This would
tend to bias the findings towards the null hypothesis.
We will explore this by assessment of the variability in
the proportion returning for their test result by cluster
and by time period.
The evaluation of diagnostic accuracy is not the pri-
mary focus of the trial and the reference standard of a
single culture could be considered an imperfect gold
standard. In the initial Xpert MTB/RIF clinical validity
studies, the reference standard used results of liquid and
solid culture on two specimens (four culture results in
total) [17]. Conversely, in the later demonstration stud-
ies, the reference standard varied between study sites
and in some sites included results of only a single cul-
ture [18]. Observational data from the district in 2007
suggested that 5% of all culture-positive cases were
multidrug-resistant [36]. Given that we will preferentially
include suspects with a high risk of MDR-TB, we expect
the overall proportion with MDR-TB to be at least 10%.
It is possible that the impact of Xpert MTB/RIF posi-
tioning may be different for the drug-susceptible and
drug-resistant cases. If this is the case then a higher or
lower than expected proportion with MDR-TB could
modify the effect of point-of-care placement, and this
will be explored in secondary analyses.
There are a number of trials evaluating the impact of
Xpert MTB/RIF in different settings and with different
research hypotheses. Information about research pro-
jects is collated by the TREAT TB Xpert Research
Mapping Project [37]. Several studies are examining
point-of-care implementation but, to our knowledge,
this is the only study directly comparing point-of-care
use to centralised laboratory use. There is already some
evidence from South Africa of the feasibility of imple-
mentation at the primary health care level, although
several operational challenges were experienced when
Table 3 Indicators for operational feasibility evaluation
Indicator Method of measurement
Power supply Time log for power cuts/
generator use
Operating temperature for
GeneXpert machine
Temperature log
Storage temperature for
Xpert MTB/RIF kits
Temperature log
Hands-on user time Activity log
Indeterminate results GeneXpert software
Data errors (incomplete
identifiers etc.)
GeneXpert software
Maintenance needs Requirement for supplier support
Training requirements Recording of initial and follow-up
training sessions
Supervision requirements Log of assistance from other
laboratory staff/PI
Waste management Recording of problems with disposal
of used cartridges
User appraisal Regular appraisal by laboratory staff
and study staff
User performance Regular independent observation of
staff performance
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implemented within a very large urban clinic [38,39].
This study should provide direct evidence of any bene-
fits of point-of-care positioning as well as further infor-
mation about the costs and logistical challenges of
such strategies. This can also be considered as a proof-
of-principle study that will help to understand the ben-
efits of bringing diagnostics closer to patients, and this
will have broader relevance as we continue to develop
and evaluate diagnostic technologies suitable for point-
of-care use [40,41].
Trial status
The study received final ethical approval in June 2011.
Enrolment commenced on 22 August 2011. Enrolment
is scheduled to complete in March 2013 and follow-up
will be complete in May 2013.
Abbreviations
ART: Antiretroviral therapy; DST: Drug susceptibility testing; GEE: Generalised
estimating equation; HIV: Human immunodeficiency virus; MDR-
TB: Multidrug-resistant TB; MGIT: Mycobacterial growth indicator tube;
NHLS: National Health Laboratory Service; PCR: Polymerase chain reaction;
PHC: Primary health care; TB: Tuberculosis; WHO: World Health Organization;
XDR-TB: Extensively drug-resistant TB.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RJL and PGF conceived and designed the trial, with additional input from
GSC, NM, MPN and MLN. NM helped with the statistical design and analysis
plan. RJL wrote the first draft of the manuscript. All authors contributed to
revision of the manuscript and approved the final version.
Acknowledgements
The authors would like to acknowledge the independent members of the
Trial Steering Committee (David Moore, Katherine Fielding and Yunus
Moosa) who contributed to discussions about trial design, conduct and
analysis. The authors would also like to thank the study team and all staff
working at the clinic.
Source of funding
This work is supported by the Wellcome Trust (grant no. 090999/Z/09/Z). NM
is supported by a Wellcome Trust fellowship grant (083495MA). The funder
had no role in the study design, data collection and analysis, decision to
publish or preparation of the manuscript.
Author details
1Department of Clinical Research, London School of Hygiene and Tropical
Medicine, Keppel Street, London WC1E 7HT, UK. 2Africa Centre for Health
and Population Studies, University of KwaZulu-Natal, Mtubatuba, South
Africa. 3Department of Infectious Disease, Imperial College, London, UK.
4Academic Unit of Primary Care and Population Sciences and Academic Unit
of Social Sciences, University of Southampton, Southampton, UK. 5Division of
Medical Microbiology, University of Cape Town, Cape Town, South Africa.
6UCL Institute of Child Health, London, UK.
Received: 22 February 2013 Accepted: 28 May 2013
Published: 12 June 2013
References
1. Chaisson RE, Martinson NA: Tuberculosis in Africa–combating an HIV-
driven crisis. N Engl J Med 2008, 358:1089–1092.
2. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD: HIV infection
and tuberculosis in South Africa: an urgent need to escalate the public
health response. Lancet 2009, 374:921–933.
3. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen
P, Bayona J: Multidrug-resistant and extensively drug-resistant
tuberculosis: a threat to global control of tuberculosis. Lancet 2010,
375:1830–1843.
4. Stop TB Partnership, World Health Organization: The global plan to stop TB,
2006–2015. Geneva: World Health Organization; 2006.
5. United Nations General Assembly: Road map toward the implementation of
the United Nations Millennium Declaration. http://www.un.org/
millenniumgoals/sgreport2001.pdf?OpenElement.
6. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A,
Spector S, Roscigno G, Nkengasong J: Laboratory diagnosis of tuberculosis
in resource-poor countries: challenges and opportunities. Clin Microbiol
Rev 2011, 24:314–350.
7. Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J: Time delays in
diagnosis of pulmonary tuberculosis: a systematic review of literature.
BMC Infect Dis 2009, 9:91.
8. Storla DG, Yimer S, Bjune GA: A systematic review of delay in the
diagnosis and treatment of tuberculosis. BMC Publ Health 2008, 8:15.
9. Botha E, den Boon S, Lawrence KA, Reuter H, Verver S, Lombard CJ, Dye C,
Enarson DA, Beyers N: From suspect to patient: tuberculosis diagnosis
and treatment initiation in health facilities in South Africa. Int J Tuberc
Lung Dis 2008, 12:936–941.
10. Botha E, Den Boon S, Verver S, Dunbar R, Lawrence KA, Bosman M, Enarson
DA, Toms I, Beyers N: Initial default from tuberculosis treatment: how
often does it happen and what are the reasons? Int J Tuberc Lung Dis
2008, 12:820–823.
11. Creek TL, Lockman S, Kenyon TA, Makhoa M, Chimidza N, Moeti T, Sarpong
BB, Binkin NJ, Tappero JW: Completeness and timeliness of treatment
initiation after laboratory diagnosis of tuberculosis in Gaborone,
Botswana. Int J Tuberc Lung Dis 2000, 4:956–961.
12. Nyirenda T, Harries AD, Banerjee A, Salaniponi FM: Registration and
treatment of patients with smear-positive pulmonary tuberculosis. Int J
Tuberc Lung Dis 1998, 2:944–945.
13. Squire SB, Belaye AK, Kashoti A, Salaniponi FM, Mundy CJ, Theobald S, Kemp
J: ‘Lost’ smear-positive pulmonary tuberculosis cases: where are they and
why did we lose them? Int J Tuberc Lung Dis 2005, 9:25–31.
14. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D,
Marra C, Lalloo UG, Friedland GH: HIV coinfection in multidrug- and
extensively drug-resistant tuberculosis results in high early mortality. Am
J Respir Crit Care Med 2010, 181:80–86.
15. Heller T, Lessells RJ, Wallrauch CG, Barnighausen T, Cooke GS, Mhlongo L,
Master I, Newell ML: Community-based treatment for multidrug-resistant
tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis
2010, 14:420–426.
16. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR,
Rodgers R, Banada P, et al: Rapid detection of Mycobacterium
tuberculosis and rifampin resistance by use of on-demand, near-patient
technology. J Clin Microbiol 2010, 48:229–237.
17. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J,
Tahirli R, Blakemore R, Rustomjee R, et al: Rapid molecular detection of
tuberculosis and rifampin resistance. N Engl J Med 2010, 363:1005–1015.
18. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT,
Blakemore R, Worodria W, Gray C, et al: Feasibility, diagnostic accuracy,
and effectiveness of decentralised use of the Xpert MTB/RIF test for
diagnosis of tuberculosis and multidrug resistance: a multicentre
implementation study. Lancet 2011, 377:1495–1505.
19. World Health Organization: Policy statement: automated real-time nucleic
acid amplification technology for rapid and simultaneous detection of
tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: World
Health Organization; 2011.
20. World Health Organization: Rapid implementation of the Xpert MTB/RIF
diagnostic test: technical and operational ‘How-to’; practical considerations.
Geneva: World Health Organization; 2011.
21. Weyer K, Mirzayev F, Migliori G, Van Gemert W, D’Ambrosio L, Zignol M,
Floyd K, Centis R, Cirillo D, Tortoli E, et al: Rapid molecular TB diagnosis:
evidence, policy-making and global implementation of Xpert(R)MTB/RIF.
Eur Respir J 2012 [Epub ahead of print].
22. Wallrauch C, Heller T, Lessells R, Kekana M, Barnighausen T, Newell ML: High
uptake of HIV testing for tuberculosis patients in an integrated primary
health care HIV/TB programme in rural KwaZulu-Natal. S Afr Med J 2010,
100:146–147.
Lessells et al. Trials 2013, 14:170 Page 9 of 10
http://www.trialsjournal.com/content/14/1/170 343
23. Herbst AJ, Cooke GS, Barnighausen T, KanyKany A, Tanser F, Newell ML:
Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-
Natal, South Africa. Bull World Health Organ 2009, 87:754–762.
24. World Health Organization: Guidelines for the programmatic management of
drug-resistant tuberculosis: emergency update 2008. Geneva: World Health
Organization; 2008.
25. Department of Health RoSA: National Tuberculosis Management Guidelines.
Pretoria: Department of Health; 2009.
26. Hayes RJ, Bennett S: Simple sample size calculation for cluster-
randomized trials. Int J Epidemiol 1999, 28:319–326.
27. Department of Health RoSA: Management of drug-resistant tuberculosis:
Policy guidelines. Pretoria: Department of Health; 2011.
28. Hayes RJ, Moulton LH: Cluster randomised trials. Boca Raton, Florida:
Chapman & Hall/CRC; 2009.
29. Glidden DV, Vittinghoff E: Modelling clustered survival data from
multicentre clinical trials. Stat Med 2004, 23:369–388.
30. Lessells RJ, Cooke GS, Newell ML, Godfrey-Faussett P: Evaluation of
tuberculosis diagnostics: establishing an evidence base around the
public health impact. J Infect Dis 2011, 204(Suppl 4):S1187–S1195.
31. Bagchi AD, Dale S, Verbitsky-Savitz N, Andrecheck S, Zavotsky K, Eisenstein
R: Examining effectiveness of medical interpreters in emergency
departments for Spanish-speaking patients with limited English
proficiency: results of a randomized controlled trial. Ann Emerg Med 2011,
57:248–256. e241-244.
32. Loten C, Attia J, Hullick C, Marley J, McElduff P: Validation of a point of
care troponin assay in real life Emergency Department conditions. Emerg
Med Australas 2009, 21:286–292.
33. Zwarenstein MF, Dainty KN, Quan S, Kiss A, Adhikari NK: A cluster
randomized trial evaluating electronic prescribing in an ambulatory care
setting. Trials 2007, 8:28.
34. Hall S, Reid E, Ukoumunne OC, Weinman J, Marteau TM: Brief smoking
cessation advice from practice nurses during routine cervical smear tests
appointments: a cluster randomised controlled trial assessing feasibility,
acceptability and potential effectiveness. Br J Cancer 2007, 96:1057–1061.
35. Kunkler IH, Prescott RJ, Lee RJ, Brebner JA, Cairns JA, Fielding RG, Bowman
A, Neades G, Walls AD, Chetty U, et al: TELEMAM: a cluster randomised
trial to assess the use of telemedicine in multi-disciplinary breast cancer
decision making. Eur J Cancer 2007, 43:2506–2514.
36. Wallengren K, Scano F, Nunn P, Margot B, Buthelezi SS, Williams B, Pym A,
Samuel EY, Mirzayev F, Nkhoma W, et al: Drug-resistant tuberculosis,
KwaZulu-Natal, South Africa, 2001–2007. Emerg Infect Dis 2011,
17:1913–1916.
37. Xpert Research Mapping Project: [http://xrmt.treattb.org/]
38. Clouse K, Page-Shipp L, Dansey H, Moatlhodi B, Scott L, Bassett J, Stevens
W, Sanne I, Van Rie A: Implementation of Xpert MTB/RIF for routine point-
of-care diagnosis of tuberculosis at the primary care level. S Afr Med J
2012, 102:805–807.
39. Van Rie A, Page-Shipp L, Hanrahan CF, Schnippel K, Dansey H, Bassett J,
Clouse K, Scott L, Stevens W, Sanne I: Point-of-care Xpert MTB/RIF for
smear-negative tuberculosis suspects at a primary care clinic in South
Africa. Int J Tuberc Lung Dis 2013, 17:368–372.
40. Batz HG, Cooke GS, Reid SD: Towards lab-free tuberculosis diagnosis. http://
www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/
TB_Report_TowardsLabFreeTBDX_2011_ENG.pdf.
41. Dheda K, Ruhwald M, Theron G, Peter J, Yam WC: Point-of-care diagnosis
of tuberculosis: past, present and future. Respirology 2013, 18:217–232.
doi:10.1186/1745-6215-14-170
Cite this article as: Lessells et al.: Impact of a novel molecular TB
diagnostic system in patients at high risk of TB mortality in rural South
Africa (Uchwepheshe): study protocol for a cluster randomised trial.
Trials 2013 14:170.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lessells et al. Trials 2013, 14:170 Page 10 of 10
http://www.trialsjournal.com/content/14/1/170 344
